Oncolytic vaccinia virus and immune checkpoint inhibitor combination therapy
By combining replicative oncolytic vaccinia virus with immune checkpoint inhibitors, tumor cells are induced to express immune checkpoint proteins, solving the problem of limited efficacy in the prior art, and significantly improving anti-tumor immunity and therapeutic effects.
Patent Information
- Application Number
- CN202410629808.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2017-08-25
- Filing Date
- 2018-04-23
- Publication Date
- 2024-11-05
AI Technical Summary
Among the existing cancer treatment methods, replicable oncolytic vaccinia virus and immune checkpoint inhibitors have limited efficacy when used alone, and tumors inhibit immune response and virus clearance are rapid, limiting their therapeutic potential.
Replicative oncolytic vaccinia virus and immune checkpoint inhibitors are administered simultaneously, and tumor cells are induced to express immune checkpoint proteins through intratumoral or systemic pathways, thereby enhancing tumor sensitivity to checkpoint inhibitors.
It significantly enhances anti-tumor immunity and improves the synergistic effect of cancer treatment, especially in tumors that do not express or express checkpoint proteins, improves treatment sensitivity, delays tumor growth and achieves tumor regression in some cases.
Smart Images

Figure CN118892540A_ABST
Abstract
Description
[0001] This application is a divisional application of the Chinese patent application with application number 201880035158.9 (application date: April 23, 2018, invention name: Combination therapy of oncolytic vaccinia virus and immune checkpoint inhibitors).
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Application No. 62 / 488,623, filed on April 21, 2017, and U.S. Provisional Application No. 62 / 550,486, filed on August 25, 2017, which are incorporated herein by reference in their entirety. Technical Field
[0004] The present invention relates generally to virology and medicine. In certain aspects, the present invention relates to a therapeutic composition comprising a replicating oncolytic vaccinia virus and an immunomodulatory agent. Background Art
[0005] Normal tissue homeostasis is a highly regulated process of cell proliferation and cell death. An imbalance in cell proliferation or cell death can develop into a cancerous state. For example, cervical cancer, kidney cancer, lung cancer, pancreatic cancer, colorectal cancer, and brain cancer are just a few examples of the many types of cancer that can result. In fact, the incidence of cancer is so high that more than 500,000 people die from cancer each year in the United States alone.
[0006] Replication-selective oncolytic viruses hold promise for cancer therapy. These viruses can cause tumor cell death through direct replication-dependent and / or viral gene expression-dependent oncolysis. However, tumor immunosuppression and premature viral clearance often elicit only weak tumor-specific immune responses, limiting the potential of these viruses as cancer therapeutics.
[0007] Likewise, immune checkpoint inhibitors have shown some promise in treating certain cancers, but only a limited percentage of patients achieve an objective clinical response. There remains a need for improved cancer therapies. Summary of the invention
[0008] The inventors found that the simultaneous administration of immune checkpoint inhibitors and replicative oncolytic vaccinia viruses administered intratumorally to a clinically relevant cancer model produced a synergistic anti-tumor effect, in which the agent was administered simultaneously for the first time and preferably multiple times continuously. Therefore, in some embodiments, the present application provides a combination therapy for treating and / or preventing cancer and / or establishing metastasis in a mammal, comprising administering (i) replicative oncolytic vaccinia virus and (ii) immune checkpoint inhibitors to a mammal simultaneously, wherein the oncolytic vaccinia virus is administered intratumorally to the mammal. In some aspects, the simultaneous administration of a drug combination partner to a mammal provides enhanced or even synergistic anti-tumor immunity compared to any single treatment.
[0009] In some embodiments, the replicating oncolytic vaccinia virus is administered intratumorally, intravenously, intraarterially, or intraperitoneally. In some embodiments, the replicating oncolytic vaccinia virus is administered intratumorally. In some embodiments, the replicating oncolytic vaccinia virus is administered in an amount effective to induce expression of immune checkpoint proteins in the tumor. In some embodiments, before administration of the replicating oncolytic vaccinia virus, the tumor does not express immune checkpoint proteins or expresses immune checkpoint proteins at relatively low levels. In some embodiments, the immune checkpoint inhibitor is an antibody or fragment thereof that specifically binds to an immune checkpoint protein, preferably a monoclonal antibody, a humanized antibody, a fully human antibody, a fusion protein, or a combination thereof.
[0010] In some embodiments, the immune checkpoint inhibitor of the composition inhibits an immune checkpoint protein selected from the group consisting of cytotoxic T lymphocyte antigen 4 (CTLA4 or CTLA-4), programmed cell death protein 1 (PD-1), B7-H3, B7-H4, T cell membrane protein 3 (TIM3), galectin 9 (GAL9), lymphocyte activation gene 3 (LAG3), V domain immunoglobulin (Ig) containing T cell activation inhibitor (VISTA), killer cell immunoglobulin-like receptor (KIR), B and T lymphocyte attenuator (BTLA), T cell immunoreceptor with Ig and II′IM domains (TIGIT), indoleamine 2,3-dioxygenase (IDO), or a combination thereof. On the other hand, the checkpoint inhibitor interacts with the ligand of the checkpoint protein, which includes but is not limited to CTLA-4, PD-1, B7-H3, B7-H4, TIM3, GAL9, LAG3, VISTA, KIR, BTLA, TIGIT or a combination thereof. In a preferred embodiment, the immune checkpoint protein inhibitor is an antibody (e.g., a monoclonal antibody, a chimeric antibody, a human antibody or a humanized antibody) that specifically binds to an immune checkpoint protein or its ligand, an antibody fragment or a fusion protein.
[0011] In some preferred embodiments, the immune checkpoint inhibitor of the composition is an antibody or an antigen-binding fragment thereof that specifically binds (and inhibits) PD-1, PD-L1, PD-L2, TIGIT, TIM3, LAG3 or CTLA4. As a non-limiting example, a method for treating and / or preventing cancer in a mammal is provided, comprising simultaneously administering to a subject an effective amount of (i) a replicating oncolytic vaccinia virus injected intratumorally and (ii) a CTLA4 and / or PD-1 inhibitor.
[0012] In some embodiments, the immune checkpoint inhibitor is a monoclonal antibody that selectively binds to PD-1 or PD-L1, preferably selected from the group consisting of BMS-936559, atezolizumab, durvalumab, avelumab, nivolumab, pembrolizumab and lambrolizumab. In some embodiments, the immune checkpoint inhibitor is a monoclonal antibody that selectively binds to CTLA4, preferably selected from the group consisting of ipilimumab and tremelimumab. In some embodiments, multiple checkpoint inhibitors are administered to the subject simultaneously with oncolytic vaccinia virus. In some embodiments, the subject is administered simultaneously: (a) a CTLA4 inhibitor, a PD-1 inhibitor, and a replicating oncolytic vaccinia virus; (b) a CTLA4 inhibitor, an IDO inhibitor, and a replicating oncolytic vaccinia virus; (c) a PD-1 inhibitor, an IDO inhibitor, and a replicating oncolytic vaccinia virus; (d) a PD-1 inhibitor, a CTLA4 inhibitor, an IDO inhibitor, and a replicating oncolytic vaccinia virus; (e) a LAG3 inhibitor, a PD-1 inhibitor, and a replicating oncolytic vaccinia virus; (f) a TIGIT inhibitor, a PD-1 inhibitor, and a replicating oncolytic vaccinia virus. In some embodiments, the replicating oncolytic vaccinia virus is a Wyeth strain, a Western Reserve Strain strain, a Lister strain, or a Copenhagen strain. In some embodiments, the vaccinia virus comprises one or more genetic modifications to increase the selectivity of the virus for cancer cells, preferably the virus is engineered to lack a functional thymidine kinase and / or lack a functional vaccinia growth factor. In some embodiments, the vaccinia virus comprises a functional 14L and / or F4L gene.
[0013] In some embodiments, the vaccinia virus is a Wyeth strain, a Western Reserve strain, a Lister strain, or a Copenhagen strain with one or more genetic modifications to increase the selectivity of the vaccinia virus for cancer cells (e.g., inactivation of thymidine kinase (TK) and / or vaccinia growth factor (VGF) genes). In a related embodiment, the vaccinia virus is engineered to express a cytokine, such as, but not limited to, GM-CSF, IL-2, IL-4, IL-5, IL-7, IL-12, IL-15, IL-18, IL-21, IL-24, IFN-γ, and / or TNF-α, preferably selected from IFN-γ, TNF-α, IL-2, GM-CSF, and IL-12.In other related embodiments, the replicating oncolytic vaccinia virus is engineered to express a tumor antigen, such as, but not limited to, BAGE, GAGE-1, GAGE-2, CEA, AIM2, CDK4, BMI1, COX-2, MUM-1, MUC-1, TRP-1, TRP-2, GP100, EGFRvIII, EZH2, LICAM, Livin, Livinβ, MRP-3, nestin, OLIG2, SOX2, human papillomavirus E6, human papillomavirus E7, ART1, ART4, SART1, SART2, SART3, B-cyclin, β-catenin, Glil, Cav-1, cathepsin B, CD74, E-cadherin, EphA2 / Eck, Fra-1 / Fos1 1. Ganglioside / GD2, GnT-V, β1,6-N, Her2 / neu, Ki67, Ku70 / 80, IL-13Ra2, MAGE-1, MAGE-3, NY-ESO-1, MART-1, PROX1, PSCA, SOX10, SOX11, survivin, caspase-8, UPAR, CA-125, PSA, p185HER2, CD5, IL-2R, Fap-a, tenascin, melanoma-associated antigen p97, WT-1, G protein signaling regulator 5 (RGS5), Surivin (BIRC5 = apoptosis-containing repeat structure Baculovirus inhibitor 5), insulin-like growth factor binding protein 3 (IGF-BP3), thymidylate synthase (TYMS), hypoxia-inducible protein 2, hypoxia-inducible lipid droplet-associated protein (HIG2), matrix metallopeptidase 7 (MMP7), prune homologous protein 2 (PRUNE2), RecQ protein-like (DNA helicase Q1-like protein) (RECQL), leptin receptor (LEPR), ERBB receptor feedback inhibitor 1 (ERRFI1), lysosomal protein transmembrane protein 4 alpha (LAPTM4A), RAB1B, RAS oncogene family (RABIB), CD24, Homo sapiens thymosin beta 4, X-linked (TMSB4X) protein, Homo sapiens S100 calcium binding protein A6 (S100A6), Homo sapiens adenosine A2 receptor (ADORA2B), chromosome 16 open reading frame 61 antibody (C16orf61), ROD1 differentiation regulator 1 (ROD1), NAD-dependent deacetylase deacetylase sirtuin-2 (SIR2L), tubulin alpha 1c (TUBA1C), ATPase inhibitory factor 1 (ATPIF1), stromal antigen 2 (STAG2), nuclear casein kinase and cyclin dependent substrate 1 (NUCKS1). In some embodiments, the tumor antigen is a renal cell carcinoma tumor antigen.In some embodiments, the renal cell carcinoma tumor antigen is selected from the group consisting of: G protein signaling regulator 5 (RGS5), Surivin (BIRC5 = repeat-containing baculovirus inhibitor of apoptosis 5), insulin-like growth factor binding protein 3 (IGF-BP3), thymidylate synthase (TYMS), hypoxia-inducible protein 2, hypoxia-induced lipid droplet-associated protein (HIG2), matrix metallopeptidase 7 (MMP7), prune homologous protein 2 (PRUNE2), RecQ protein-like (DNA helicase Q1-like protein) (RECQL), leptin receptor (LEPR), ERBB receptor feedback inhibitor 1 (ERRFI1), lysosomal protein transmembrane protein 4 alpha (LAPTM4A), RAB1B, RAS oncogene family (RABIB), CD24, Homo sapiens thymosin beta 4, X-linked (TMSB4X) protein, Homo sapiens S100 calcium-binding protein A6 (S100A6), Homo sapiens adenosine A2 receptor (ADORA2B), chromosome 16 open reading frame 61 antibody (C16orf61), ROD1 differentiation regulator 1 (ROD1), NAD-dependent deacetylase sirtuin-2 (SIR2L), tubulin alpha 1c (TUBA1C), ATPase inhibitory factor 1 (ATPIF1), stromal antigen 2 (STAG2), and nuclear casein kinase and cyclin-dependent substrate 1 (NUCKS1).
[0014] In some embodiments, the vaccinia virus is present in an amount of about 10 7 to about 10 11 pfu, preferably about 10 8 -10 10 pfu, more preferably about 10 9 -10 10 In some embodiments, the checkpoint inhibitor is administered in an amount of about 2 mg / kg to 15 mg / kg.
[0015] In some embodiments, the pharmaceutical composition is applied to a mammal to treat and / or prevent cancer in a mammal. In some embodiments, the cancer is a cancer of a solid tumor type. In some embodiments, the cancer is selected from a group consisting of the following items: melanoma, hepatocellular carcinoma, renal cell carcinoma, bladder cancer, head and neck cancer, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, mesothelioma, gastrointestinal cancer, leukemia, lung cancer (including non-small cell lung cancer), gastric cancer, esophageal cancer, mesothelioma, colorectal cancer, sarcoma or thyroid cancer. In other preferred embodiments, the pharmaceutical composition is applied to a mammal to treat metastasis. In some embodiments, the subject suffers from renal cell carcinoma.
[0016] In a preferred embodiment, the mammal to be treated with the pharmaceutical composition is a human subject. In related aspects, the subject in need of treatment is a person suffering from a cancer that is refractory (or resistant) to one or more chemotherapeutic agents and / or refractory to one or more antibody treatments. In a specific embodiment, the cancer (e.g., colorectal cancer) suffered by the person is refractory (or resistant) to the treatment comprising an immune checkpoint inhibitor, and is optionally also refractory to the treatment of one or more chemotherapeutic agents. In other embodiments, the person in need of treatment is a person identified as a candidate for treatment using one or more immune checkpoint inhibitors.
[0017] In some embodiments, at least one previous chemotherapy or immunotherapy treatment of the subject has failed. In some embodiments, the subject suffers from cancer that is refractory to immune checkpoint inhibitor therapy, preferably, the cancer is resistant to treatment with anti-PD-1 antibodies and / or anti-CTLA-4 antibodies. In some embodiments, the subject is identified as a candidate for immune checkpoint inhibitor therapy. In some embodiments, the method includes administering to the subject other therapies selected from chemotherapy (alkylating agents, nucleoside analogs, cytoskeleton modifiers, cell inhibitors) and radiotherapy. In some embodiments, the method includes administering other oncolytic virus therapeutic agents (e.g., rhabdovirus, Semliki Forest virus) to the subject. In some embodiments, the subject is human. In some embodiments, the first dose of replicative oncolytic vaccinia virus and the first dose of immune checkpoint inhibitor are simultaneously applied to the subject, and then the virus and the checkpoint inhibitor are continuously and simultaneously applied to the subject at least once. In some embodiments, the method includes applying replicative oncolytic vaccinia virus and checkpoint inhibitor to the subject at least the first, second and third time continuously. In some embodiments, the method comprises administering a replicative oncolytic vaccinia virus and a checkpoint inhibitor to a subject at least the first, second, third, and fourth times continuously and simultaneously. In some embodiments, a first dose of a replicative oncolytic vaccinia virus and a first dose of an immune checkpoint inhibitor are administered simultaneously, followed by at least one continuous simultaneous administration of the virus and the checkpoint inhibitor to the subject, and then at least one dose of the checkpoint inhibitor is administered to the subject alone. In some embodiments, the method comprises an interval of 1-3 weeks between the continuous simultaneous administration of the agents, preferably comprising an interval of about 1 week, about 2 weeks, or about 3 weeks.
[0018] The present application demonstrates that intratumoral administration of replicating oncolytic vaccinia virus (i) attracts host immune cells (e.g., tumor-infiltrating T cells) to tumors and (ii) induces expression of multiple checkpoint proteins (including PD-1, PD-L1, CTLA-4, LAG3, TIM3, and TIGIT) in tumor cells, thereby sensitizing tumor cells to simultaneous treatment with (one or more) checkpoint protein inhibitors.
[0019] Therefore, in some aspects, the expression level of one or more of these checkpoint proteins is used as a biomarker to select human cancer patients for treatment with the combination therapy described herein based on their expression level. In some embodiments, the expression can be measured using any assay for measuring protein levels. In some embodiments, the protein expression can be measured using an assay such as a FACS or Nanotring assay.
[0020] In a related embodiment, the person in need of treatment is a person with a tumor that does not express a checkpoint protein (e.g., a checkpoint inhibitor refractory subject) or expresses a checkpoint protein at a relatively low level, in which case the oncolytic vaccinia virus component of the combination therapy is administered in an amount that effectively sensitizes the tumor to the immune checkpoint inhibitor of the composition by inducing the expression of a checkpoint protein (e.g., PD-L1). In some embodiments, the person may have a tumor that does not express PD-1, PD-L1, CTLA-4, LAG3, TIM3, and / or TIGIT or expresses one or more of these checkpoint proteins at a relatively low level, and the oncolytic vaccinia virus is administered in an amount that effectively sensitizes the tumor to PD-1, PD-L1, CTLA-4, LAG3, TIM3, and / or TIGIT inhibitors. In other related embodiments, the level of checkpoint proteins is measured in the tumor before administering the oncolytic vaccinia virus and checkpoint inhibitor combination therapy, and if it is determined that the checkpoint protein is not expressed in the tumor or is expressed at a relatively low level, the combination therapy is administered to the subject. In other related embodiments, a method for sensitizing a tumor to a checkpoint inhibitor is provided, comprising administering an oncolytic vaccinia virus to a person with a tumor in an amount that effectively induces the expression of a checkpoint protein in a tumor, and administering the checkpoint inhibitor to the person at the same time. In some aspects, a tumor that does not express a checkpoint protein or expresses a checkpoint protein at a relatively low level refers to a tumor cell that is less than 50%, less than 25%, less than 15%, less than 10%, less than 5%, less than 1% or less than 0.5% positive for checkpoint protein staining according to the immunohistochemistry (IHC) assessment of a tumor sample. See, for example, Ilie et al., Virchows Arch, 468(5):511-525(2016). In some aspects, the person suffers from non-small cell lung cancer, gastric cancer, renal cell carcinoma, pancreatic cancer or colorectal cancer.
[0021] In other related embodiments, the person in need of treatment is a person with an immunologically "cold" tumor, which means that the tumor is substantially or relatively free of immune cells in the tumor microenvironment. Treatment using oncolytic vaccinia virus attracts immune cells (e.g., T cells) to the tumor and is coordinated with simultaneously administered checkpoint inhibitors to treat the tumor. "Cold" tumors can be identified by methods known in the art, including but not limited to single staining or multiple immunohistochemistry (IHC) for immune markers (such as CD3 and CD8) at the center of the tumor and the invasive edge, flow cytometry for phenotypic analysis, genomic analysis of tumor tissue, RNA analysis of tumor tissue, and / or cytokine analysis in serum.
[0022] The oncolytic vaccinia virus and immune checkpoint inhibitor of the composition are administered concurrently (e.g., simultaneously), and can be administered as part of the same preparation or in the form of different preparations. Simultaneous (or concurrent) administration refers to administration of each combination partner of the first dose at the same time or approximately the same time (within 24 hours of each other, preferably within 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 hours or within 1 hour of each other), and preferably at least one subsequent dose of each combination partner is administered at the same time or approximately the same time. Therefore, on the one hand, the combination therapy described herein comprises a first dose of replicative oncolytic vaccinia virus administered simultaneously with a first dose of a checkpoint inhibitor (e.g., a combination therapy for treatment of a subject requires at least the first administration, wherein the oncolytic vaccinia virus and the checkpoint inhibitor are administered to the subject simultaneously), and preferably further comprises at least one, two, three, four or more additional continuous simultaneous administrations of the oncolytic vaccinia virus and the checkpoint inhibitor. Therefore, the simultaneous treatment regimen of the pharmaceutical composition may include at least two, at least three, at least four, at least five, at least six, at least seven or more continuous simultaneous administrations of doses of the agent. In a preferred embodiment, the interval between the continuous simultaneous administration of doses of oncolytic vaccinia virus and checkpoint inhibitors ranges from about 1 day to about 3 weeks, or any interval therebetween, such as 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 15 days, 16 days, 17 days, 18 days, 19 days, 20 days or 21 days. In some preferred embodiments, the interval between the continuous simultaneous administration of doses of oncolytic vaccinia virus and checkpoint inhibitors is about 1 week or about 2 weeks. After simultaneously administering at least one initial dose of oncolytic virus and immune checkpoint inhibitor, one or more doses of checkpoint inhibitors may be administered to the subject alone.
[0023] In other aspects, the present invention provides a commercial package comprising a composition of an oncolytic vaccinia virus and an immune checkpoint inhibitor as described herein as an active agent, and instructions for simultaneous use in treating and / or preventing cancer as described herein. In a preferred aspect, the commercial package comprises a composition of a Western Reserve, Copenhagen, Wyeth or Lister strain vaccinia virus and a PD-1, PD-L1, TIGIT or CTLA4 inhibitor as an active agent.
[0024] In some embodiments, the present invention provides a method for treating a human tumor, comprising administering to the person simultaneously a composition comprising (a) a replicative oncolytic vaccinia virus and (b) an inhibitor of an immune checkpoint protein. In some embodiments, the replicative oncolytic virus is administered intratumorally. In some embodiments, the replicative oncolytic virus is administered intravenously. In some embodiments, the replicative oncolytic virus is administered intraarterially. In some embodiments, the replicative oncolytic virus is administered intraperitoneally. In some embodiments, the replicative oncolytic virus is delivered only by intratumoral administration. In some embodiments, the replicative oncolytic virus is administered intratumorally, while the checkpoint inhibitor is administered systemically. In some embodiments, the replicative oncolytic virus is administered intravenously, while the checkpoint inhibitor is administered systemically. In some embodiments, the replicative oncolytic virus is administered intraperitoneally, while the checkpoint inhibitor is administered systemically. In some embodiments, the replicative oncolytic virus is administered intraarterially, while the checkpoint inhibitor is administered systemically. In some embodiments, the replicative oncolytic virus is administered intraarterially, while the checkpoint inhibitor is administered systemically. In some embodiments, the replicative oncolytic virus is administered intraarterially, while the checkpoint inhibitor is administered systemically. In some embodiments, the replicative oncolytic virus is administered intraarterially, while the checkpoint inhibitor is administered systemically. In some embodiments, the replicative oncolytic virus is administered intraarterially, while the checkpoint inhibitor is administered systemically. In some embodiments, the replicative oncolytic virus is administered in an amount that effectively induces the expression of immune checkpoint proteins in tumors. In some embodiments of the method of treatment, the immune checkpoint protein is selected from PD-1, PD-L1, CTLA-4, LAG3, TIM3 and TIGIT. In some embodiments, the present invention provides a method for treating a human tumor, comprising administering a composition to the person simultaneously, the composition comprising (a) a replicating oncolytic vaccinia virus and (b) an inhibitor of the immune checkpoint protein in an amount that effectively induces the expression of the immune checkpoint protein in the tumor. In some embodiments, the replicating oncolytic vaccinia virus is administered intratumorally. In some embodiments, the replicating oncolytic vaccinia virus is administered by IV. In some embodiments of the method of treatment, the immune checkpoint protein is selected from PD-1, PD-L1, CTLA-4, LAG3, TIM3 and TIGIT. In some embodiments of the method of treatment, the immune checkpoint protein is CTLA-4. In some embodiments of the method of treatment, the immune checkpoint protein is PD-L1. In some embodiments of the method of treatment, the immune checkpoint protein is LAG3. In some embodiments of the method of treatment, the immune checkpoint protein is TIGIT. In some embodiments of the method of treatment, the immune checkpoint protein is PD-1. In some embodiments of the method of treatment, the immune checkpoint protein is TIM3. In some embodiments of the method of treatment, the tumor is a solid cancer. In some embodiments of the method of treatment, the tumor is colorectal cancer. In some embodiments of the method of treatment, the tumor is renal cell carcinoma.
[0025] In some embodiments of the dual therapy method, the inhibitor of the immune checkpoint protein is a monoclonal antibody that selectively binds to PD-1 or PD-L1. In some embodiments, the monoclonal antibody that selectively binds to PD-1 or PD-L1 is selected from the group consisting of: BMS-936559, atezolizumab, durvalumab, avelumab, nivolumab, pembrolizumab, and lanrolizumab.
[0026] In some embodiments of the dual therapy method, the inhibitor of the immune checkpoint protein is a monoclonal antibody that selectively binds to CTLA-4. In some embodiments, the monoclonal antibody that selectively binds to CTLA-4 is selected from the group consisting of lanrolizumab and tesimumab.
[0027] In some embodiments of the dual therapy approach, prior to administration of the replicating oncolytic vaccinia virus, the tumor does not express the immune checkpoint protein or expresses the immune checkpoint protein at relatively low levels.
[0028] In some embodiments of the dual therapy method, the method comprises the step of measuring the expression level of the immune checkpoint protein in the tumor prior to administering the composition.
[0029] In some embodiments, the present invention provides a method for treating a human tumor, comprising administering to the person simultaneously a composition comprising (a) a replicating oncolytic vaccinia virus, (b) an inhibitor of PD-1 and / or PD-L1, and (c) an inhibitor of an immune checkpoint protein. In some embodiments, the replicating oncolytic vaccinia virus is administered in an amount that effectively induces the expression of immune checkpoint proteins. In some embodiments, the replicating oncolytic virus is administered intratumorally. In some embodiments, the replicating oncolytic virus is administered intravenously. In some embodiments, the replicating oncolytic virus is administered intraarterially. In some embodiments, the replicating oncolytic virus is administered intraperitoneally. In some embodiments, the replicating oncolytic virus is delivered only by intratumoral administration. In some embodiments, the replicating oncolytic virus is administered intratumorally, and the checkpoint inhibitor is administered systemically. In some embodiments, the replicating oncolytic virus is administered intravenously, and the checkpoint inhibitor is administered systemically. In some embodiments, the replicating oncolytic virus is administered intraperitoneally, and the checkpoint inhibitor is administered systemically. In some embodiments, the replicating oncolytic virus is administered intra-arterially, while the checkpoint inhibitor is administered systemically. In some embodiments, the present invention provides a method for treating a human tumor, comprising administering to the person simultaneously a composition comprising (a) a replicating oncolytic vaccinia virus effective to induce the expression of immune checkpoint proteins in a tumor, (b) an inhibitor of PD-1 and / or PD-L1, and (c) an inhibitor of immune checkpoint proteins, wherein the replicating oncolytic vaccinia virus is administered intratumorally. In some embodiments of the method of treatment, the immune checkpoint protein is selected from CTLA-4, LAG3, TIM3 and TIGIT. In some embodiments of the method of treatment, the immune checkpoint protein is CTLA-4. In some embodiments of the method of treatment, the immune checkpoint protein is LAG3. In some embodiments of the method of treatment, the immune checkpoint protein is TIGIT. In some embodiments of the method of treatment, the immune checkpoint protein is TIM3. In some embodiments of the method of treatment, the tumor is a solid cancer. In some embodiments of the method of treatment, the tumor is colorectal cancer. In some embodiments of the method of treatment, the tumor is renal cell carcinoma.
[0030] In some embodiments of the triple therapy approach, the inhibitor of the immune checkpoint protein is a monoclonal antibody that selectively binds to PD-1 or PD-L1. In some embodiments, the monoclonal antibody that selectively binds to PD-1 or PD-L1 is selected from the group consisting of: BMS-936559, atezolizumab, durvalumab, avelumab, nivolumab, pembrolizumab, and lanrolizumab.
[0031] In some embodiments of the triple therapy method, the inhibitor of the immune checkpoint protein is a monoclonal antibody that selectively binds to CTLA-4. In some embodiments, the monoclonal antibody that selectively binds to CTLA-4 is selected from the group consisting of lanrolizumab and tesimumab.
[0032] In some embodiments of the triple therapy approach, the tumor does not express the immune checkpoint protein or expresses the immune checkpoint protein at relatively low levels prior to administration of the replicating oncolytic vaccinia virus.
[0033] In some embodiments of the triple therapy approach, the method comprises the step of measuring the expression level of an immune checkpoint protein in the tumor prior to administering the composition.
[0034] Other embodiments of the present invention are discussed throughout this application. Any embodiment discussed with respect to one aspect of the present invention is also applicable to other aspects of the present invention, and vice versa. The embodiments in the Examples section should be understood to be embodiments of the present invention applicable to all aspects of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] The following drawings constitute part of this specification and are included to further illustrate certain aspects of the present invention. The present invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.
[0036] Figures 1A-1C . Figure 1A : A diagram depicting a simultaneous combination therapy regimen of intratumoral (IT) injection of mJX-594 and intraperitoneal administration of an anti-PD-1 checkpoint inhibitor antibody. 5×10 5 Renca (kidney cancer) cells. Once the tumor size reaches ≥50mm 3 , with PBS (control, days 0, 3, 6, and 9), anti-PD-1 antibody alone (days 0, 3, 6, and 9), mJX-594 alone (days 0, 2, and 4), or co-delivered anti-PD-1 and mJX-594 (agents were co-administered on days 0, 2, and 4, followed by anti-PD-1 alone on day 6 and mJX-594 at 1x10 7 Mice were treated with anti-PD-1 at 10 mg / kg intratumorally (IT) and 10 mg / kg intraperitoneally (IP). Figure 1B Eight-week-old female BALB / c mice were injected with RENCA cells (2×10 6On day 10 post-implantation, the cells were injected into the subcapsule of the left kidney with (i) PBS (control), (ii) vaccinia virus (JX-929) monotherapy (6×10 cells on days 10, 11, and 12 post-implantation) according to the indicated schedule. 7 PFU, 3 doses in total), (iii) anti-PD-1 monotherapy (BioXcell, West Lebanon, NH, 100 μl) (days 10, 11, and 12 after implantation, 3 doses in total), or (iv) concurrent JX929 + anti-PD-1 therapy (administered on days 10, 11, and 12 after implantation, with JX-929 in the morning and ICI in the afternoon of the same day, 9 hours apart) was intraperitoneally (ip) treated with Renca tumors (50 mm 3 -100mm 3 ,pass Spectrum in vivo imaging system). Figure 1C : According to the treatment plan shown, carry more than 50mm 3 Balb / c mice bearing Renca tumors were given four intratumoral doses of mJX594 (1x10 7 ) or PBS control.
[0037] Figure 2A-2B . Figure 2A : Describe Figure 1A Graph of the effect of the treatment regimens described in on tumor volume. Simultaneous combination treatment (PD1+mJX594) significantly inhibited tumor growth (after day 18 post-implantation) compared to all other treatment groups. Figure 2B : Describe Figure 1A Photographs and graphs of tumor weights in each treatment group are described in. Simultaneous combination therapy (PD1+mJX594) synergized to significantly reduce tumor volume relative to either monotherapy.
[0038] Figure 3A-3B Simultaneous combination treatment with IT mJX-594 and anti-PD-1 significantly increased intratumoral T cell infiltration compared to control and monotherapy. Mice were treated according to the administration schedule shown in Figure 1. Figure 3A : Images showing that CD8 T cell infiltration in both peritumoral and intratumoral areas was significantly increased in the simultaneous combination treatment group compared with the control and single-drug treatment groups. Figure 3B : A graph showing that the peritumoral and intratumoral CD8 T cell infiltration was significantly increased in the simultaneous combination group compared with the control and either monotherapy.
[0039] Figures 4A-4BSimultaneous combination therapy with IT mJX-594 and anti-PD-1 upregulates intratumoral PD-L1 expression. Mice were treated according to the administration schedule shown in Figure 1. Figure 4A : Images showing that PD-L1 expression levels were significantly increased in both peripheral and central tumor areas in the simultaneous combination treatment group compared with the control and either monotherapy (PD-L1 staining). Figure 4B : Images showing a significant increase in intratumoral apoptosis in the simultaneous combination treatment group compared to the control and either monotherapy group.
[0040] Figure 5A-5B Compared with the control, CD8 T cells and CD11b+Grl+ myeloid-derived suppressor cells (MDSCs) were increased in the combined treatment group. Figure 5A : Flow cytometry graphs showing CD8 and Gr-1 positivity in tumors from each treatment group, with a significant increase in CD8+T cells in tumors from the combined group compared to either monotherapy. Also shown is an increase in MDSC relative to either monotherapy. Figure 5B : Bar graph depicting flow cytometry results.
[0041] Figure 6 . A diagram depicting a combination therapy regimen using IT injected mJX-594 and intraperitoneally delivered anti-PD1 (+ / - anti-CTLA4) checkpoint inhibitor antibodies. 5 Renca cells were injected subcutaneously into the right flank of 8-week-old BALB / c mice. 3 Treatment was started at 1x10 50 μg / mL (day 0). On day 0, mice (bearing Renca tumors) were treated with PBS (control), a combination of mJX-594+anti-PD1 delivered sequentially, a combination of mJX-594+anti-PD-1 delivered simultaneously, and a triple combination of mJX-594+anti-PD-1+anti-CTLA4 delivered simultaneously. mJX-594 was administered at 1x10 7 pfu IT, anti-PD1 was administered at 10 mg / kg IP, and anti-CTLA4 was administered at 4 mg / kg IP.
[0042] Figure 7 .describe Figure 6 Figure 2 shows the effect of the treatment regimens described in on tumor volume. Concurrent combination treatment with αPD 1+mJX594 and αPD1+mJX594+αCTLA4 significantly inhibited tumor growth from day 6 (after treatment) compared to all other treatment groups, and both simultaneous combination treatment groups significantly delayed tumor growth compared to the control and sequential combination treatment groups (mJX594→αPD1), with tumor regressions observed from day 12 onwards.
[0043] Figure 8 Figure 2 depicts a combination therapy regimen using IT-injected mJX-594 and an anti-CTLA4 checkpoint inhibitor antibody delivered intraperitoneally. 5 Renca cells were injected subcutaneously into the right flank of 8-week-old BALB / c mice. 3 Treatment was initiated at 1x10 400 μg / mL (day 0). On day 0, mice (bearing Renca tumors) were treated with PBS (control), anti-CTLA4 alone, mJX-594 alone, a combination of mJX-594+CTLA4 delivered sequentially, and a combination of mJX-594+CTLA4 delivered simultaneously. mJX-594 was administered at 1x10 7 pfu IT, and anti-CTLA4 was administered at 4 mg / kg.
[0044] Fig. 9 .Describe Figure 8 Figure 2 shows the effect of the treatment regimens described in on tumor volume. Concurrent combination therapy with mJX594+αCTLA4 significantly delayed tumor growth compared with sequential combination therapy with mJX594+αCTLA4 and either monotherapy.
[0045] Figures 10A-10B The simultaneous combination of IT-administered mJX594 and anti-CTLA4 significantly increased CD8+ T-cell tumor infiltration and decreased MDSC levels compared with sequential combination therapy and either monotherapy. Fig. 10A : Flow cytometry images showing the positivity of CD8 and Gr-1 in the tumors of each treatment group. Compared with the sequential treatment group and any single drug treatment, the CD8+T cells in the tumors of the combination group were significantly increased and MDSCs were significantly decreased. Fig. 10B : Bar graph depicting flow cytometry results.
[0046] Fig.11 . A diagram depicting a combination therapy regimen of mJX-594 delivered intravenously (IV) and an anti-PD1 checkpoint inhibitor antibody delivered intraperitoneally. 5 Renca cells were injected subcutaneously into the right flank of 8-week-old BALB / c mice. 3 Treatment was initiated at 2 × 10 7 pfu was administered IV, and anti-PD1 was administered IP at 10 mg / kg.
[0047] Fig.12 .Describe Fig.11 Figure 2. Effects of the treatment regimens described in on tumor volume. Simultaneous combination therapy with mJX594IV+αPD1 was inferior to treatment with mJX594 alone and was not superior to treatment with αPD1 alone.
[0048] Fig.13 : It is shown that by administering four 1×10 7 Fold changes in immune checkpoint proteins (relative to pretreatment levels) in Renca tumor-bearing mice treated intratumorally with pfu doses of mJX594 (Wyeth vaccinia virus engineered to contain a viral thymidine kinase gene disruption and a murine GM-CSF insertion).
[0049] Fig.14 . Provides data on the number of mJX594 injections and tumor growth inhibition. To discover the best immunotherapy with mJX594, various doses were tested in Renca kidney cancer. Tumor growth was reduced, depending on the increasing dose of mJX594.
[0050] Fig.15 Images showing recruitment of CD8+ T cells within tumors after mJX594 treatment.
[0051] Fig.16 Images showing intratumoral recruitment of CD8+ T cells after mJX594 treatment. Aggregates of CD8+ lymphoid cells resembling lymphoid follicles were observed in mJX594-treated tumors.
[0052] Fig.17 . Data showing that mJX594 increases the number and effector function of CD8+ T cells within tumors. The ratio of CD8+ T cells to regulatory T cells gradually increased after mJX594 treatment. The expression of ICOS and granzyme B in CD8+ T cells increased after mJX594 treatment. Although the number of CD4+Foxp3+CD25+ regulatory T cells and CD8+ and CD4+ T cells increased simultaneously in the lymphoid cell compartment, the ratio of CD8+ effector T cells to regulatory T cells increased compared with controls. In addition, the expression of ICOS and granzyme B (GzB), co-stimulatory and activation markers of T cells, was increased in CD8+ T cells.
[0053] Fig.18Data showing that mJX594 treatment repolarized myeloid cells (Ly6G-Ly6C+↑, Ly6G+Ly6Cint↓). mJX594 increased CD11b+Ly6G-Ly6C+ mononuclear myeloid cells and decreased CD11b+Ly6G+Ly6Cint granulocytic myeloid cells. In subgroup analysis of the myeloid cell compartment, we found an increase in CD11b+Ly6G-Ly6C+ mononuclear myeloid cells and a decrease in granulocytic myeloid cells with CD11b+Ly6G+Ly6Cint, indicating that the monocyte to granulocyte ratio was significantly increased by administration of mJX594.
[0054] Fig.19 Figure 3. Schematic diagram of data showing treatment with depletion antibody experiments. To determine which components of the immune system are responsible for the therapeutic effects following mJX594 treatment, the role of CD8+ T cell, CD4+ T cell, and GM-CSF depletion on tumor growth and anticancer immunity was investigated.
[0055] Fig. 20 Data indicating that depletion of T cells or GM-CSF significantly abolished the anticancer effects of mJX594. Both CD8+ and CD4+ T cells are essential mediators in the anticancer effects of mJX594 treatment, while GM-CSF may also provide immunotherapeutic benefits. Although efficient tumor suppression was detected with mJX594 monotherapy, depletion of CD8+ or CD4+ T cells resulted in abrogation of the therapeutic effect.
[0056] Fig.21 . Data showing that depletion of CD4+T cells or GM-CSF after mJX594 attenuated CD8+T cell infiltration within the tumor. Depletion of CD4+T cells reduced CD8+T cells within the tumor, suggesting that CD4+T cells are involved in the activation of CD8+T cells. Depletion of GM-CSF reduced both CD8+ and CD4+T cells. Depletion of CD4+T cells using mJX594 injection reduced CD8+T cells within the tumor, suggesting that CD4+T cells are involved in the activation of CD8+T cells. In contrast, depletion of CD8+T cells did not induce significant changes in CD4+T cells, indicating that CD8+T cells do not affect CD4+T cells. These data indicate that treatment with mJX594 induces the activation of CD8+ and CD4+T cells, which indicates anti-cancer immunity. The infiltration of CD8+ and CD4+T cells indicates an anti-cancer effect.
[0057] Fig. 22 Schematic diagram of the triple combination therapy experiment of mJX594, αPD-1 and αCTLA-4. mJX594
[0058] Fig.23. Data showing that the triple combination of mJX594, αPD-1 and αCTLA-4 significantly delayed tumor growth. Notably, the triple combination of mJX594, αPD-1 and αCTLA-4 caused complete regression of Renca tumors in some mice (37.5%). Although the dual combination of αPD-1 and αCTLA-4 delayed tumor growth by 14.5% compared to controls and mJX594 monotherapy inhibited tumor growth by 36.9%, the triple combination showed a 76.5% tumor growth inhibition rate. Notably, the triple combination of mJX594, αPD-1 and αCTLA-4 produced complete regression of tumors (complete response rate: 37.5%), which was not observed in tumors treated with the dual combination or mJX594 monotherapy.
[0059] Fig.24 . Data showing that triple immunotherapy with mJX594, PD-1, and CTLA-4 prolonged overall survival. Mice treated with triple therapy showed significant anti-cancer treatment effects. In addition, to confirm whether these potent anti-cancer effects caused by triple therapy can be translated into long-term survival benefits, survival analysis of tumor-bearing mice was performed. Mice treated with triple therapy showed survival benefits compared with monotherapy or dual immunotherapy.
[0060] Fig.25 Schematic diagram of the experiment of triple combination therapy of mJX594, αPD-1 and αLAG3.
[0061] Fig.26 . Data showing that the triple combination of mJX594, αPD-1, and αLAG3 modestly delayed tumor growth. In this experiment, the triple combination did not show a statistically significant difference compared to the dual combination of mJX594 and αPD-1. Compared with the control, the dual combination of mJX594 and αPD-1 delayed tumor growth by 41.9%, and αLAG3 monotherapy inhibited tumor growth by 5.7%. The triple combination showed a 30.1% tumor growth inhibition rate.
[0062] Fig. 27 Data showing that the triple combination of mJX594, αPD-1, and αLAG3 increased both CD8+ and CD4+ T cells. Subgroup analysis of the lymphoid cell compartment showed that dual and triple therapy increased the absolute numbers of CD8+ and CD4+ T cells within the tumor.
[0063] Fig.28 Schematic diagram of the triple combination therapy experiment with mJX594, αPD-1, and αTIGIT.
[0064] Fig.29Data showing that the triple combination of mJX594, αPD-1, and αTIGIT modestly delayed tumor growth. The triple combination did not show significant differences in Renca tumors compared to the double combination of mJX594 and αPD-1.
[0065] Fig.30 Data showing that the triple combination of mJX594, αPD-1, and αTIGIT increased both CD8+ and CD4+ T cells. Subgroup analysis of the lymphoid cell compartment showed that dual and triple therapy increased the absolute numbers of CD8+ and CD4+ T cells within the tumor.
[0066] Fig.31 . Data showing that mJX594 synergizes with anti-PD1 therapy to delay colon cancer growth. To overcome resistance to ICI monotherapy, the combined efficacy of mJX594 and immune checkpoint blockade was evaluated in the CT26 colon cancer model. In this model, αPD-1 monotherapy had little effect on tumor growth, while mJX594 monotherapy modestly inhibited tumor growth. However, antibody dual therapy of mJX594 and αPD-1 combination significantly hindered tumor growth.
[0067] Fig.32 : Data showing that the combination of mJX594 and anti-PD1 therapy increased CD8+ T cells within the tumor. In addition to inhibiting tumor growth, microscopic analysis showed that CD8+ T cells were significantly recruited both in the periphery and in the center of the tumor after treatment with the combination therapy.
[0068] Figures 33A-33G mJX594(JX) triggers dynamic changes in immune-related genes in the immunosuppressive TME. Renca tumors were implanted subcutaneously (sc) into BALB / c mice and when tumors reached >50 mm 3 When injected once with 1×10 7 pfu of mJX-594. (A) Representative images of Renca tumors treated with JX. Tumors were stained with vaccinia virus (VV), CD31, CD8, CD11c, and PD-L1. (B) + 、CD31 + Blood vessels, CD8 + Cytotoxic T cells, CD11c + Dendritic cells and PD-L1 + Quantification of expression of cells. (C) Temporal changes of VV, CD8, and PD-L1 in the tumor microenvironment after JX treatment. (D) Images showing upregulated PD-L1 expression (red) in various cell types (green) in the TME after JX treatment. Note that PD-L1 expression is mainly in Pan-CK +Observed in tumor cells (arrows), but some CD11b + Myeloid cells (arrows) also occasionally express PD-L1, while CD3 + T cells do not express it. (E) NanoString immune-related gene expression heat map. Red and green represent upregulation and downregulation, respectively. (F) Volcano plot showing gene expression in JX-treated tumors. Genes related to immune stimulation are indicated. Red line indicates p<0.05. (G) Comparison of gene expression related to inhibitory immune checkpoints (IC), agonist IC, Th1 response, Th2 response, TME, and myeloid cells. Unless otherwise stated, n=5 per group. Values are mean±SEM. *p<0.05 relative to control. Scale bar, 50 μm. Some data are also shown in Fig.13 middle.
[0069] Figures 34A-34M JX inhibited tumor growth by increasing T cell infiltration and regulating myeloid cells. Mice bearing Renca tumors were treated with PBS or 1x10 7 pfu of JX were treated 1-3 times it. (AB) Comparison of tumor growth in mice treated with JX. Average (A) and individual (B) tumor growth curves over time. (CD) CD8 + Representative images of T cells (C) and comparison (D). (E) shows CD8 + and CD4 + Representative flow cytometry plots of the T cell fraction. (F) CD8 T cells per gram of tumor calculated by flow cytometry + and CD4 + (G) The absolute number of T cells in tumors treated with three doses of JX + 、CD8 + and CD4 + Comparison of the fractions of CD4 in tumors. + Foxx3 + CD25 + (Treg) fraction, CD8 / Treg ratio, CD8 + ICOS + and CD8 + G JZ + (K) CD11b in tumors + Grl + Comparison of myeloid cell fractions. (L) shows CD11b in tumors + Representative flow cytometry images of myeloid cell fractions. (M) Regarding CD11b in tumors + Ly6G- Ly6C + Mononuclear myeloid cells, Ly6G + Ly6C int Comparison of the fraction of granulocytic myeloid cells and the ratio of monocytes to granulocytes. Unless otherwise stated, n = 5-6 per group. Values are mean ± SEM. *p < 0.05 relative to control; # Relative to JXx1, p < 0.05; $ p<0.05 relative to JXX2. ns, not significant. Scale bar, 100 μm. Some data are also shown in Figure 19-21 middle.
[0070] Figures 35A-35F Intratumoral injection of JX induces CD8 + Lymphocyte infiltration. Mice were injected sc with Renca in the right flank and subcutaneously with Renca or CT26 tumors in the left flank. Arrows indicate intratumoral (it) JX treatment. (A) Schematic diagram of tumor implantation and treatment and growth curves of JX-injected and uninjected Renca tumors. (B-C) CD8 + Representative images of T cells (green) (B) and contrast (C). (D) Schematic diagram of implantation and treatment of Renca tumors injected with JX and CT26 tumors without injection, as well as growth curves. (EF) CD8 + Representative images of T cells (green) (E) and controls (F). Unless otherwise indicated, n = 5 per group. Values are mean ± SEM. *p < 0.05 relative to control, ns, not significant. Scale bar, 50 μm.
[0071] Figures 36A-36E Antitumor immunity plays an important role in the overall efficacy of JX. Mice were implanted with Renca sc and treated with JX iteratively or with depleting antibodies i.p. for CD8 + 、CD4 + T cells or mouse GM-CSF. (A) Treatment regimen. (BC) Comparison of tumor growth in mice treated with JX or depleting antibodies. Average (B) and individual (C) tumor growth curves over time. *p < 0.05 relative to control; $ p<0.05 vs. aGM-CSF. (DE) CD8 per gram of tumor treated with JX and immune cell depleting antibodies + (D) and CD4 +(E) Absolute number of T cells. Unless otherwise stated, n = 7-8 for each group. Values are mean ± SEM. *p < 0.05 relative to control; # Relative to VX, p < 0.05; $ p < 0.05 vs. aGM-CSF. ns, not significant.
[0072] Figures 37A-37E Combination therapy of JX and αPD-1 synergistically induces CD8 + T cell-mediated tumor immunity. Mice bearing Renca tumors were treated with PBS, JX, αPD-1 antibody, or JX + αPD-1 antibody. (AB) Comparison of tumor growth in mice treated with JX and / or αPD-1 antibody. Average (A) and individual (B) tumor growth curves over time. (CD) CD8 + T cells, CD31 + Blood vessels, activated caspase 3 (Casp3) + Apoptotic cells and PD-L1 + Representative images of cells (C) and comparison (D). (E) Graph depicting overcoming the immunosuppressive TME by combined treatment with JX and αPD-1 blockade. n = 7 per group unless otherwise stated. Values are mean ± SEM. *p < 0.05 relative to control; # Relative to JX, p < 0.05; $ p<0.05 relative to αPD-1. ns, not significant. Scale bar, 100 μm. Some data are also shown in Figure 19-21 middle.
[0073] Figures 38A-38F . The efficacy of combined immunotherapy with intratumoral JX and systemic ICI is largely unaffected by treatment schedule. Mice were implanted with Renca tumors sc and treated with JX+ICI on various schedules. (A) Diagram depicting various treatment schedules. Arrows indicate treatment with it-delivered JX (red arrows) or systemically delivered immune checkpoint blockers (blue arrows). (BC) Comparison of tumor growth in mice treated with JX and αPD-1 antibody using different schedules. Average (B) and individual (C) tumor growth curves over time. (D) Tumor-infiltrating CD8 + and CD4 + Representative flow cytometry plots of the T cell fraction. (EF) CD8 + 、CD4 + 、CD8 + ICOS + and CD8 + G JZ+ Comparison of absolute number of cells. Unless otherwise stated, n=7 per group. Values are mean±SEM. *p<0.05 relative to control, ns, not significant.
[0074] Figures 39A-39E . The triple combination of JX, αPD-1, and αCTLA-4 antibodies caused complete regression and improved overall survival. Mice were implanted with Renca tumors sc and treated with JX in the presence or absence of immune checkpoint blockers against PD-1 and CTLA-4. (AB) Comparison of tumor growth in mice treated with JX and / or immune checkpoint blockers. Average (A) and individual (B) tumor growth curves over time. (C) Waterfall plot showing the maximum percentage change in tumor size from baseline. (D) Kaplan-Meier plot of overall survival. (E) Comparison of tumor size after re-challenge with Renca tumor cells in mice with complete tumor regression. Unless otherwise stated, n=8 per group. *p<0.05 relative to control; # Relative to JX, p < 0.05; $ Relative to αPD-1+αCTLA-4, p<0.05. ns, not significant. Some data are also shown in Fig.23 and 24 middle.
[0075] Figures 40A-40L . Triple therapy delays tumor growth and metastasis in a spontaneous breast cancer model. Tumor growth of spontaneous mammary tumors in MMTV-PyMT mice was analyzed weekly starting at 9 weeks after birth. Samples were collected at 13 weeks after birth. (A) Diagram depicting the treatment schedule. Arrows indicate treatment with JX delivered it or systemic delivery of αPD-1 and αCTLA-4 antibodies. (B) Representative images showing the gross appearance of tumors. Dashed circles delineate palpable mammary tumor nodules. (C) Comparison of total tumor burden. Tumor burden was calculated by adding the volume of each tumor nodule for each mouse. (D) Comparison of the number of palpable tumor nodules. (E) Comparison of the volume of each tumor nodule. Each tumor nodule in MMTV-PyMT mice was plotted as a single point. (F) Kaplan-Meier curve for overall survival. (G) Tumor sections with H&E showing intratumoral areas. The acinar structures in the JX and JX+P+C groups are early, less invasive lesions (Ea), which show a clear boundary with the surrounding mammary adipose tissue (Adi). In contrast, the invasive ductal carcinoma areas (Ca) in Cont and P+C have extensively invaded the surrounding tissue and formed solid sheets of tumor cells without residual acinar structures. Scale bar, 200 μm. (HJ) CD8 + T cells (H and I) and CD31+ Representative images and comparison of tumor vessels (H and J). (K) Representative lung sections stained with H&E. Arrows indicate metastases. Scale bar, 200 μm. (L) Comparison of the number of metastases per lung section. Unless otherwise indicated, n = 6-7 per group. Values are mean ± SEM. *p < 0.05 compared with control; # Compared with JX, p < 0.05; $ Compared with αPD-1+αCTLA-4, p<0.05. ns, not significant. Scale bar, 100 μm.
[0076] Fig.41 . No vaccinia virus was detected in distant tumors. Although robust vaccinia virus (VV) replication (green) was observed in the injected tumor on the right, no vaccinia virus was detected in the non-injected tumor on the left. Scale bar, 100 μm.
[0077] Figures 42A-42H . Combination therapy of JX and αCTLA-4 synergistically elicits CD8+ T cell-mediated tumor immunity. Mice bearing Renca tumors were treated with PB, JX, αCTLA-4 antibody, or JX+αCTLA-4 antibody. (AB) Comparison of tumor growth in mice treated with JX and / or αCTLA-4 antibody. Average (A) and individual (B) tumor growth curves over time. (CE) Images and comparison of CD8+ T cells (C and D) and CD31+ blood vessels (C and E) in tumors. (FH) Absolute numbers of CD45+ immune cells (F), CD8+ T cells (G), and CD4+ cells (H) per gram of tumors treated with JX and / or αCTLA-4 antibody. Values are mean ± SEM. *p < 0.05 compared with control; # p<0.05 vs. JX; $p<0.05 vs. αCTLA-4. ns, not significant. Scale bar, 100 μm.
[0078] Figures 43A-43E . Regardless of the treatment regimen, JX can enhance anti-cancer efficacy through the immune response of αCTLA-4. (AB) Comparison of tumor growth in mice treated with JX and αCTLA-4 antibody using different time regimens. Average (A) and single (B) tumor growth curves over time. (C) Representative flow cytometer graphs of tumor-infiltrating CD8+ and CD4+ T cell fractions in tumors are shown. (DE) Absolute number of CD8+, CD4+, CD8+ICOS+ and CD8+GzB+ cells per gram of tumor treated with JX and αCTLA-4 antibody. Values are mean ± SEM. *p<0.05, ns, not significant compared to control. Some data are also shown in Figure 38. DETAILED DESCRIPTION
[0079] I. Select Definition
[0080] When used in the claims and / or specification, the terms "inhibit," "reduce," or "prevent" or any variation of these terms includes any measurable decrease or complete inhibition to achieve the desired result.
[0081] As used herein, the term "combination" refers to the combined administration of anticancer agents, i.e., oncolytic vaccinia viruses and immune checkpoint inhibitors, which can be administered independently or by different fixed combinations of different amounts of combination partners. The term "combination" also defines a "kit" comprising combination partners to be administered simultaneously. Preferably, the time interval between the continuous simultaneous administration of the combination partners is selected so that the combination of agents exhibits a synergistic effect. As used herein, the term "synergistic" or "synergistic" refers to the effect achieved with the combination of anticancer agents encompassed by the present invention being greater than the sum of the effects produced by using anticancer agents (i.e., oncolytic vaccinia viruses and immune checkpoint inhibitors) as monotherapy. Advantageously, this synergy provides greater efficacy at the same dose, and / or prevents or delays the formation of multidrug resistance.
[0082] As used herein, the term "refractory cancer" refers to a cancer that does not respond favorably to anti-tumor therapy, or a cancer that recurs or relapses after a favorable response to anti-tumor therapy. Therefore, as used herein, "refractory cancer" refers to a cancer that does not respond favorably to or is resistant to anti-tumor therapy, or a cancer that recurs or relapses after a favorable response to treatment. For example, such prior treatment may be a chemotherapy regimen, or may be an immunotherapy regimen (including administration of a monoclonal antibody that specifically binds to PD-1, PD-L1, or CTLA4).
[0083] When used in conjunction with the term "comprising" in the claims and / or the specification, the use of the terms "a" or "an" may mean "one", but is also consistent with the meaning of "one or more", "at least one", and "one or more than one".
[0084] It is contemplated that any implementation discussed herein can be implemented with respect to any method or composition of the invention, and vice versa.In addition, the compositions and kits of the invention can be used to implement the methods of the invention.
[0085] Throughout this application, the term "about" is used to indicate a value that includes the standard deviation of error for the device or method being employed to determine the value.
[0086] Unless explicitly stated to refer to only alternatives or the alternatives are mutually exclusive, the term "or" used in the claims is used to mean "and / or," although the present disclosure supports a definition that refers only to alternatives and "and / or."
[0087] As used in this specification and claims, the words "comprising" (and any forms of comprising, such as "comprise" and "comprises"), "having" (and any forms of having, such as "have" and "has"), "including" (and any forms of including, such as "includes" and "include"), or "containing" (and any forms of containing, such as "contains" and "contain") are inclusive or open-ended, and do not exclude additional unrecited elements or method steps.
[0088] Through the following detailed description, other purposes, features and advantages of the present invention will become apparent. However, it should be understood that although the detailed description and specific examples indicate specific embodiments of the present invention, they are only given by way of illustration, because from this detailed description, various changes and modifications within the spirit and scope of the present invention will become apparent to those skilled in the art.
[0089] It has been found that the combined treatment with oncolytic vaccinia virus and checkpoint inhibitors can produce unexpected improvements in cancer treatment. When the agent is administered simultaneously and the oncolytic vaccinia virus is administered, these agents interact and even synergize to provide significantly improved anti-tumor effects compared to the single administration of any one agent. Surprisingly, if the agents are administered sequentially, these effects are not significantly observed. In some embodiments, when the replicating oncolytic virus is administered intratumorally, the combined therapy produces a synergistic effect. In some embodiments, when the replicating oncolytic virus is administered intravenously, the combined therapy produces a synergistic effect. In some embodiments, when the replicating oncolytic virus is administered intraperitoneally, the combined therapy produces a synergistic effect. In some embodiments, when the replicating oncolytic virus is delivered only by intratumoral administration. In some embodiments, when the replicating oncolytic virus is delivered only by intra-arterial administration. In some embodiments, the checkpoint inhibitor is administered systemically. In some embodiments, when the replicating oncolytic virus is administered intratumorally and the checkpoint inhibitor is administered systemically, the combined therapy produces a synergistic effect. In some embodiments, when the replicative oncolytic virus is administered intratumorally and the checkpoint inhibitor is administered systemically, the combination therapy produces a synergistic effect. In some embodiments, when the replicative oncolytic virus is administered intraperitoneally and the checkpoint inhibitor is administered systemically, the combination therapy produces a synergistic effect. In some embodiments, when the replicative oncolytic virus is administered intraarterially and the checkpoint inhibitor is administered systemically, the combination therapy produces a synergistic effect.
[0090] The further discovery that oncolytic vaccinia virus upregulates the expression of checkpoint proteins such as PD-1, PD-L1, CTLA-4, TIM3, LAG3 and TIGIT in human tumors, thereby sensitizing the tumors to treatment with checkpoint inhibitors, supports the present combination therapy not only in patients with tumors expressing the checkpoint inhibitors of the combination but also in patients with tumors that do not express the checkpoint inhibitors of the combination or express relatively low levels of checkpoint inhibitors.
[0091] In some embodiments, a combination therapy for treating and / or preventing cancer and / or establishing metastasis in a mammal (preferably a human) is provided, comprising administering (i) a replication-competent oncolytic vaccinia virus and (ii) one or more immune checkpoint inhibitors to the mammal simultaneously. In some embodiments, the replication-competent oncolytic vaccinia virus is administered intratumorally. In some embodiments, the replication-competent oncolytic vaccinia virus is administered intravenously. In some embodiments, the replication-competent oncolytic vaccinia virus is administered only intratumorally. In some embodiments, the replication-competent oncolytic vaccinia virus is administered only intraarterially. In some embodiments, when the replicative oncolytic virus is administered intraperitoneally, the combination therapy produces a synergistic effect. In some embodiments, the checkpoint inhibitor is administered systemically. In some embodiments, the replicative oncolytic virus is administered intratumorally, while the checkpoint inhibitor is administered systemically. In some embodiments, the replicative oncolytic virus is administered intratumorally, while the checkpoint inhibitor is administered systemically. In some embodiments, the replicative oncolytic virus is administered intraperitoneally, while the checkpoint inhibitor is administered systemically. In some embodiments, the replicative oncolytic virus is administered intraperitoneally, while the checkpoint inhibitor is administered systemically. In some embodiments, the replicative oncolytic virus is administered intraarterially, while the checkpoint inhibitor is administered systemically.
[0092] Ⅱ. Oncolytic vaccinia virus
[0093] Vaccinia virus is a large, complex enveloped virus with a linear double-stranded DNA genome of about 190K bp and encoding about 250 genes. Vaccinia is well known for its use as a vaccine to eradicate smallpox. After smallpox was eradicated, scientists have been exploring the use of vaccinia as a tool for delivering genes into biological tissues (gene therapy and genetic engineering). Vaccinia virus is unique among DNA viruses because it replicates only in the cytoplasm of host cells. Therefore, a large genome is required to encode various enzymes and proteins required for viral DNA replication. During replication, vaccinia produces several different infection forms with different outer membranes: intracellular mature virions (EVIV), intracellular enveloped virions (TEV), cell-associated enveloped virions (CEV) and extracellular enveloped virions (EEV). EVIV is the most abundant infection form and is considered to be the cause of transmission between hosts. On the other hand, CEV is considered to play a role in cell-to-cell transmission, while EEV is considered to be important for long-distance transmission in the host organism.
[0094] Any known vaccinia virus oncolytic strain can be administered simultaneously with a checkpoint inhibitor according to the methods described herein. In a preferred embodiment, the replicative oncolytic vaccinia virus is a Copenhagen strain, a Western Reserve strain, a Lister strain, or a Wyeth strain, most preferably a Western Reserve strain or a Wyeth strain. The genome of the Western Reserve vaccinia vaccine strain has been sequenced (accession number AY243312). In some embodiments, the replicative oncolytic vaccinia virus is a Copenhagen strain. In some embodiments, the replicative oncolytic vaccinia virus is a Western Reserve strain. In some embodiments, the replicative oncolytic vaccinia virus is a Lister strain. In some embodiments, the replicative oncolytic vaccinia virus is a Wyeth strain.
[0095] Replicative oncolytic vaccinia viruses can be engineered to lack one or more functional genes to improve the cancer selectivity of the virus. In some preferred embodiments, oncolytic vaccinia viruses are engineered to lack thymidine kinase (TK) activity. TK-deficient vaccinia viruses require thymidine triphosphate for DNA synthesis, so that they are preferentially replicated in dividing cells (especially cancer cells). On the other hand, oncolytic vaccinia viruses can be engineered to lack vaccinia growth factor (VGF). This secreted protein is produced early in the infection process and can be used as a mitogen to trigger infection of surrounding cells. On the other hand, oncolytic vaccinia viruses can be engineered to lack VFG and TK activity. In other aspects, oncolytic vaccinia viruses can be engineered to lack one or more genes involved in escaping host interferon (IFN) responses, such as E3L, K3L, B18R or B8R. In some preferred embodiments, replicative oncolytic vaccinia viruses are Western Reserve strains, Copenhagen strains, Lister strains or Wyeth strains, and lack functional TK genes. In other embodiments, the oncolytic vaccinia virus is a Western Reserve strain, Copenhagen strain, Lister strain, or Wyeth strain lacking a functional B18R and / or B8R gene. In some embodiments, the replicating oncolytic vaccinia virus is a Western Reserve strain, a Copenhagen strain, a Lister strain, or a Wyeth strain, and lacks a functional TK gene. In some embodiments, the replicating oncolytic vaccinia virus is a Western Reserve strain, and lacks a functional TK gene. In some embodiments, the replicating oncolytic vaccinia virus is a Copenhagen strain, and lacks a functional TK gene. In some embodiments, the replicating oncolytic vaccinia virus is a Lister strain, and lacks a functional TK gene. In some embodiments, the replicating oncolytic vaccinia virus is a Wyeth strain, and lacks a functional TK gene. In some embodiments, the oncolytic vaccinia virus is a Western Reserve strain, a Copenhagen strain, a Lister strain, or a Wyeth strain lacking a functional B18R and / or B8R gene. In some embodiments, the oncolytic vaccinia virus is a Western Reserve strain lacking a functional B18R and / or B8R gene. In some embodiments, the oncolytic vaccinia virus is a Copenhagen strain lacking a functional B18R and / or B8R gene. In some embodiments, the oncolytic vaccinia virus is a Lister strain lacking a functional B18R and / or B8R gene. In some embodiments, the oncolytic vaccinia virus is a Wyeth strain lacking a functional B18R and / or B8R gene.In some embodiments, the replicating oncolytic vaccinia virus is a Western Reserve strain, a Copenhagen strain, a Lister strain, or a Wyeth strain, and lacks a functional TK gene and lacks a functional B18R and / or B8R gene. In some embodiments, the replicating oncolytic vaccinia virus comprises a functional 14L and / or F4L gene. In some embodiments, the replicating oncolytic vaccinia virus does not express a chemokine (e.g., the vaccinia virus does not express CXCL-11).
[0096] In some embodiments, the replicative oncolytic vaccinia virus of the composition comprises a functional 14L and / or F4L gene.
[0097] In other embodiments, the replicating oncolytic vaccinia virus of the composition does not express a chemokine (eg, the vaccinia virus does not express CXCL-11).
[0098] Heterologous sequences (e.g., encoding cytokines and / or tumor antigens) can be placed under the control of a vaccinia promoter and integrated into the genome of the vaccinia virus. Alternatively, expression of heterologous sequences can be achieved by transfecting a shuttle vector or plasmid containing a vaccinia promoter control sequence (such as those in Table 1 of Current Techniques in Molecular Biology (Ed. Ausubel et al.) Unit 16.17.4 (1998)) into cells infected with vaccinia virus and introducing the heterologous sequence by homologous recombination. When high levels of expression are required, strong late vaccinia promoters are preferred. Early and mid promoters can also be used. In some embodiments, the heterologous sequence is under the control of a vaccinia promoter containing early and late promoter elements. Suitable early promoters include, but are not limited to, promoters of vaccinia genes encoding 42K, 19K, or 25K polypeptides. Suitable early late promoters include, but are not limited to, promoters of vaccinia genes encoding 7.5K polypeptides. Suitable late promoters include, but are not limited to, promoters of vaccinia virus genes encoding 11K or 28K polypeptides. In a related embodiment, heterologous sequences are inserted into the TK and / or VGF sequences to inactivate the TK and / or VGF sequences.
[0099] In some embodiments, the replicative oncolytic vaccinia virus described herein is administered in combination with one or more checkpoint inhibitors. In some embodiments, the replicative oncolytic vaccinia virus described herein is administered intratumorally in combination with one or more checkpoint inhibitors. In some embodiments, the replicative oncolytic vaccinia virus described herein is administered intravenously (IV; or intravascularly) in combination with one or more checkpoint inhibitors. In some embodiments, the replicative oncolytic vaccinia virus described herein is administered intraperitoneally (IP) in combination with one or more checkpoint inhibitors. In some embodiments, the replicative oncolytic vaccinia virus described herein is administered intraarterially in combination with one or more checkpoint inhibitors. In some embodiments, the replicative oncolytic virus is delivered only by intratumoral administration. In some embodiments, the replicative oncolytic virus is administered intratumorally, and the checkpoint inhibitor is administered systemically. In some embodiments, the replicative oncolytic virus is administered intravenously, and the checkpoint inhibitor is administered systemically. In some embodiments, the replicative oncolytic virus is administered intraperitoneally, and the checkpoint inhibitor is administered systemically. In some embodiments, the replicative oncolytic virus is administered intraarterially, and the checkpoint inhibitor is administered systemically. In some embodiments, the replicative oncolytic virus is administered intraarterially, and the checkpoint inhibitor is administered systemically. Administration within a tumor generally requires injection into a tumor mass or a vasculature associated with the tumor. In some aspects, the tumor is imaged before or during administration of the virus. Intravascular administration generally requires injection into the vascular system and is a form of systemic administration. Intraperitoneal administration generally requires injection into the peritoneum (e.g., body cavity). In some embodiments, the replicative oncolytic vaccinia virus described herein is administered in combination with one or more checkpoint inhibitors, and both are administered systemically, for example, by IV administration. In some embodiments, the replicative oncolytic vaccinia virus described herein is co-administered with one or more checkpoint inhibitors, wherein the replicative oncolytic vaccinia virus is administered intratumorally, and one or more checkpoint inhibitors are administered systemically, for example, by IV administration. In some embodiments, the replicative oncolytic vaccinia virus described herein is co-administered with one or more checkpoint inhibitors, wherein the replicative oncolytic vaccinia virus is administered intraperitoneally, and one or more checkpoint inhibitors are administered systemically, for example, by IV administration. In some embodiments, the replicating oncolytic vaccinia virus described herein is administered in combination with one or more checkpoint inhibitors, wherein the replicating oncolytic vaccinia virus is administered intra-arterially and the one or more checkpoint inhibitors are administered systemically, e.g., by IV administration.
[0100] The oncolytic vaccinia virus described herein can be administered once or multiple times (e.g., 2, 3, 4, 5, 6, 7, 8 or more times). The virus can be administered at 1×10 5 Plaque forming units (PFU), 5×10 5 PFU, 1×10 6 PFU, at least 1×10 6PFU, 5×10 6 or about 5×10 6 PFU, 1×10 7 , at least 1×10 7 PFU, 1×10 8 or about 1×10 8 PFU, at least 1×10 8 PFU, about or at least 5x10 8 PFU, 1x10 9 PFU or at least 1x10 9 PFU, 5x10 9 PFU or at least 5x10 9 PFU, 1x10 10 PFU or at least 1x10 10 PFU, 5x10 10 PFU or at least 5x10 10 PFU, 1×10 11 or at least 1×10 11 , 1×10 12 or at least 1×10 12 , 1×10 13 or at least 1×10 13 For example, the virus may be administered at a dose of about 10 6 -10 13 pfu, about 10 7 -10 13 pfu, about 10 8 -10 13 pfu, about 10 9 -10 12 pfu, about 10 8 -10 12 pfu, about 10 7 -10 12 pfu, about 10 6 -10 12 pfu, about 10 6 -10 9 pfu, about 10 6 -10 8 pfu, about 10 7 -10 10 pfu, about 10 7 -10 9 pfu, about 10 8 -10 10 pfu, or about 10 8 -10 9 Preferably, the virus is administered at a dose of at least 10 7 pfu, 10 7 -1010 pfu, 10 7 -10 9 pfu, 10 7 -10 8 pfu, 10 8 -10 10 pfu, 10 8 -10 9 pfu or 10 9 -10 10 pfu doses were administered.
[0101] It is contemplated that a single dose of the virus refers to the amount administered to a subject or tumor within 0.1, 0.5, 1, 2, 5, 10, 15, 20, or 24 hours (including all values therebetween). The dose can be distributed over time or injected alone. Typically, multiple doses are administered to the same general target area, such as near a tumor. In certain aspects, the viral dose is delivered by an injection device that includes multiple ports in a syringe or a single-port needle or a single needle or multiple tips connected to a syringe, or a combination thereof. A single dose of vaccinia virus or multiple doses may be administered during a treatment period that includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 weeks or more. For example, vaccinia virus may be administered every other day, every week, every other week, every three weeks, for 1, 2, 3, 4, 5, 6 months or more.
[0102] Vaccinia virus can be propagated using the methods described by Earl and Moss in Ausubel et al., 1994 or by the methods described in WIPO Publication No. WO2013 / 022764 (both of which are incorporated herein by reference).
[0103] III. Immune checkpoint inhibitors (ICIs)
[0104] Immune checkpoint proteins interact with specific ligands that send signals to T cells that inhibit T cell function. Cancer cells take advantage of this by driving high levels of checkpoint proteins on their surface, thereby suppressing anti-cancer immune responses.
[0105] The immune checkpoint inhibitor (also referred to as ICI) used in the drug combination described herein is any compound that can inhibit the function of immune checkpoint protein. Inhibition includes reduced function and complete blocking. In particular, immune checkpoint protein is human checkpoint protein. Therefore, immune checkpoint inhibitor is preferably an inhibitor of human immune checkpoint.
[0106] Checkpoint proteins include, but are not limited to, CTLA-4, PD-1 (and its ligands PD-L1 and PD-L2), B7-H3, B7-H4, HVEM, TIM3, GAL9, LAG3, VISTA, KIR, BTLA, TIGIT and / or IDO. Pathways involving LAG3, BTLA, B7-H3, B7-H4, TIM3 and KIR are recognized in the art as constituting immune checkpoint pathways similar to CTLA-4 and PD-1 dependent pathways (see, e.g., Pardoll, 2012, Nature Rev Cancer 12:252-264; Mellman et al., 2011, Nature 480:480-489). In some embodiments, the immune checkpoint inhibitor is an inhibitor of CTLA-4, PD-1 (and its ligands PD-L1 and PD-L2), B7-H3, B7-H4, HVEM, TIM3, GAL9, LAG3, VISTA, KIR, BTLA, TIGIT and / or IDO. In some embodiments, the immune checkpoint inhibitor is an inhibitor of PD-1, PD-L1, CTLA-4, LAG3, TIGIT and / or TIM3. In some embodiments, the immune checkpoint inhibitor is an inhibitor of PD-1. In some embodiments, the immune checkpoint inhibitor is an inhibitor of PD-L1. In some embodiments, the immune checkpoint inhibitor is a CTLA-4 inhibitor. In some embodiments, the immune checkpoint inhibitor is an inhibitor of TIGIT. In some embodiments, the immune checkpoint inhibitor is an inhibitor of LAG3. In some embodiments, the immune checkpoint inhibitor is an inhibitor of TIM3.
[0107] In some embodiments, the immune checkpoint inhibitor of the composition is an antibody. As used herein, the term "antibody" includes naturally occurring and engineered antibodies and full-length antibodies or their functional fragments or analogs, which can bind to, for example, target immune checkpoints or epitopes (e.g., retaining antigen binding moieties). The antibodies used according to the methods described herein can be from any source, including but not limited to human, humanized, animal or chimeric antibodies, and can be any isotype, preferably IgG1 or IgG4 isotypes, and can also be glycosylated or non-glycosylated. The term antibody also includes bispecific or multispecific antibodies, as long as the antibody shows the binding specificity described herein.
[0108] Humanized antibodies refer to non-human (e.g., mouse, rat, etc.) antibodies whose protein sequences have been modified to increase similarity to human antibodies. Chimeric antibodies refer to antibodies that contain one or more elements from one species and one or more elements from another species, such as a non-human antibody that contains at least a portion of a human immunoglobulin constant region (Fc).
[0109] Various forms of antibodies can be engineered for use in the compositions of the present invention, representative examples of which include Fab fragments (monovalent fragments consisting of VL, VH, CL and CH1 domains), F(ab')2 fragments (bivalent fragments comprising two Fab fragments connected by at least one disulfide bond in the hinge region), Fd fragments (consisting of VH and CHI domains), Fv fragments (consisting of the VL and VH domains of a single arm of an antibody), dAb fragments (consisting of a single variable domain fragment (VH or VL domain)), single-chain Fv (scFv) (comprising two domains of the Fv fragment (VL and VH, which are fused together to ultimately form a single-chain protein with a linker)).
[0110] In some embodiments, the immune checkpoint protein inhibitor (also referred to as ICI) of the combined therapy is an antibody or fragment thereof that specifically binds to an immune checkpoint protein, which is selected from the group consisting of the following items: CTLA4, PD-1, PD-L1, PD-L2, B7-H3, B7-H4, TIM3, GAL9, LAG3, VISTA, KIR, BTLA and TIGIT. In a particularly preferred embodiment, the immune checkpoint inhibitor is a monoclonal antibody, a fully human antibody, a chimeric antibody, a humanized antibody or a fragment thereof that can at least partially antagonize CTLA4, PD-1, PD-L1, PD-L2, TIM3, LAG3 or TIGIT. In some embodiments, the immune checkpoint protein inhibitor of the combined therapy is an antibody or fragment thereof that specifically binds to CTLA4. In some embodiments, the immune checkpoint protein inhibitor of the combined therapy is an antibody or fragment thereof that specifically binds to PD-1. In some embodiments, the immune checkpoint protein inhibitor of the combined therapy is an antibody or fragment thereof that specifically binds to PD-L1. In some embodiments, the immune checkpoint protein inhibitor of the combination therapy is an antibody or fragment thereof that specifically binds to PD-L2. In some embodiments, the immune checkpoint protein inhibitor of the combination therapy is an antibody or fragment thereof that specifically binds to B7-H3. In some embodiments, the immune checkpoint protein inhibitor of the combination therapy is an antibody or fragment thereof that specifically binds to B7-H4. In some embodiments, the immune checkpoint protein inhibitor of the combination therapy is an antibody or fragment thereof that specifically binds to TIM3. In some embodiments, the immune checkpoint protein inhibitor of the combination therapy is an antibody or fragment thereof that specifically binds to GAL9. In some embodiments, the immune checkpoint protein inhibitor of the combination therapy is an antibody or fragment thereof that specifically binds to LAG3. In some embodiments, the immune checkpoint protein inhibitor of the combination therapy is an antibody or fragment thereof that specifically binds to VISTA. In some embodiments, the immune checkpoint protein inhibitor of the combination therapy is an antibody or fragment thereof that specifically binds to KIR. In some embodiments, the immune checkpoint protein inhibitor of the combination therapy is an antibody or fragment thereof that specifically binds to BTLA. In some embodiments, the immune checkpoint protein inhibitor of the combination therapy is an antibody or fragment thereof that specifically binds to TIGIT.
[0111] In some embodiments, the pharmaceutical composition comprises a Western Reserve, Wyeth, Lister or Copenhagen vaccinia virus strain and a CTLA-4 inhibitor, preferably a monoclonal antibody that specifically binds to (and inhibits) CTLA-4. The complete human CTLA-4 nucleic acid sequence can be found according to GenBank accession number LI 5006. Monoclonal antibodies that specifically bind to CTLA4 include, but are not limited to, ipilimumab ( BMS) and tesimumab (AstraZeneca / MedImmune) and antibodies disclosed in U.S. Patent Application Publication Nos. 2005 / 0201994, 2002 / 0039581, and 2002 / 086014 (the contents of each of which are incorporated herein by reference) and U.S. Patent Nos. 5,811,097, 5,855,887, 6,051,22 7, 6,984,720, 6,682,736, 6,207,156, 5,977,318, 6,682,736, 7,109,003, 7,132,281, and 8,491,895 (the contents of each of which are incorporated herein by reference), or an antibody comprising the heavy and light chain variable regions of any of these antibodies.
[0112] In some embodiments, the pharmaceutical composition comprises a Western Reserve, Wyeth, Lister or Copenhagen vaccinia virus strain and a PD-1 inhibitor, preferably a monoclonal antibody that specifically binds to (and inhibits) PD-1. The complete nucleotide and amino acid sequences of human PD-1 can be found according to GenBank accession numbers U64863 and NP_005009.2. Monoclonal antibodies against PD-1 include, but are not limited to, lanrolizumab (disclosed, for example, as hPD109A and its humanized derivatives h409A1, h409A16 and h409A17 in U.S. Pat. No. 8,354,509, which are incorporated herein by reference), nivolumab ( Bristol-Myers Squibb; code name BMS-936558) disclosed in U.S. Pat. No. 8,008,449, which is incorporated herein by reference, pembrolizumab and Pidilizumab (CT-011; disclosed in Rosenblatt et al., Immunother. 34:409-418 (2011)) or antibodies comprising the heavy chain region and light chain region of these antibodies. Other anti-PD-1 antibodies are described in, for example, WO2004 / 004771, WO2004 / 056875, WO2006 / 121168, WO2008 / 156712, WO2009 / 014708, WO2009 / 114335, WO2013 / 043569, and WO2014 / 047350. In a related embodiment, the checkpoint inhibitor of the pharmaceutical composition is an anti-PD-1 fusion protein, such as AMP-224 (composed of the extracellular domain of PD-L2 and the Fc region of human IgG1).
[0113] In some embodiments, the pharmaceutical composition comprises a Western Reserve, Wyeth, Lister, or Copenhagen vaccinia virus strain and a PD-L1 inhibitor, preferably a monoclonal antibody that specifically binds to (and inhibits) PD-L1. Monoclonal antibodies against PD-L1 include, but are not limited to, pembrolizumab (MK-3475, disclosed in WO2009 / 114335), BMS-936559 (MDX-1105), atezolizumab (Genentech / Roche; MPDL33280A, disclosed in U.S. Pat. No. 8,217,149, the contents of which are incorporated herein by reference, durvalumab (AstraZeneca / MedImmune; MEDI4736), disclosed in U.S. Pat. No. 8,779,108, the contents of which are incorporated herein by reference, MIH1 (Affymetrix available through eBioscience (16.5983.82)), and avelumab (MSB0010718C; Merck KGaA) or an antibody comprising the heavy chain and light chain variable regions of any of these antibodies. In a related embodiment, the immune checkpoint inhibitor is an anti-PD-L1 fusion protein, such as the PD-L2-Fc fusion protein known as AMP-224 (disclosed in Mkritchyan M. et al., Journal of Immunology (J. Immunol.), 189: 2338-47 (2010).
[0114] In some embodiments, the pharmaceutical composition comprises a Western Reserve, Wyeth, Lister, or Copenhagen vaccinia virus strain and a PD-L2 inhibitor such as MIH18 (described in Pfistershammer et al., Eur J Immunol., 36:1104-1113 (2006)).
[0115] In some embodiments, the pharmaceutical composition comprises a Western Reserve, Wyeth, Lister, or Copenhagen vaccinia virus strain and a LAG3 inhibitor, such as soluble LAG3 (IMP321 or LAG3-Ig, disclosed in U.S. Patent Application Publication No. 2011-0008331, incorporated herein by reference, and disclosed in Brignon et al., Clin. Cancer Res. 15:6225-6231 (2009)), IMP701 or other humanized antibodies that block human LAG3 (described in U.S. Patent Application Publication No. 2010-0233183, incorporated herein by reference, U.S. Patent No. 5,773,578, incorporated herein by reference), or BMS-986016 or other fully human antibodies that block LAG3 (described in U.S. Patent Application Publication No. 2011-0150892, incorporated herein by reference)
[0116] In some embodiments, the pharmaceutical composition comprises a Western Reserve, Wyeth, Lister, or Copenhagen vaccinia virus strain and a BLTA inhibitor such as antibody 4C7 disclosed in U.S. Pat. No. 8,563,694, incorporated herein by reference.
[0117] In some embodiments, the pharmaceutical composition comprises a Western Reserve, Wyeth, Lister, or Copenhagen vaccinia virus strain and a B7H4 checkpoint inhibitor, such as an antibody disclosed in U.S. Patent Application Publication No. 2014 / 0294861, incorporated herein by reference, or a soluble recombinant form of B7H4 as disclosed in U.S. Patent Application Publication No. 20120177645, incorporated herein by reference.
[0118] In some embodiments, the pharmaceutical composition comprises a Western Reserve, Wyeth, Lister, or Copenhagen vaccinia virus strain and a B7-H3 checkpoint inhibitor (such as antibody MGA271 disclosed as BRCA84D or a derivative disclosed in U.S. Patent Application Publication No. 20120294796, incorporated herein by reference).
[0119] In some embodiments, the pharmaceutical composition comprises a Western Reserve, Wyeth, Lister, or Copenhagen vaccinia virus strain and a TIM3 checkpoint inhibitor (e.g., an antibody disclosed in U.S. Pat. No. 8,841,418 (incorporated herein by reference) or an anti-human TIM3 blocking antibody F38-2E2 disclosed in Jones et al., J. Exp. Med., 205(12):2763-79 (2008).
[0120] In some embodiments, the pharmaceutical composition comprises a Western Reserve, Wyeth, Lister, or Copenhagen vaccinia virus strain and a KIR checkpoint inhibitor such as the antibody Liriumab (described in Romag et al., Blood, 114(13):2667-2677 (2009)).
[0121] In some embodiments, the pharmaceutical composition comprises Western Reserve, Wyeth, Lister or Copenhagen vaccinia virus strains and TIGIT inhibitors. TIGIT checkpoint inhibitors preferably inhibit the interaction of TIGIT with poliovirus receptor (CD155), and include but are not limited to antibodies targeting human TIGIT (such as those disclosed in U.S. Patent No. 9,499,596 (incorporated herein by reference) and U.S. Patent Application Publication No. 20160355589, No. 20160176963 (incorporated herein by reference)) and poliovirus receptor variants (such as those disclosed in U.S. Patent No. 9,327,014 (incorporated herein by reference)).
[0122] In some embodiments, the pharmaceutical composition comprises Western Reserve, Wyeth, Lister or Copenhagen vaccinia virus strains and an IDO inhibitor. IDO is considered to be an immune checkpoint protein whose expression in tumor cells contributes to immune tolerance by shutting down effector T cells. IDO is considered to contribute to resistance to anti-CLTA-4 therapy. The IDO inhibitors used according to the methods described herein include, but are not limited to, tryptophan mimetics such as D-1MT (D isomers of 1-methyl-DL-tryptophan (MT)), L-1MT (L isomers of MT), MTH-Trp (methylthiohydantoin-dl-tryptophan; IDO transcription inhibitors) and β-carboline, indole mimetics such as naphthoquinone-based agents, S-allyl-brassinonin, S-benzyl-brassinonin, 5-bromo-brassinonin, and phenylimidazole-based agents, 4-phenylimidazole, Exiguamine A, epacadostat, rosmarinic acid, norharman and NSC401366. Preferred IDO inhibitors include INCB 024360 (epatuzumab; 1,2,5-oxadiazole-3-carboximide, 4-((2-(aminosulfonyl)amino)ethyl)amino)-N-(3-bromo-4-fluorophenyl)-N'-hydroxy-, (C(Z))-; Incyte), indoximod (LG2101; D-1MT; NewLink Genetics), IDO peptide vaccine (University of Copenhagen) and NLG919 (NewLink Genetics).
[0123] In some embodiments, the pharmaceutical composition comprises a Western Reserve, Wyeth, Lister or Copenhagen vaccinia virus strain, a PD-1 inhibitor (preferably a monoclonal antibody that specifically binds (and inhibits) PD-1) and a CTLA-4 inhibitor (preferably a monoclonal antibody that specifically binds (and inhibits) CTLA-4). The complete nucleotide and amino acid sequences of human PD-1 can be found according to GenBank accession numbers U64863 and NP_005009.2. Monoclonal antibodies against PD-1 include, but are not limited to, lanrolizumab (e.g., disclosed as hPD109A and its humanized derivatives h409A11, h409A16 and h409A17 in U.S. Pat. No. 8,354,509 (incorporated herein by reference), nivolumab ( Bristol-Myers Squib; code name BMS-936558, disclosed in U.S. Pat. No. 8,008,449 (incorporated herein by reference)), pembrolizumab and pidilizumab (CT-011; disclosed in Rosenblatt et al., Immunother 34:409-418 (2011)) or antibodies comprising the heavy and light chain regions of these antibodies. Other anti-PD-1 antibodies are described in, for example, WO2004 / 004771, WO2004 / 056875, WO2006 / 121168, WO2008 / 156712, WO2009 / 014708, WO2009 / 114335, WO2013 / 043569, and WO2014 / 047350. In a related embodiment, the checkpoint inhibitor of the pharmaceutical composition is an anti-PD-1 fusion protein, such as AMP-224 (composed of the extracellular domain of PD-L2 and the Fc region of human IgG1). The complete human CTLA-4 nucleic acid sequence can be found according to GenBank accession number LI5006. Monoclonal antibodies that specifically bind to CTLA4 include, but are not limited to, ipilimumab ( Nos. 5,811,097, 5,855,887, 6,051,227, 6,984,720, 6,682,736, 6,207,156, 5,977,318, 6,682,736, 7109,003, 7,132,281, and 8,491,895, each of which is incorporated herein by reference, or antibodies comprising the heavy and light chain variable regions of any of these antibodies.
[0124] In some embodiments, the pharmaceutical composition comprises a Western Reserve, Wyeth, Lister or Copenhagen vaccinia virus strain, a PD-L1 inhibitor (preferably a monoclonal antibody that specifically binds to (and inhibits) PD-L1), and a CTLA-4 inhibitor (preferably a monoclonal antibody that specifically binds to (and inhibits) CTLA-4). Monoclonal antibodies against PD-L1 include, but are not limited to, pembrolizumab (MK-3475, disclosed in WO2009 / 114335), BMS-936559 (MDX-1105), atezolizumab (Genentech / Roche; MPDL33280A, disclosed in U.S. Pat. No. 8,217,149 (the contents of which are incorporated herein by reference), durvalumab (AstraZeneca / MedImmune; MEDI4736, disclosed in U.S. Pat. No. 8,779,108 (incorporated herein by reference), MIH1 (Affymetrix available through eBioscience (16.5983.82)), and avelumab (MSB0010718C; Merck KGaA) or an antibody comprising the heavy chain and light chain variable regions of any of these antibodies. In a related embodiment, the immune checkpoint inhibitor is an anti-PD-L1 fusion protein, such as the PD-L2-Fc fusion protein known as AMP-224 (disclosed in Mkritchyan M. et al., Journal of Immunology (J.Immunol.), 189:2338-47 (2010). The complete human CTLA-4 nucleic acid sequence can be found according to GenBank accession number LI 5006. Monoclonal antibodies that specifically bind to CTLA4 include, but are not limited to, ipilimumab ( Nos. 5,811,097, 5,855,887, 6,051,227, 6,984,720, 6,682,736, 6,207,156, 5,977,318, 6,682,736, 7,109,003, 7,132,281, and 8,491,895 (each of which is incorporated herein by reference), or antibodies comprising the heavy and light chain variable regions of any of these antibodies.
[0125] In some embodiments, the pharmaceutical composition comprises a Western Reserve, Wyeth, Lister, or Copenhagen vaccinia virus strain, a PD-1 inhibitor (preferably a monoclonal antibody that specifically binds to (and inhibits) PD-1), and a LAG3 inhibitor (such as soluble LAG3 (IMP321 or LAG3-Ig, disclosed in U.S. Patent Application Publication No. 2011-0008331 (incorporated herein by reference) and Brignon et al., Clin. Cancer Res. Res.)》15:6225-6231 (2009)), IMP701 or other humanized antibodies that block human LAG3 (described in U.S. Patent Application Publication No. 2010-0233183 (incorporated herein by reference), U.S. Patent No. 5,773,578 (incorporated herein by reference)), or BMS-986016 or other fully human antibodies that block LAG3 (described in U.S. Patent Application Publication No. 2011-0150892 (incorporated herein by reference)). The complete nucleotide and amino acid sequence of human PD-1 can be found according to GenBank Accession Nos. U64863 and NP Anti-PD-1 monoclonal antibodies include, but are not limited to, lanrolizumab (disclosed, for example, as hPD109A and its humanized derivatives h409A1, h409A16, and h409A17 in U.S. Pat. No. 8,354,509 (incorporated herein by reference), nivolumab ( Bristol-Myers Squibb; code name BMS-936558), disclosed in U.S. Pat. No. 8,008,449 (incorporated herein by reference), pembrolizumab and pidilizumab (CT-011; disclosed in Rosenblatt et al., Immunother. 34:409-418 (2011)) or antibodies comprising the heavy and light chain regions of these antibodies. Other anti-PD-1 antibodies are described in, for example, WO2004 / 004771, WO2004 / 056875, WO2006 / 121168, WO2008 / 156712, WO2009 / 014708, WO2009 / 114335, WO2013 / 043569, and WO2014 / 047350. In a related embodiment, the checkpoint inhibitor of the pharmaceutical composition is an anti-PD-1 fusion protein, such as AMP-224 (composed of the extracellular domain of PD-L2 and the Fc region of human IgG1).
[0126] In some embodiments, the pharmaceutical composition comprises a Western Reserve, Wyeth, Lister or Copenhagen vaccinia virus strain, a PD-L1 inhibitor (preferably a monoclonal antibody that specifically binds to (and inhibits) PD-L1) and a LAG3 inhibitor (such as soluble LAG3 (IMP321 or LAG3-Ig, disclosed in U.S. Patent Application Publication No. 2011-0008331 (incorporated herein by reference) and Brignon et al., Clin. Cancer Res. Res.)》15:6225-6231 (2009)), IMP701 or other humanized antibodies that block human LAG3 (described in U.S. Patent Application Publication No. 2010-0233183 (incorporated herein by reference), U.S. Patent No. 5,773,578 (incorporated herein by reference)) or BMS-986016 or other fully human antibodies that block LAG3 (described in U.S. Patent Application Publication No. 2011-0150892 (incorporated herein by reference)). Monoclonal antibodies against PD-L1 include but are not limited to pembrolizumab (MK-3475, disclosed in WO2009 / 114335) ), BMS-936559 (MDX-1105), atezolizumab (Genentech / Roche; MPDL33280A), disclosed in U.S. Pat. No. 8,217,149 (the contents of which are incorporated herein by reference), durvalumab (AstraZeneca / Medlmmune; MEDI4736), disclosed in U.S. Pat. No. 8,779,108 (incorporated herein by reference), MIH1 (Affymetrix available through eBioscience (16.5983.82)) and avelumab (MSB0010718C; Merck KGaA), or an antibody comprising the heavy and light chain variable regions of any of these antibodies. In a related embodiment, the immune checkpoint inhibitor is an anti-PD-L1 fusion protein, such as the PD-L2-Fc fusion protein known as AMP-224 (disclosed in Mkritchyan M. et al., J. Immunol., 189:2338-47 (2010).
[0127] In some embodiments, the pharmaceutical composition comprises a Western Reserve, Wyeth, Lister or Copenhagen vaccinia virus strain, a PD-1 inhibitor (preferably a monoclonal antibody that specifically binds to (and inhibits) PD-1) and a TIM3 checkpoint inhibitor (such as an antibody disclosed in U.S. Pat. No. 8,841,418 (incorporated herein by reference) or an anti-human TIM3 blocking antibody F38-2E2 disclosed in Jones et al., Journal of Experimental Medicine (J. Exp. Med.), 205(12): 2763-79 (2008). The complete nucleotide and amino acid sequence of human PD-1 can be found according to GenBank accession numbers U64863 and NP005009.2. Monoclonal antibodies against PD-1 include, but are not limited to, lanrolizumab (disclosed, for example, as hPD109A and its humanized derivatives h409A1, h409A16, and h409A17 in U.S. Pat. No. 8,354,509 (incorporated herein by reference), nivolumab ( Bristol-Myers Squibb; code name BMS-936558), disclosed in U.S. Pat. No. 8,008,449 (incorporated herein by reference), pembrolizumab and pidilizumab (CT-011; disclosed in Rosenblatt et al., Immunother 34:409-418 (2011)) or antibodies comprising the heavy and light chain regions of these antibodies. Other anti-PD-1 antibodies are described in, for example, WO2004 / 004771, WO2004 / 056875, WO2006 / 121168, WO2008 / 156712, WO2009 / 014708, WO2009 / 114335, WO2013 / 043569, and WO2014 / 047350. In a related embodiment, the checkpoint inhibitor of the pharmaceutical composition is an anti-PD-1 fusion protein, such as AMP-224 (composed of the extracellular domain of PD-L2 and the Fc region of human IgG1).
[0128] In some embodiments, the pharmaceutical composition comprises a Western Reserve, Wyeth, Lister or Copenhagen vaccinia virus strain, a PD-L1 inhibitor (preferably a monoclonal antibody that specifically binds to (and inhibits) PD-L1), and a TIM3 checkpoint inhibitor (such as an antibody disclosed in U.S. Pat. No. 8,841,418 (incorporated herein by reference) or the anti-human TIM3 blocking antibody F38-2E2 disclosed in Jones et al., J. Exp. Med., 205(12):2763-79 (2008)). Monoclonal antibodies against PD-L1 include, but are not limited to, pembrolizumab (MK-3475, disclosed in WO2009 / 114335), BMS-936559 (MDX-1105), atezolizumab (Genentech / Roche; MPDL33280A), disclosed in U.S. Pat. No. 8,217,149 (the contents of which are incorporated herein by reference), durvalumab (AstraZeneca / MedImmune; MEDI4736), disclosed in U.S. Pat. No. 8,779,108 (incorporated herein by reference), MIH1 (Affymetrix available through eBioscience (16.5983.82)), and avelumab (MSB0010718C; Merck KGaA), or an antibody comprising the heavy and light chain variable regions of any of these antibodies. In a related embodiment, the immune checkpoint inhibitor is an anti-PD-L1 fusion protein, such as the PD-L2-Fc fusion protein known as AMP-224 (disclosed in Mkritchyan M. et al., J. Immunol., 189:2338-47 (2010)).
[0129] In some embodiments, the pharmaceutical composition comprises Western Reserve, Wyeth, Lister or Copenhagen vaccinia virus strains and TIGIT inhibitors.TIGIT checkpoint inhibitors preferably inhibit the interaction of TIGIT with poliovirus receptor (CD155), including but not limited to antibodies targeting human TIGIT (such as U.S. Patent No. 9,499,596 (incorporated herein by reference) and U.S. Patent Application Publication No. 20160355589, No. 20160176963) and poliovirus receptor variants (such as those disclosed in U.S. Patent No. 9,327,014 (incorporated herein by reference)).
[0130] In some embodiments, the pharmaceutical composition comprises a Western Reserve, Wyeth, Lister, or Copenhagen vaccinia virus strain and an IDO inhibitor (indoleamine-pyrrole 2,3-dioxygenase). IDO inhibitors include metabolic inhibitors, preferably inhibitors that inhibit metabolic pathways, including but not limited to Norharmane (see Chiarugi A et al., "Combined inhibition of indolamine 2,3-dioxygenase and nitric oxide synthase modulates neurotoxin release by interferon-gamma-activated macrophages", Journal of Leukocyte Biology. 68(2):260-6. (2000)), rosmarinic acid (see Lee HJ et al., "Rosmarinic acid inhibits indoleamine 2,3-dioxygenase expression inmurine dendritic cells", Biochemical Pharmacology. Pharmacology. 73(9):1412-21(2007)), COX-2 inhibitors (see Cesario A et al., "The interplay between indoleamine 2,3-dioxygenase 1 (IDO1) and cyclooxygenase (COX)-2 in chronic inflammation and cancer", Current Medicinal Chemistry.18(15):2263-71 (2011)), 1-methyltryptophan (Hou DY et al., “Inhibition of indoleamine 2,3-di oxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses”. Cancer Research. 67(2):792-801 (2007) and Chauhan N et al., (April 2009). “Reassessment of the action mechanism in the heme dioxygenases”. Journal of the American Chemical Society. Society. 131(12):4186-7(2009), including, for example, a specific racemic 1-methyl-D-tryptophan (known as indoximod) (a clinical trial candidate), epacadostat (INCB24360), navoximod (GDC-0919) (see Jochems C et al., "The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells"). cells), "Oncotarget". 7(25):37762-37772. (2016)) and or BMS-986205. In some embodiments, the IDO inhibitor is selected from the group consisting of norharman, rosmarinic acid, COX-2 inhibitors, 1-methyltryptophan, Indoximod, epatostat (INCB24360), navoximod (GDC-0919) and / or BMS-986205.
[0131] Those skilled in the art will appreciate that alternative and / or equivalent names may be used for some of the above antibodies. Such alternative and / or equivalent names are interchangeable in the context of the present invention.
[0132] In some aspects, the pharmaceutical compositions described herein include (i) more than one immune checkpoint inhibitor and (ii) replicative oncolytic vaccinia virus. In a preferred embodiment, the PD-1 inhibitor and the CTLA-4 inhibitor are administered simultaneously with the vaccinia virus. Other examples include, but are not limited to, the simultaneous administration of LAG3 inhibitors and PD-1 inhibitors with vaccinia virus, or the simultaneous administration of LAG3 inhibitors and PD-L1 inhibitors. Other examples include the simultaneous administration of IDO inhibitors and CTLA-4 inhibitors and / or PD-1 inhibitors. In some embodiments, the IDO inhibitor is selected from the group consisting of the following items: norharman, rosmarinic acid, COX-2 inhibitors, 1-methyltryptophan, Indoximod, ipatostat (INCB24360), Navoximod (GDC-0919) and / or BMS-986205.
[0133] IV. Cytokines
[0134] In some embodiments, the replicating oncolytic vaccinia virus of the pharmaceutical composition comprises a heterologous sequence encoding a cytokine, wherein the cytokine is expressed by the virus.
[0135] In some embodiments, a replicating oncolytic vaccinia virus is provided, which is engineered to express a cytokine selected from the group consisting of granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-2 (IL-2), interleukin-4 (IL-4), interleukin-5 (IL-5), interleukin-7 (IL-7), interleukin-12 (IL-12), interleukin-15 (IL-15), interleukin-18 (IL-18), interleukin-21 (IL-21), interleukin-24 (IL-24), interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α). In particularly preferred embodiments, the replicating oncolytic vaccinia virus is a Wyeth, Western Reserve, Copenhagen or Lister strain. In some embodiments, the replicating oncolytic vaccinia virus is engineered to express GM-CSF. In some embodiments, the replicating oncolytic vaccinia virus is engineered to express interleukin-2 (IL-2). In some embodiments, the replicating oncolytic vaccinia virus is engineered to express interleukin-4 (IL-4). In some embodiments, the replicating oncolytic vaccinia virus is engineered to express interleukin-5 (IL-5). In some embodiments, the replicating oncolytic vaccinia virus is engineered to express interleukin-7 (IL-7). In some embodiments, the replicating oncolytic vaccinia virus is engineered to express interleukin-12 (IL-12). In some embodiments, the replicating oncolytic vaccinia virus is engineered to express interleukin-15 (IL-15). In some embodiments, the replicating oncolytic vaccinia virus is engineered to express interleukin-18 (IL-18). In some embodiments, the replicating oncolytic vaccinia virus is engineered to express interleukin-21 (IL-21). In some embodiments, the replicating oncolytic vaccinia virus is engineered to express interleukin-24 (IL-24), interferon-γ (IFN-γ). In some embodiments, the replicating oncolytic vaccinia virus is engineered to express tumor necrosis factor-α (TNF-α). In some embodiments, the replicating oncolytic vaccinia virus is mJX594, which is engineered to express GM-CSF.
[0136] V. Tumor Antigens
[0137] In several embodiments, the replicating oncolytic vaccinia virus comprises a heterologous nucleic acid sequence encoding a tumor antigen and an optional cytokine, wherein the tumor antigen and the optional cytokine are expressed in cells (preferably tumor cells) infected with the virus. Tumor antigens include tumor-specific antigens and tumor-associated antigens. Replication-competent oncolytic vaccinia viruses can express full-length tumor antigens or immunogenic peptides thereof. In some embodiments, cytokines are expressed in cells infected with replicating oncolytic vaccinia viruses. In some embodiments, the replicating oncolytic vaccinia virus comprises a heterologous nucleic acid sequence encoding a tumor antigen and a cytokine, wherein the tumor antigen and the cytokine are expressed in cells infected with replicating oncolytic vaccinia viruses. In some embodiments, the cell is a tumor cell.
[0138] In some embodiments, tumor antigens may include, but are not limited to, MAGE-1, MAGE-3, BAGE, GAGE-1, GAGE-2, N-acetylglucosamine transferase-V, p-15, gp100, MART-1 / MelanA, TRP-1 (gp75), TRP-2, tyrosinase, cyclin-dependent kinase 4, β-catenin, MUM-1, CDK4, HER-2 / neu, human papillomavirus-E6, human papillomavirus E7, CD20, carcinoembryonic antigen (CEA) , epidermal growth factor receptor, MUC-1, caspase-8, CD5, mucin-1, Lewisx, CA-125, p185HER2, IL-2R, Fap-a, tenascin, antigen associated with metalloproteinases, CAMPATH-1, RCC: regulator of G protein signaling 5 (RGS5), surivin (BIRC5 = baculovirus inhibitor of apoptosis 5), insulin-like growth factor binding protein 3 (IGF-BP3), thymidylate synthase (TYMS), hypoxia-inducible protein white 2, hypoxia-induced lipid droplet-associated protein (HIG2), matrix metallopeptidase 7 (MMP7), prune homologous protein 2 (PRUNE2), RecQ protein-like (DNA helicase Q1-like protein) (RecQ1), leptin receptor (LEPR), ERBB receptor feedback inhibitor 1 (ERRFII), lysosomal protein transmembrane protein 4 alpha (LAPTM4A), RABIB, RAS oncogene family (RABIB), cd24, Homo sapiens thymosin beta 4, X-linked (TMSB4X) protein, Homo sapiens S100 calcium binding protein A6 (S100A6), Homo sapiens adenosine A2 receptor (ADORA2B), chromosome 16 open reading frame 61 antibody (C16orf61), ROD1 differentiation regulator 1 (ROD1), NAD-dependent deacetylase deacetylase sirtuin-2 (SIR2L), tubulin alpha 1c (TUBA1C), ATPase inhibitory factor 1 (ATPIF1), stromal antigen 2 (STAG2), and nuclear casein kinase and cyclin-dependent substrate 1 (NUCKS1). In some embodiments, the antigen is an antigen listed in U.S. Pat. No. 9,919,047 (incorporated herein by reference). In some embodiments, the tumor antigen is a renal cell carcinoma tumor antigen.In some embodiments, the renal cell carcinoma tumor antigen is selected from the group consisting of: G-protein signaling regulator 5 (RGS5), Surivin (BIRC5 = baculovirus inhibitor of apoptosis containing repeat structure 5), insulin-like growth factor binding protein 3 (IGF-BP3), thymidylate synthase (TYMS), hypoxia-inducible protein 2, hypoxia-induced lipid droplet-associated protein (HIG2), matrix metallopeptidase 7 (MMP7), prune homologous protein 2 (PRUNE2), RecQ protein-like (DNA helicase Q1-like protein) (RECQL), leptin receptor (LEPR), ERBB receptor feedback inhibitor 1 (ERRFII), lysosomal protein transmembrane protein 4 alpha (LAPT M4A), RABIB, RAS oncogene family (RAB1B), CD24, Homo sapiens thymosin beta 4, X-linked (TMSB4X) protein, Homo sapiens S100 calcium binding protein A6 (S100A6), Homo sapiens adenosine A2 receptor (ADORA2B), chromosome 16 open reading frame 61 antibody (C16orf61), ROD1 differentiation regulator 1 (ROD1), NAD-dependent deacetylase deacetylase sirtuin-2 (SIR2L), microtubule protein alpha 1c (TUBA1C), ATPase inhibitory factor 1 (ATPIF1), stromal antigen 2 (STAG2), and nuclear casein kinase and cyclin-dependent substrate 1 (NUCKS1). In some embodiments, the tumor antigen includes but is not limited to KS1 / 4 pan-cancer antigen, ovarian cancer antigen (CA125), prostatic acid phosphate (prostaticacid phosphate), prostate-specific antigen, melanoma-associated antigen p97, melanoma antigen gp75, high molecular weight melanoma antigen (HMW-MAA), prostate-specific membrane antigen, CEA, polymorphic epithelial mucin antigen, milk fat globulin antigen, colorectal tumor-associated antigens (such as CEA, TAG-72, C017-1A, GICA19-9, CTA-1 and LEA), Burkitt's lymphoma antigen-38.13, CD19, B-lymphoma antigen-CD20, CD33, melanoma-specific antigens (such as gangliosides GD2, ganglioside GD3, ganglioside GM2, ganglioside GM3), tumor-specific transplantable cell surface antigens (TSTA) (such as virus-induced tumor antigens, including T antigen DNA tumor virus and RNA tumor virus envelope antigen), carcinoembryonic antigen-alpha-fetoprotein (such as colon CEA), bladder tumor carcinoembryonic antigen, differentiation antigens (such as human lung cancer antigens L6 and L20), fibrosarcoma antigen, leukemia T cell antigen-Gp37, pseudoglycoproteins, sphingolipids, breast cancer antigens (such as EGFR (epidermal growth factor receptor)), HER2 antigen (p185). HER2) and HER2 neu epitopes), polymorphic epithelial mucin (PEM), malignant human lymphocyte antigen-APO-1, differentiation antigens (such as I antigen found in fetal erythrocytes and primary endoderm, I antigen found in adult erythrocytes and preimplantation embryos, I (Ma) found in gastric adenocarcinoma, M18 and M39 found in breast epithelium, SSEA-1 found in myeloid cells, VEP8, VEP9, Myl, VIM-D5, D found in colorectal cancer, etc. 156 -22, TRA-1-85 (blood type H), C14 found in colon adenocarcinoma, F3 found in lung adenocarcinoma, AH6 found in gastric cancer, Y hapten, Le found in embryonal carcinoma cells y , TL5 (blood type A), EGF receptor found in A431 cells, E1 series found in pancreatic cancer (blood type B), FC10.2 found in embryonic carcinoma cells, gastric adenocarcinoma antigen, CO-514 found in adenocarcinoma (blood type Le a ), NS-10 found in adenocarcinoma, CO-43 (blood type Le b ), G49 found in the EGF receptor of A431 cells, MH2 found in colon adenocarcinoma (blood type ALe b / Le y ), 19.9 found in mucins of colon and gastric cancers, T5A7 found in myeloid cells, and R found in melanoma. 24 ,4.2,G D3 ,D1.1,OFA-1,G M2 , OFA-2, G D2 , as well as Ml:22:25:8 found in embryonic carcinoma cells, and SSEA-3 and SSEA-4 found in embryos at the 4- to 8-cell stage), T-cell receptor-derived peptides from cutaneous T-cell lymphoma, C-reactive protein (CRP), cancer antigen-50 (CA-50), cancer antigen 15-3 (CA15-3) associated with breast cancer, cancer antigen-19 (CA-19) and cancer antigen-242 associated with gastrointestinal cancer, tumor-associated antigen (CAA), chromogranin A, epithelial mucin antigen (MC5), human on E1A, Lewis(a) antigen, melanoma antigen, melanoma-associated antigens 100, 25, and 150, mucinoid tumor-associated antigen, multidrug resistance-associated protein (MRPm6), multidrug resistance-associated protein (MRP41), Neu oncogene protein (C-erbB-2), neuron-specific enolase (NSE), P-glycoprotein (mdr1 gene product), multidrug resistance-associated antigen, p170, multidrug resistance-associated antigen, prostate-specific antigen (PSA), CD56, and NCAM.
[0139] In some embodiments, other tumor antigens include, but are not limited to, AIM2 (absent in melanoma 2), BMI1 (BMI1 polycomb ring finger oncogene), COX-2 (cyclooxygenase-2), EGFRvIII (epidermal growth factor receptor variant III), EZH2 (enhancer of Zeste homolog 2), LICAM (human L1 cell adhesion molecule), Livin, Livinβ, MRP-3 (multidrug resistance protein 3), nestin, OLIG2 (oligodendrocyte transcription factor), SOX2 (SRY-related HMG-box2), ART1 (antigen recognized by T cells 1), ART4 (antigen recognized by T cells 4), SART1 (squamous cell carcinoma antigen recognized by T cells 1), SART2, SART3, B cell cyclin, Glil (glioma-associated oncogene homolog 1), Cav-1 (caveolin-1), cathepsin B, CD74 (cluster of differentiation 74), E-cadherin (epithelial calcium-dependent adhesion), EphA2 / Eck (EPH receptor A2 / epithelial kinase), Fra-1 / Fosl 1 (Fos-related antigen 1), Ki67 (nuclear proliferation-associated antigen of antibody Ki67), Ku70 / 80 (human Ku heterodimeric protein subunits), IL-13Ra2 (interleukin-13 receptor subunit alpha-2), NY-ESO-1 (New York esophageal squamous cell carcinoma 1), PROX1 (Breasto Homebox protein 1), PSCA (prostate stem cell antigen), SOX10 (SRY-related HMG-box10), SOX11, Survivin, UPAR (urokinase-type plasminogen activator receptor), and WT-1 (Wilms tumor protein 1).
[0140] VI. Treatment options and drug preparations
[0141] The replicative oncolytic vaccinia virus and immune checkpoint inhibitor of the pharmaceutical composition are administered simultaneously, wherein the oncolytic vaccinia virus is delivered by intratumoral administration. Simultaneous administration can be performed, for example, in the form of a fixed combination comprising these agents, or by administering each agent simultaneously in the form of an independent preparation. In some embodiments, the replicative oncolytic vaccinia virus and PD-1 or PD-L1 immune checkpoint inhibitor of the pharmaceutical composition are administered simultaneously. In some embodiments, the replicative oncolytic vaccinia virus and CTLA-4 immune checkpoint inhibitor of the pharmaceutical composition are administered simultaneously. In some embodiments, the replicative oncolytic vaccinia virus and TIGIT immune checkpoint inhibitor of the pharmaceutical composition are administered simultaneously. In some embodiments, the replicative oncolytic vaccinia virus, PD-1 or PD-L1 immune checkpoint inhibitor and CTLA-4 immune checkpoint inhibitor of the pharmaceutical composition are administered simultaneously. In some embodiments, the replicative oncolytic vaccinia virus, PD-1 or PD-L1 immune checkpoint inhibitor and TIGIT immune checkpoint inhibitor of the pharmaceutical composition are administered simultaneously. In some embodiments, the replicating oncolytic vaccinia virus is administered intratumorally, intravenously, intraarterially, and / or intraperitoneally. In some embodiments, the replicating oncolytic vaccinia virus is administered intratumorally. In some embodiments, the replicating oncolytic vaccinia virus is administered intravenously. In some embodiments, the replicating oncolytic vaccinia virus is administered intraperitoneally. In some embodiments, the replicating oncolytic vaccinia virus is administered intraarterially. In some embodiments, the replicating oncolytic vaccinia virus is administered intraarterially. In some embodiments, the replicating oncolytic vaccinia virus is administered only intratumorally. In some embodiments, immune checkpoint inhibitors are systemically administered. In some embodiments, the replicating oncolytic virus is administered intratumorally, while the checkpoint inhibitor is administered systemically. In some embodiments, the replicating oncolytic virus is administered intravenously, and the checkpoint inhibitor is administered systemically. In some embodiments, the replicating oncolytic virus is administered intraperitoneally, and the checkpoint inhibitor is administered systemically. In some embodiments, the replicating oncolytic virus is administered intraarterially, while the checkpoint inhibitor is administered systemically. In some embodiments, the replicating oncolytic virus is administered intraarterially, while the checkpoint inhibitor is administered systemically. In some embodiments, the replicating oncolytic vaccinia virus comprises a heterologous nucleic acid sequence encoding a tumor antigen and optionally a cytokine, wherein the tumor antigen and optionally the cytokine are expressed in cells (preferably tumor cells) infected by the virus.
[0142] In some embodiments, the present invention provides a method for treating a human tumor, comprising administering to the human a composition comprising (a) a replicating oncolytic vaccinia virus and (b) an inhibitor of an immune checkpoint protein. In some embodiments of the treatment method, the immune checkpoint protein is selected from PD-1, PD-L1, CTLA-4, LAG3, TIM3, and TIGIT. In some embodiments of the treatment method, the immune checkpoint protein is CTLA-4. In some embodiments of the treatment method, the immune checkpoint protein is PD-L1. In some embodiments of the treatment method, the immune checkpoint protein is LAG3. In some embodiments of the treatment method, the immune checkpoint protein is TIGIT. In some embodiments of the treatment method, the immune checkpoint protein is PD-1. In some embodiments of the treatment method, the immune checkpoint protein is TIM3. In some embodiments of the treatment method, the tumor is a solid cancer. In some embodiments of the treatment method, the tumor is colorectal cancer. In some embodiments of the treatment method, the tumor is renal cell carcinoma. In some embodiments, the replicating oncolytic vaccinia virus is administered by intratumoral, IV, and / or intraperitoneal administration. In some embodiments, the replicative oncolytic vaccinia virus is administered intratumorally. In some embodiments, the replicative oncolytic vaccinia virus is administered by IV. In some embodiments, the replicative oncolytic vaccinia virus is administered intraperitoneally. In some embodiments, the replicative oncolytic vaccinia virus is administered intraarterially. In some embodiments, the replicative oncolytic vaccinia virus is only administered intratumorally. In some embodiments, immune checkpoint inhibitors are systemically administered. In some embodiments, the replicative oncolytic virus is administered intratumorally, and the checkpoint inhibitor is systemically administered. In some embodiments, the replicative oncolytic virus is administered intravenously, and the checkpoint inhibitor is systemically administered. In some embodiments, the replicative oncolytic virus is administered intraperitoneally, and the checkpoint inhibitor is systemically administered. In some embodiments, the replicative oncolytic virus is administered intraarterially, and the checkpoint inhibitor is systemically administered. In some embodiments, the replicative oncolytic virus comprises a heterologous nucleic acid sequence encoding a tumor antigen and optionally a cytokine, wherein the tumor antigen and optionally a cytokine are expressed in cells (preferably tumor cells) infected by the virus.
[0143] In some embodiments, the present invention provides a method for treating a human tumor, comprising administering to the human a composition comprising (a) a replicating oncolytic vaccinia virus, (b) an inhibitor of PD-1 and / or PD-L1, and (c) an inhibitor of an immune checkpoint protein. In some embodiments of the treatment method, the immune checkpoint protein is selected from CTLA-4, LAG3, TIM3, and TIGIT. In some embodiments of the treatment method, the immune checkpoint protein is CTLA-4. In some embodiments of the treatment method, the immune checkpoint protein is LAG3. In some embodiments of the treatment method, the immune checkpoint protein is TIGIT. In some embodiments of the treatment method, the immune checkpoint protein is TIM3. In some embodiments of the treatment method, the tumor is a solid cancer. In some embodiments of the treatment method, the tumor is colorectal cancer. In some embodiments of the treatment method, the tumor is renal cell carcinoma. In some embodiments, the replicating oncolytic vaccinia virus is administered by intratumoral, IV, and / or intraperitoneal administration. In some embodiments, the replicating oncolytic vaccinia virus is administered intratumorally. In some embodiments, the replicating oncolytic vaccinia virus is administered by IV. In some embodiments, the replicative oncolytic vaccinia virus is administered intraperitoneally. In some embodiments, the replicative oncolytic vaccinia virus is administered only intratumorally. In some embodiments, immune checkpoint inhibitors are administered systemically. In some embodiments, the replicative oncolytic virus is administered intratumorally, and the checkpoint inhibitor is administered systemically. In some embodiments, the replicative oncolytic virus is administered intravenously, and the checkpoint inhibitor is administered systemically. In some embodiments, the replicative oncolytic virus is administered intraperitoneally, and the checkpoint inhibitor is administered systemically. In some embodiments, the replicative oncolytic virus is administered intraperitoneally, and the checkpoint inhibitor is administered systemically. In some embodiments, the replicative oncolytic virus is administered intraarterially, and the checkpoint inhibitor is administered systemically. In some embodiments, the replicative oncolytic vaccinia virus comprises a heterologous nucleic acid sequence encoding a tumor antigen and optionally a cytokine, wherein the tumor antigen and optionally a cytokine are expressed in cells (preferably tumor cells) infected by the virus.
[0144] In some embodiments of the method of treatment, before the administration of the replicative oncolytic vaccinia virus, the tumor does not express immune checkpoint proteins or expresses immune checkpoint proteins at relatively low levels. In some embodiments, the high level is represented by a tumor proportion score equal to or greater than 50%. In some embodiments, the high level is represented by a tumor proportion score greater than 60%, greater than 70%, greater than 80%, greater than 90%, greater than 95%, about 99% or about 100%. In some embodiments, the high level of a previously treated tumor is represented by a tumor proportion score greater than 1%. In some embodiments, the high level is represented by tumor cells expressing PD-L1 equal to or greater than 50% (for example, more than 50% of tumor cells express PD-L1). In some embodiments, the high level is represented by tumor cells expressing PD-L1 higher than 60%, higher than 70%, higher than 80%, higher than 90%, higher than 95%, about 99% or about 100%. In some embodiments, high levels of previously treated tumors are represented by greater than 1% of tumor cells expressing PD-L1 (e.g., more than 1% of tumor cells express PD-L1). In some embodiments, PD-L1 expression can be measured using any PD-L1 diagnostic test. In some embodiments, when the PD-L1 checkpoint is measured, the PD-L1 DaKo Companion diagnostic test is used to measure PD-L1 levels.
[0145] In some embodiments of the method of treatment, the method comprises the step of measuring the expression level of the checkpoint protein in the tumor prior to administering the composition.
[0146] Taking into account the toxicity of treatment (if any), the administration of oncolytic vaccinia virus and immune checkpoint inhibitors will follow the general scheme for the administration of each specific therapy. It is expected that the treatment cycle will be repeated as needed. It can also be expected that in addition to the combined therapy of the present invention, various standard therapies and surgical treatments can also be applied.
[0147] Treatment options may vary and often depend on the tumor type, tumor location, disease progression, and the patient's health and age. Certain tumor types will require more aggressive treatments, while at the same time, some patients cannot tolerate more onerous treatment regimens.
[0148] In certain embodiments, the treated tumor may be at least initially unresectable. Treatment using the combination therapy of the present invention can increase the resectability of the tumor, either due to shrinkage at the margins or by eliminating certain particularly invasive portions. After treatment, resection is possible. Other treatments after resection will be used to eliminate minimal residual disease at the tumor site.
[0149] Determine the synergistic interaction between one or more components, can be by applying different w / w ratio ranges and dosage components to patients in need of treatment, finally determine the best range of effect and the absolute dosage range for each component of effect.For humans, the complexity and cost of clinical research on patients make it impractical to use this form of test as the main model of synergy.However, the synergy observed in a species can predict the effect in other species, and as described herein, there are animal models to measure synergy, and the results of these studies can also be used to predict the effective dose and plasma concentration ratio range and the required absolute dose and plasma concentration of other species by applying pharmacokinetic / pharmacodynamic methods.The correlation established between the effect observed in tumor models and people shows that the synergy in animals can be confirmed, for example, in human xenograft tumor models.
[0150] In some embodiments, the composition is used to treat and / or prevent mammalian cancer. In some embodiments, cancer includes but is not limited to brain cancer, head and neck cancer, esophageal cancer, skin cancer, lung cancer, thymus cancer, gastric cancer, colon cancer, liver cancer, ovarian cancer, uterine cancer, bladder cancer, kidney cancer, testicular cancer, rectal cancer, breast cancer and pancreatic cancer. In some embodiments, cancer is selected from the group consisting of the following items: brain cancer, head and neck cancer, esophageal cancer, skin cancer, lung cancer, thymus cancer, gastric cancer, colon cancer, liver cancer, ovarian cancer, uterine cancer, bladder cancer, kidney cancer, testicular cancer, rectal cancer, breast cancer and pancreatic cancer. In a preferred embodiment, the composition is used to treat and / or prevent metastasis. In other preferred embodiments, the composition is used to treat cancer, including but not limited to hepatocellular carcinoma, colorectal cancer, renal cell carcinoma, bladder cancer, lung cancer (including non-small cell lung cancer), gastric cancer, esophageal cancer, sarcoma, mesothelioma, melanoma, pancreatic cancer, head and neck cancer, ovarian cancer, cervical cancer and liver cancer. In some embodiments, the composition is used to treat a cancer selected from the group consisting of hepatocellular carcinoma, colorectal cancer, renal cell carcinoma, bladder cancer, lung cancer (including non-small cell lung cancer), gastric cancer, esophageal cancer, sarcoma, mesothelioma, melanoma, pancreatic cancer, head and neck cancer, ovarian cancer, cervical cancer and liver cancer. In some embodiments, the composition is used to treat colorectal cancer, in particular metastatic colorectal cancer. In some embodiments, the mammal to be treated is a human. In another preferred aspect, the composition is used to treat cancer that is resistant to one or more immune checkpoint inhibitors (e.g., the cancer is resistant to immunotherapy using PD-1, CTLA-4, LAG3 and / or TIGIT inhibitors). In some embodiments, the cancer is a solid cancer or a solid tumor.
[0151] The method includes administering a therapeutically effective amount of a replicative oncolytic vaccinia virus and an immune checkpoint inhibitor simultaneously. A therapeutically effective amount of an oncolytic virus is defined as an amount sufficient to induce oncolysis-the destruction or dissolution of cancer cells. Preferably, the oncolytic vaccinia virus and the immune checkpoint inhibitor are administered in a synergistically effective amount. The term includes slowing, inhibiting or reducing the growth or size of a tumor, and in some cases including eradication of the tumor. In some embodiments, an effective amount of an oncolytic vaccinia virus causes the therapeutic virus to spread systemically to the tumor, such as infecting an uninjected tumor. In some embodiments, the effective amount of an oncolytic vaccinia virus is an amount sufficient to induce oncolysis-the destruction or dissolution of cancer cells.
[0152] In some embodiments, cancer treatment and / or prevention indicates that the tumor size and / or presence after treatment is reduced (reduction) and / or decreased (decrease) by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99% or about 100%. In some embodiments, cancer treatment and / or prevention indicates that the tumor completely regresses after treatment. In some embodiments, cancer treatment and / or prevention indicates that the tumor completely remits after treatment. In some embodiments, cancer is refractory or resistant to immune checkpoint inhibitor therapy. In some embodiments, cancer is refractory or resistant to treatment using anti-PD-1 antibodies, anti-PD-L1 antibodies and / or anti-CTLA-4 antibodies. In some embodiments, the cancer is resistant to treatment with an anti-PD-1 antibody. In some embodiments, the cancer is resistant to treatment with an anti-CTLA-4 antibody. In some embodiments, treatment comprises administering a replicating oncolytic vaccinia virus. In some embodiments, treatment comprises administering a replicating oncolytic vaccinia virus and an immune checkpoint inhibitor. In some embodiments, treatment comprises administering a replicating oncolytic vaccinia virus and an immune checkpoint inhibitor, wherein the immune checkpoint inhibitor is an inhibitor of PD-1, PD-L1, CTLA-4, LAG3, TIGIT, and / or TIM3. In some embodiments, treatment comprises administering a replicating oncolytic vaccinia virus, a PD-1 or PD-L1 inhibitor, and an immune checkpoint inhibitor. In some embodiments, treatment comprises administering a replicating oncolytic vaccinia virus, a PD-1 or PD-L1 inhibitor, and an immune checkpoint inhibitor, wherein the immune checkpoint inhibitor is a CTLA-4 inhibitor, a LAG3 inhibitor, a TIGIT inhibitor, or a TIM3 inhibitor. In some embodiments, treatment comprises administering a replicating oncolytic vaccinia virus, a PD-1 inhibitor, and an immune checkpoint inhibitor, wherein the immune checkpoint inhibitor is a CTLA-4 inhibitor. In some embodiments, treatment comprises administering a replicating oncolytic vaccinia virus, a PD-L1 inhibitor, and an immune checkpoint inhibitor, wherein the immune checkpoint inhibitor is a CTLA-4 inhibitor. In some embodiments, treatment comprises administering a replicating oncolytic vaccinia virus, a PD-1 inhibitor, and an immune checkpoint inhibitor, wherein the immune checkpoint inhibitor is a LAG3 inhibitor. In some embodiments, treatment comprises administering a replicating oncolytic vaccinia virus, a PD-L1 inhibitor, and an immune checkpoint inhibitor, wherein the immune checkpoint inhibitor is a LAG3 inhibitor. In some embodiments, treatment comprises administering a replicating oncolytic vaccinia virus, a PD-1 inhibitor, and an immune checkpoint inhibitor, wherein the immune checkpoint inhibitor is a TIGIT inhibitor.In some embodiments, treatment comprises administration of a replicative oncolytic vaccinia virus, a PD-L1 inhibitor, and an immune checkpoint inhibitor, wherein the immune checkpoint inhibitor is a TIGIT inhibitor. In some embodiments, treatment comprises administration of a replicative oncolytic vaccinia virus, a PD-1 inhibitor, and an immune checkpoint inhibitor, wherein the immune checkpoint inhibitor is a TIM3 inhibitor. In some embodiments, treatment comprises administration of a replicative oncolytic vaccinia virus, a PD-L1 inhibitor, and an immune checkpoint inhibitor, wherein the immune checkpoint inhibitor is a TIM3 inhibitor.
[0153] In some embodiments, the replicating oncolytic vaccinia virus is administered intratumorally, IV, and / or intraperitoneally. In some embodiments, the replicating oncolytic vaccinia virus is administered intratumorally. In some embodiments, the replicating oncolytic vaccinia virus is administered IV. In some embodiments, the replicating oncolytic vaccinia virus is administered intraperitoneally. In some embodiments, the replicating oncolytic vaccinia virus is administered intraarterially. In some embodiments, the replicating oncolytic vaccinia virus is administered intratumorally only. In some embodiments, the replicating oncolytic vaccinia virus is administered intratumorally only.
[0154] Checkpoint inhibitors disclosed herein can be administered by various routes, including, for example, oral or parenteral administration, such as intravenous, intramuscular, subcutaneous, intraorbital, intracapsular, intraperitoneal, intrarectal, intracisternal, intratumoral, intravascular, intradermal administration or respectively using, for example, a skin patch or transdermal iontophoresis to passively absorb or promote absorption through the skin. In some embodiments, checkpoint inhibitors are systemically administered. Checkpoint inhibitors can also be applied to the site of a pathological condition, such as intravenous or intraarterial administration to a blood vessel supplying a tumor. In some embodiments, checkpoint inhibitors are inhibitors of PD-1, PD-L1, CTLA-4, LAG3, TIGIT and / or TIM3.
[0155] In some embodiments, the replicating oncolytic virus is administered intratumorally, while the checkpoint inhibitor is administered systemically. In some embodiments, the replicating oncolytic virus is administered intravenously, while the checkpoint inhibitor is administered systemically. In some embodiments, the replicating oncolytic virus is administered intraperitoneally, while the checkpoint inhibitor is administered systemically. In some embodiments, the replicating oncolytic virus is administered intraarterially, while the checkpoint inhibitor is administered systemically.
[0156] The total amount of the medicament to be administered in the method for implementing the present invention can be administered to the subject as a single dose, or in a large dose or by infusion in a relatively short period of time, or can be administered using a graded treatment regimen, wherein multiple doses are administered over an extended period of time. Those skilled in the art will know that the amount of the composition for treating the subject's pathological condition depends on a variety of factors, including the age and overall health of the subject and the route of administration and the number of treatments to be administered. Taking these factors into account, those skilled in the art will adjust the specific dosage as needed. Typically, the formulation of the composition and the route of administration and frequency are initially determined using Phase I and Phase II clinical trials.
[0157] In certain embodiments, the checkpoint inhibitor is administered at a dose of 0.01-0.05 mg / kg, 0.05-0.1 mg / kg, 0.1-0.2 mg / kg, 0.2-0.3 mg / kg, 0.3-0.5 mg / kg, 0.5-0.7 mg / kg, 0.7-1 mg / kg, 1-2 mg / kg, 2-3 mg / kg, 3-4 mg / kg, 4-5 mg / kg, 5-6 mg / kg, 6-7 mg / kg, 7-8 mg / kg, 8-9 mg / kg, 9-10 mg / kg, at least 10 mg / kg, or any combination thereof. A suitable dose range for a checkpoint inhibitor is about 0.5 mg / kg to 25 mg / kg, preferably about 1 mg / kg to about 20 mg / kg, more preferably about 2 mg / kg to about 15 mg / kg. In certain embodiments, the checkpoint inhibitor is administered at least once a week, at least twice a week, at least three times a week, at least once every two weeks, or at least once a month or at least once a few months. In certain embodiments, the checkpoint inhibitor is administered in the form of a single dose, two doses, three doses, four doses, five doses, or 6 or more doses. Preferably, the checkpoint inhibitor is administered intravenously (e.g., by intravenous infusion or injection) or intratumorally. As a non-limiting example, ipilimumab is preferably administered by intravenous infusion at a dose of 3 mg / kg every three weeks, for a total of four doses. In some embodiments, the checkpoint inhibitor is an inhibitor of PD-1, PD-L1, CTLA-4, LAG3, TIGIT, and / or TIM3.
[0158] A. Other anticancer treatments
[0159] One or more other chemotherapeutic agents may be administered with the compositions of the invention, including but not limited to 5-fluorouracil (FU), folic acid (FA) (or leucovorin), methotrexate, capecitabine (Xeloda; an oral prodrug of 5-FU), oxaliplatin (Eloxatin), bevacizumab (Avastin), cetuximab (Erbitux) and panitumumab (Vectibix), in any combination. These agents may be administered according to known treatment regimens. Typically, except for capecitabine, which is an oral formulation, the other chemotherapeutic agents are administered intravenously.
[0160] In other aspects, the methods of the invention further comprise administering other cancer therapies, such as radiation therapy, hormone therapy, surgery, and combinations thereof.
[0161] Radiotherapy includes but is not limited to the directional delivery of gamma rays, X-rays and / or radioisotopes to tumor cells. Other forms of DNA damaging factors, such as microwaves and UV radiation, are also considered. All of these factors are most likely to cause extensive damage to the replication and repair of DNA, DNA precursors, DNA, and the assembly and maintenance of chromosomes. The dosage range of X-rays is from 50 to 200 roentgens per day, and the duration is extended (3 to 4wk) to a single dose of 2000 to 6000 roentgens. The dosage range of radioisotopes varies greatly and depends on the half-life of the isotope, the intensity and type of the emitted radiation, and the absorption of tumor cells.
[0162] Approximately 60% of cancer patients will undergo some type of surgery, including preventive, diagnostic or staging, curative, and palliative surgery. Radical surgery is a cancer therapy that can be used in conjunction with other therapies, such as the therapy of the present invention, chemotherapy, radiation therapy, hormone therapy, gene therapy, and / or alternative therapies.
[0163] Radical surgery includes resection, in which all or part of the cancerous tissue is physically removed, excised and / or destroyed. Tumor resection refers to the physical removal of at least part of the tumor. In addition to tumor resection, surgical treatments include laser surgery, cryosurgery, electrosurgery, and microscopically controlled surgery (Mohs surgery). It is also contemplated that the present invention may be used in conjunction with the removal of superficial cancers, precancerous lesions, or incidental amounts of normal tissue.
[0164] When part or all of the cancer cells, tissues or tumors are removed, cavities may form in the body. Treatment can be accomplished by perfusing the area, injecting directly or applying other anticancer therapies locally. Such treatments can be repeated, for example, every 1, 2, 3, 4, 5, 6 or 7 days, or every 1, 2, 3, 4, 5 weeks or every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 months. These treatments can also have different dosages.
[0165] Another form of treatment used in conjunction with current methods includes hyperthermia, which is the process of exposing a patient's tissue to high temperatures (up to 106°F). External or internal heating devices may involve the application of local, regional, or whole-body hyperthermia. Local hyperthermia involves the application of heat to a small area, such as a tumor. Heat may be generated externally using high-frequency waves from a device outside the body, aimed at the tumor. Internal heating may involve a sterile probe that includes a thin heating wire or a hollow tube filled with warm water, an implanted microwave antenna, or radiofrequency electrodes.
[0166] The patient's organs or limbs are heated for regional treatment, which is achieved by using a device that produces high energy, such as a magnet. Alternatively, some of the patient's blood can be removed and heated before being perfused into the area to be heated internally. Whole body heating can also be performed if the cancer has spread throughout the body. Warm water blankets, hot wax, induction coils, and hot chambers can be used for this purpose.
[0167] Hormonal therapy can also be used in conjunction with the present invention or in conjunction with any of the other cancer therapies described above. The use of hormones can be used to treat certain cancers, such as breast cancer, prostate cancer, ovarian cancer, or cervical cancer, to reduce the level of certain hormones (such as testosterone or estrogen) or block their effects.
[0168] B. Compositions and preparations
[0169] The replicating oncolytic vaccinia virus of the pharmaceutical composition is administered to treat cancer and / or directly to tumor cells, and therefore, the pharmaceutical compositions disclosed herein are formulated for the desired route of administration (e.g., by intratumoral injection, intravenous, intraarterial, and / or intraperitoneal administration). In some embodiments, the replicating oncolytic vaccinia virus of the pharmaceutical composition is formulated for administration by intratumoral, intravenous, intraarterial, and / or intraperitoneal administration routes. In some embodiments, the replicating oncolytic vaccinia virus of the pharmaceutical composition is formulated for administration by intratumor. In some embodiments, the replicating oncolytic vaccinia virus of the pharmaceutical composition is formulated for administration by intravenous administration. In some embodiments, the replicating oncolytic vaccinia virus of the pharmaceutical composition is formulated for administration by intraarterial administration. In some embodiments, the replicating oncolytic vaccinia virus of the pharmaceutical composition is formulated for administration by intraperitoneal administration. In some embodiments, the replicating oncolytic vaccinia virus of the pharmaceutical composition is formulated for administration only by intratumoral administration.
[0170] Intratumoral injection of oncolytic vaccinia virus can be performed by a syringe or any other method for injecting a solution, as long as the expression construct can be injected through the specific needle specifications required. A novel needle-free injection system has recently been described (U.S. Patent No. 5,846,233, which is incorporated herein by reference), which has a nozzle defining an ampoule chamber for containing a solution and an energy device for pushing the solution from the nozzle to a delivery location. A syringe system used in gene therapy has also been described, which allows for multiple injections of a predetermined amount of solution at any depth accurately (U.S. Patent No. 5,846,225, which is incorporated herein by reference).
[0171] The solution of the active compound as a free alkali or a pharmacologically acceptable salt can be prepared by mixing with a surfactant (such as hydroxypropylcellulose) in water. Dispersions can also be prepared in glycerol, liquid polyethylene glycol, and mixtures thereof, and oils. Under conventional storage and use conditions, these preparations contain preservatives to prevent the growth of microorganisms. The pharmaceutical form suitable for injection purposes includes sterile aqueous solutions or dispersions and sterile powders (U.S. Patent No. 5,466,468, incorporated herein by reference) for the temporary preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that it is easy to inject. It must be stable under production and storage conditions, and its preservation must prevent the contamination of microorganisms (such as bacteria and fungi). The carrier can be a solvent or a dispersion medium, which includes, for example, water, ethanol, a polyol (such as glycerol, propylene glycol, and liquid polyethylene glycol, etc.), a suitable mixture thereof, and / or a vegetable oil. For example, a coating such as lecithin can be used, and in the case of a dispersion, the desired particle size can be maintained and appropriate fluidity can be maintained by using a surfactant. The prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be achieved by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
[0172] For example, for intratumoral injection in aqueous solution, if necessary, the solution can be appropriately buffered, and the liquid diluent is first made isotonic with enough saline or glucose. In this regard, according to the present disclosure, those skilled in the art will know the sterile aqueous medium that can be used. For example, a dose can be dissolved in 1ml isotonic NaCl solution, or added to 1000ml subcutaneous injection or injected at the proposed infusion site (see, for example, "Remington's Pharmaceutical Sciences" 15th edition, 1035-1038 and 1570-1580 pages). Depending on the condition of the subject, some changes in dosage will inevitably occur. In any case, the person responsible for administration should determine the dosage suitable for individual subjects. In addition, for human administration, the preparation should meet the sterility, pyrogenicity, general safety and purity standards required by the standards of the Office of Biology of the U.S. Food and Drug Administration (FDA Office of Biologies).
[0173] As required, sterile injectable solutions are prepared by incorporating the desired amount of the active compound into a suitable solvent with the various other ingredients listed above. Typically, dispersions are prepared by incorporating various sterilized active ingredients into a sterile vehicle containing a basic dispersion medium and the desired other ingredients from the above listing. As for sterile powders for the preparation of sterile injectable solutions, preferred preparation methods are vacuum drying and freeze drying techniques, which produce powders of the active ingredient and any other desired ingredients from their previously sterile filtered solutions.
[0174] Compositions disclosed herein can be formulated into neutral or salt forms. Pharmaceutically acceptable salts include acid addition salts (formed with the free amino groups of proteins), and are formed with inorganic acids (such as, for example, hydrochloric acid or phosphoric acid) or organic acids (such as acetic acid, oxalic acid, tartaric acid, mandelic acid) and the like. The salts formed with free carboxyl groups can also be derived from inorganic bases, such as, for example, hydroxides of sodium, potassium, ammonium, calcium or iron, and organic bases, such as isopropylamine, trimethylamine, histidine, procaine, etc. After preparation, the solution will be used in a manner compatible with the dosage formulation and in a therapeutically effective amount. The preparation is easy to use in various dosage forms (such as injectable solutions, drug release capsules, etc.).
[0175] As used herein, "carrier" includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like. The use of these media and agents for pharmaceutically active substances is well known in the art. Unless any conventional media or agents are incompatible with the active ingredient, they are contemplated for use in therapeutic compositions. Supplementary active ingredients may also be incorporated into the composition.
[0176] The phrase "pharmaceutically acceptable" or "pharmacologically acceptable" refers to molecular entities and compositions that do not produce allergic or similar adverse reactions when administered to humans. The preparation of aqueous compositions containing proteins as active ingredients is well known in the art. Typically, such compositions are prepared as injectables, either liquid solutions or suspensions; solid forms suitable for dissolution or suspension in liquids prior to injection can also be prepared.
[0177] Example
[0178] The following examples are given to illustrate various embodiments of the present invention, but are not intended to limit the present invention in any way. Those skilled in the art will readily appreciate that the present invention is well suited to achieve the stated objects and obtain the stated goals and advantages, as well as those objects, ends and advantages inherent herein. The examples of the present invention and the methods described herein are currently representative of preferred embodiments, are exemplary, and are not intended to limit the scope of the present invention. Those skilled in the art will appreciate variations and other uses contained within the spirit of the present invention, as defined by the scope of the claims.
[0179] Example 1
[0180] The ability of a combination of oncolytic vaccinia virus and checkpoint inhibitors to regress tumors in a syngeneic mouse model of metastatic renal cell carcinoma (Renca) was evaluated. The growth pattern of the tumor accurately mimics that of adult renal cell carcinoma, particularly in terms of spontaneous metastasis to the lungs and liver. The RenCa model is multivascular, resistant to anti-PD-1 immunotherapy, and immunoreactive. Since infection is independent of the tissue of origin, the Renca model is relevant to all cancers.
[0181] Materials and methods
[0182] Mice and Cell Lines - Specific pathogen-free BALB / c male mice were housed in filtered water cages with water and food provided on a 12-hour reversed day and night cycle. All mice were anesthetized by intramuscular injection of a combination of anesthetics (80 mg / kg ketamine and 12 mg / kg xylazine) before being sacrificed. Renca renal carcinoma cell line and CT26 colon carcinoma cell line were obtained from ATCC and cultured in RPMI-1640 medium containing 10% FBS and 1% penicillin-streptomycin antibiotics at 37°C and 5% CO2.
[0183] Virus Amplification
[0184] mJX594 is a Western Reserve vaccinia virus engineered to contain a disrupted viral thymidine kinase gene and to insert mouse GMCSF-GFP (mGMSCF-GFP) under the control of a synthetic early late promoter. HeLaS3 cells at 100% confluence were infected with mJX594 at a multiplicity of infection (moi) = 1-3 and placed in a CO2 incubator at 37°C for 1.5 hours, and then incubated with DMEM containing 2.5% FBS for 48 to 72 hours. The cells were collected by centrifugation and the supernatant was discarded. The cells were resuspended in 10mM Tris-Cl at pH 9.0, homogenized in a Dounce homogenizer and centrifuged. The cell pellet was resuspended in 10mM Tris-Cl at pH 9.0, centrifuged, and the supernatant was combined with the first supernatant. The supernatant was combined with the first supernatant. The sonicated lysate was placed on 36% sucrose and centrifuged at 32900x g for 80 minutes at 4°C. The pellet was then resuspended in 10 mM Tris-Cl, pH 9.0 and stored below -60°C.
[0185] ICI inhibitors (also referred to herein as immune checkpoint inhibitors) -
[0186] Antibodies against CTLA-4 and PD-1 were purchased from BioxCell. 9D9 monoclonal antibody reacts with mouse CTLA-4. Isotype: mouse IgG2b. J43 monoclonal antibody reacts with mouse PD-1. Isotype: Armenian hamster IgG.
[0187] Tumor Models and Treatment Options -
[0188] To generate a clinically relevant renal tumor model, Renca tumor cells (renal carcinoma, syngeneic) (5 × 10 5 A suspension of 100 cells (100 μg / ml) was injected subcutaneously into the right dorsal flank of 8- to 10-week-old immunocompetent Balb / c male mice. 3 At 4 hr, mice were randomized and received the following treatment regimens.
[0189] Tumor size was measured every 3 days in all groups using a digital caliper. Tumor size was measured according to the formula 0.5 × A × B 2 Tumor volume was calculated, where A is the maximum diameter of the tumor and B is its perpendicular diameter. After the indicated days, mice were sacrificed by CO2 and tissues were collected for further analysis.
[0190] Histological analysis-
[0191] For immunofluorescence studies, samples were fixed in 1% PFA, dehydrated overnight in 20% sucrose solution, and embedded in tissue freezing medium (Leica). The frozen blocks were cut into 50 μm sections. The samples were blocked with 5% goat (or donkey) serum in PBST (0.03% Triton X-100 in PBS) and then incubated with the following primary antibodies for 3 hours at room temperature (RT): anti-GFP (rabbit, Millipore), anti-CD31 (hamster, clone 2H8, Millipore), anti-VEGFR2 (rabbit, cell signaling), anti-CD8a (rat, BD PharMingen), anti-CD11b (rat, BD PharMingen), anti-FoxP3 (rat, eBioscience), anti-caspase 3 (rabbit, R&D systems), anti-vaccinia (rabbit, Abcam) and anti-PD-L1 (rat, eBioscience). After washing several times, the samples were incubated with the following secondary antibodies for 2 hours at room temperature: FITC, Cy3 or Cy5 conjugated anti-hamster IgG (Jackson ImmunoResearch), FITC or Cy3 conjugated anti-rabbit IgG (Jackson ImmunoResearch), Cy3 conjugated anti-rat IgG (Jackson ImmunoResearch) or Cy3 conjugated anti-mouse IgG (Jackson ImmunoResearch). Cell nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI, Invitrogen). The samples were then mounted with fluorescent mounting medium (DAKO) and immunofluorescence images were obtained using a Zeiss LSM880 confocal microscope (Carl Zeiss).
[0192] Morphometric analysis-
[0193] The density of blood vessels, CD8 T cells, or apoptotic areas was measured using ImageJ software (http: / / rsb.info.nih.gov / ij). In the peritumoral and intratumoral regions, the density of blood vessels, CD8 T cells, or apoptotic areas was measured every random 0.42 mm 2 CD31, CD8 or caspase 3+ area. All measurements were performed in at least five different fields per mouse.
[0194] Flow cytometry-
[0195] The collected tumor tissue was minced and incubated in FACS buffer (1% FBS in PBS) containing collagenase D (Roche) and DNase I (Roche) at 37°C in a shaking water bath for 1-2 hours. The digested cells were filtered with a 40 μm nylon mesh to remove cell clumps. RBCs were removed by incubating the cell suspension in ACK lysis buffer for 5 minutes at RT. The resulting single cells were incubated with the following antibodies in FACS buffer for 30 minutes: PerCP-cy5.5-conjugated anti-mouse CD45 (rat, eBioscience), APC-conjugated anti-mouse CD3e (hamster, eBioscience), FITC-conjugated anti-mouse CD4 (rat, eBioscience), PE-conjugated anti-CD8a (rat, eBioscience), FITC-conjugated anti-mouse CD11b (rat, eBioscience), APC-conjugated anti-mouse Gr1 (rat, eBioscience) and APC-conjugated anti-mouse CD11c (hamster, eBioscience).
[0196] Statistical analysis -
[0197] Values are expressed as mean ± standard deviation. Statistical differences between means were determined by unpaired Student t-test or one-way ANOVA followed by Student-Newman-Keuls test. Statistical significance was set at p < 0.05.
[0198] result
[0199] Anti-tumor effect of vaccinia virus + anti-PD-1 combination therapy
[0200] For combination therapy with anti-PD-1 and mJX-594, 5 × 10 5 Renca tumor cells were injected into the right dorsal flank of BALB / c mice, and when the tumor reached a size of 50-100 mm 3 Treatment was started at 1:00 pm (day 0). The mice were randomly divided into 4 treatment groups: (i) control group: PBS was injected into the tumor every 3 days; (ii) mJX-594 monotherapy group: 1×10 7 pfu of mJX-594, for a total of 3 injections; (iii) anti-PD-1 monotherapy group: 10 mg / kg antibody was injected intraperitoneally every 3 days on days 0, 3, 6, and 9, for a total of 4 injections; (iv) mJX-594 + anti-PD-1 combination group: mJX-594 and anti-PD-1 were administered simultaneously, where mJX-594 was injected intratumorally every two days on days 0, 2, and 4, for a total of three injections, and anti-PD-1 was injected intraperitoneally on days 0, 2, 4, 6, and 9, for a total of five injections (see Figure 1A ).
[0201] Compared with the control, tumor growth inhibition was observed in the mJX-594 monotherapy group and the mJX-594 / anti-PD-1 combination group (“combination group”) (see Figure 2A The inhibition of tumor growth was more significant in the combination group (see Figure 2A , comparing “PD1+mJX594” to “mJX594” and “PD1”). No tumor growth inhibition was observed in the anti-PD-1 monotherapy group ( Figure 2A , comparing "PD1" to "control"). The mJX-594 monotherapy group showed a reduction in tumor weight (see Figure 2B A significant reduction in tumor weight was observed in the combination group, which was substantially greater than the reduction observed in the mJX-594 monotherapy group (see Figure 2B ). Thus, co-administration of mJX-594 and anti-PD-1 resulted in significant reductions in tumor weight and volume compared with either monotherapy.
[0202] In the PD-1 monotherapy group, the mJX-594 monotherapy group, and the concurrent combination therapy group, CD8 T cell infiltration in both the peritumoral and intratumoral areas increased. (See Figure 3A ). In the anti-PD-1 monotherapy group, CD8 T cell infiltration increased in the peripheral area rather than in the central area, while the mJX-594 group showed higher numbers of CD8 T cell infiltration in both the central and peripheral areas. (See Figure 3B Coadministration of mJX-594 and anti-PD-1 antibody significantly increased intratumoral T cell infiltration as measured by peritumoral and intratumoral CD8+ staining compared with controls and monotherapy with either agent alone (see Figure 3B ). A decrease in vascular density was also observed in the treated group compared to the control (see Figure 3B ).
[0203] In the anti-PD-1 monotherapy group, the mJX-594 monotherapy group, and the concurrent combination therapy group, the PD-L1 expression levels in both peripheral and central tumor areas were higher than those in the control group. (See Figure 4A Although the anti-PD-1 monotherapy group showed increased PD-L1 expression levels in the peripheral area but not in the central area, the mJX-594 monotherapy group showed similar increased PD-L1 expression levels in both the peripheral and central areas (see Figure 4A Coadministration of JX-595 and anti-PD-1 antibody increased intratumoral PD-L1 expression compared with monotherapy with either agent alone (see Figure 4A). Renca tumors are resistant to anti-PD1 immunotherapy. The increase in tumor PD-L1 expression in the concurrent combination treatment group reflects the sensitivity of these tumors to anti-PD-1 therapy accompanied by CD8+ T cell infiltration into the tumor and is an indicator of treatment efficacy. These patterns suggest that at baseline, T cells are immunosuppressed and unable to infiltrate the tumor microenvironment. mJX-594 causes inflammation and vasodilation, allowing T cells to exert their anti-tumor effects. Concurrent administration of mJX-594 and anti-PD-1 antibodies activated T cells and allowed them to infiltrate central tumor areas.
[0204] Increased intratumoral apoptosis was observed in the PD-1 monotherapy group, the mJX-594 monotherapy group, and the combined treatment group compared with the control group as measured by caspase 3 staining (see Figure 4B Compared with either monotherapy group, a significant increase in intratumoral apoptosis was confirmed in the simultaneous combination group (see Figure 4B ). Meanwhile, the anti-vascular effect in the combined group ( Figure 3B The combination of 24-week-old and 24-week-old apoptosis (shown) showed significant tumor necrosis in the simultaneous combination group.
[0205] Changes in the immune microenvironment were observed following concomitant mJX-594 and anti-PD-1 antibody treatment compared to controls and monotherapy with either agent, as measured by CD4 and CD11b. Figure 5A ). Importantly, tumor infiltration rates of CD8 T cells were highest in the simultaneous combination group. Depletion of CD8+ cells using anti-CD8 antibodies resulted in reduced tumor growth inhibition, confirming the role of these cells in the anti-tumor effect (data not shown). Myeloid-derived suppressor cells (MDSC) were increased in the mJX-594 and simultaneous combination groups compared to controls. Traditionally, CD11b+Gr1+ cells have been simply considered immunosuppressive cells; however, recent evidence has demonstrated that these cells cannot be so simply defined (compare the relative increase in MDSC observed in the simultaneous combination group using αPD1 with the decrease in MDSC observed in the simultaneous combination group using O.CTLA4) ( Figures 10A-10B ).
[0206] The effects of sequential or simultaneous co-administration of mJX-594 and PD-1±CTLA4 on tumor growth were evaluated. 5 Renca (renal carcinoma, syngeneic) cells were injected subcutaneously into the right flank of 8-week-old BALB / c immune-competent mice. 3 Treatment started at (day 0)
[0207] The mice were divided into four treatment groups: (i) control group: PBS was injected on days 0, 3, 6, 9, 12, and 15; (ii) mJX-594+anti-PD-1 sequential combination group: mJX-594 was injected intratumorally on days 0, 3, 6, and 9, and anti-PD-1 was injected intraperitoneally on days 6, 9, 12, and 15; (iii) mJX-594+anti-PD-1 simultaneous combination group: mJX-594 and anti-PD-1 were administered simultaneously, mJX-594 was injected intratumorally on days 0, 3, 6, and 9, and anti-PD-1 was injected intraperitoneally on days 0, 3, 6, 9, 12, and 15; (iv) mJX-594+anti-PD-1+anti-CTLA4 triple combination group: mJX-594 was injected intratumorally on days 0, 3, 6, and 9, and anti-PD-1 was injected intraperitoneally on days 0, 3, 6, 9, 12, and 15 (see Figure 6 ).
[0208] Compared with the control, tumor growth was inhibited in the mJX-594+anti-PD-1 sequential administration group and the simultaneous administration group and the mJX-594+anti-PD-1+anti-CTLA4 triple simultaneous administration group (see Figure 7 Unexpectedly, co-administration of mJX-594 and anti-PD-1 resulted in more significant tumor growth inhibition (delay) compared with sequential administration of these agents (see Figure 7 A further delay in tumor growth was observed in the triple combination group ("Combi(mJX-594+αPD1+αCTLA4")) (see Figure 7 ).
[0209] When the tumor size per mouse was compared between the treatment groups, tumor regression was confirmed in the combination group compared to the control. While tumor regression was observed from day 12 in the sequential, tumors tended to regress from day 6 in the simultaneous and triple combination groups.
[0210] These results surprisingly show that the dosing regimen and possible routes of administration can significantly affect the anti-tumor effect of the combination therapy. In particular, if vaccinia virus and checkpoint inhibitors are administered simultaneously, vaccinia virus and checkpoint inhibitors (anti-PD-1, CTLA-4) synergize to induce a strong anti-tumor immune response. In some cases, when vaccinia virus is administered intratumorally as part of the simultaneous administration, there is a strong anti-tumor immune response. The synergistic anti-tumor effect observed when vaccinia virus and checkpoint inhibitors are administered simultaneously is particularly surprising, because immune checkpoint inhibitors are considered in the art to inhibit the replication of oncolytic viruses (such as vaccinia virus) (Rojas et al., "Journal of Immunology (J.Immunol.)", 192 (1 supplement): 142.3 (2014)).
[0211] Vaccinia virus + anti-CTLA4
[0212] 5×10 5 Renca (kidney cancer) cells were injected subcutaneously into the right flank of 8-week-old BALB / c immune-competent mice. When the tumor size reached 50-100 mm 3 Treatment was started at 1:00 p.m. (day 0).
[0213] The mice were randomly divided into 5 treatment groups: (i) control group: PBS was injected into the tumor on days 0, 3, 6, 9, 12, and 15; (ii) mJX-594 monotherapy group: 1×10 7 pfu of mJX-594; (iii) anti-CTLA4 monotherapy group: 4 mg / kg antibody was injected intraperitoneally on days 0, 3, 6, 9, 12, and 15; (iv) mJX-594+anti-CTLA4 sequential combination group: mJX-594 and anti-CTLA4 were administered sequentially, mJX-594 was injected intratumorally on days 0, 3, 6, and 9, and anti-CTLA4 was injected intraperitoneally on days 6, 9, 12, and 15; (v) mJX-594 and anti-CTLA4 simultaneous combination group: mJX-594 and anti-CTLA4 were administered sequentially, mJX-594 was injected intratumorally on days 0, 3, 6, and 9, and anti-CTLA4 was injected intraperitoneally on days 0, 3, 6, 9, 12, and 15 (see Figure 8 ).
[0214] Tumor size was measured every 3 days in all groups. At the end of observation (day 16), mice were sacrificed by CO2, and tumors were removed and analyzed by flow cytometry (CD4+ and CD8+ tumor infiltrating lymphocytes (TIL), Gr1+ / CD11b+MDSC).
[0215] It was demonstrated that tumor growth was inhibited in all treatment groups compared to the control. (See Fig. 9 Significantly more tumor growth inhibition was observed in the combination treatment group, with the greatest tumor growth inhibition observed in the simultaneous administration group (see Fig. 9 ).
[0216] When the tumor size per mouse was compared between treatment groups, tumor regression was demonstrated in the combination group compared to the monotherapy and control groups. Increased CD8 T cell infiltration was observed in all treatment groups compared to controls. (See Fig. 10A ). Compared with the control, the MDSC level was increased in the mJX-594 monotherapy group, while no significant change was observed in the sequential combination therapy group, and a decrease in the MDSC level was observed in the simultaneous combination therapy group (see Fig. 10B ).
[0217] Concurrent administration of JX929 and immune checkpoint inhibitors
[0218] In the above mouse Renca model, IT administration of JX929 (6×10 7 pfu) and PD-1 checkpoint inhibitors were administered intraperitoneally to test the antitumor effect. JX929 is a novel cytokine that disrupts the viral TK and VGF genes (TK - / VGF - phenotype) and does not express GM-CSF.
[0219] Cell lines-
[0220] Murine RENCA cells (ATCC) were cultured in RPMI1640 supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and maintained at 37°C and 5% CO2.
[0221] In vivo studies-
[0222] Eight-week-old female BALB / c mice were inoculated with RENCA cells (2 × 10 6 cells) were injected into the capsule of the left kidney. Figure 1B The indicated regimens were treated with (i) PBS (control) (ii) vaccinia virus (JX-929) monotherapy (days 10, 11, and 12 post-implantation, 60x10 7 PFU, 3 doses in total) (iii) anti-PD-1 monotherapy (BioXcell, West Lebanon, NH, 100 μl) (days 10, 11, and 12 after implantation, 3 doses in total) or (iv) JX929 + anti-PD-1 concomitant therapy (each administered on days 10, 11, and 12 after implantation, JX-929 in the morning and ICI in the afternoon of the same day, 9 hours apart) were intraperitoneally (ip) treated with Renca tumors (50 mm 3 -100mm 3 ,pass Spectrum in vivo imaging system).
[0223] Two days after the final treatment, mice were sacrificed for further histological and flow cytometric analysis.
[0224] Flow cytometry-
[0225] Peripheral blood samples were collected and erythrocytes were lysed with RBC lysis buffer. Cells were washed with PBS containing 1% FBS and then stained with monoclonal mouse anti-CD8, rabbit anti-CD4, rabbit anti-CD3 antibodies (Santa Cruz Biotechnology, California, USA). Cells were fixed with 4% paraformaldehyde and then incubated with FITC-conjugated goat anti-rabbit or goat APC-conjugated anti-mouse antibodies (Santa Cruz Biotechnology, USA). For each sample, 10,000 cells were analyzed using a FACS Calibur instrument (BD Biosciences, California, USA).
[0226] Histological analysis-
[0227] Mice were euthanized, and vital organs, including tumor-bearing kidneys and lungs, were obtained and fixed with 10% neutral formalin (BBC Biochemical, WA, USA). Tissues were embedded in paraffin and sections (4 μm thick) were stained with hematoxylin and eosin for basic histological analysis. For immunofluorescence and immunohistochemistry, sections were stained by standard methods using a mouse monoclonal antibody specific for CD8 (Santa Cruz Biotechnology, CA, USA). Sections were then incubated with FITC-conjugated goat anti-mouse antibody (Santa Cruz Biotechnology, CA, USA) for immunofluorescence or with Immunohistochemistry was performed by incubation with Elite ABC-peroxidase kit (Vector Laboratories, CA, USA) and visualization by Vector SG (Vector Laboratories).The weight and volume of tumors harvested from each treatment group were measured and compared.
[0228] ELISpot assay-
[0229] IFNγ-secreting cells were evaluated using the ELISpot mouse IFNγ kit (Mabtech, Cincinnati, Ohio) according to the manufacturer's protocol. Spleens were isolated and prepared into single cell suspensions. Splenocytes were mixed with RENCA tumor cells or splenocytes from mice infected with vaccinia virus in a ratio of 5:1 and incubated at 37°C for 24 hours. The intensity of specific spots was analyzed using ImageJ software (NTH).
[0230] Statistical analysis -
[0231] All values are expressed as mean ± standard deviation (SD). Statistical analysis was performed using Instat3 (GraphPad Software, California, USA). Multiple comparisons were analyzed using one-way analysis of variance (ANOVA) and Bonferroni post hoc paired comparison test.
[0232] mJX594 treatment induces expression of checkpoint proteins
[0233] according to Figure 1C The treatment options shown are for patients with a load of more than 50 mm 3 Balb / c mice bearing Renca tumors were given four intratumoral doses of mJX594 (1 × 10 7 ) or PBS control.
[0234] Levels of immune checkpoint proteins were measured in tumors of control and mJX594-treated animals on day 0 (before treatment) and on day 12 after sacrifice. Fig.13 Fold changes in checkpoint proteins after treatment in mJX594-treated mice relative to control mice are shown. Fig.13 As shown, mJX594 treatment induced expression of checkpoint proteins, including PD-1 (4-fold increase), PD-L1, PD-L2, CTLA4 (more than 2-fold increase), LAG3, TIM3 (more than 3-fold increase), and TIGIT (more than 2-fold increase). Treatment with a replicating oncolytic vaccinia virus produced dynamic changes in the tumor immune microenvironment, including significant increases in checkpoint proteins PD-1, PD-L1, CTLA-4, LAG3, TIM3, and TIGIT, thereby sensitizing tumors to blockade of each of these checkpoint proteins with their respective checkpoint inhibitors. Clinical trials have demonstrated that tumor infiltrating cells and checkpoint protein (e.g., PD-L1) expression are indicators of potential for treatment with checkpoint inhibitors (e.g., anti-PD-L1 therapy), which supports the efficacy of the combination therapy described herein not only in patients with tumors expressing specific checkpoint proteins, but also in patients with tumors that express (or do not express) specific checkpoint proteins at lower levels.
[0235] Example 2
[0236] Modification of the tumor microenvironment by intratumoral oncolytic vaccinia virus enhances the efficacy of immune checkpoint blockade
[0237] summary
[0238] Cancer immunotherapy is an effective and durable treatment modality, but its clinical benefit remains incomplete. Here, we used mJX-594, a targeted and GM-CSF-armed oncolytic vaccinia virus (VV), as a combination partner to immune checkpoint inhibitors (ICIs) in mice transplanted with renal cancer, colon cancer, and spontaneous breast cancer. Intratumoral injection of VV induced a profound remodeling of the tumor microenvironment, transforming tumors from non-T cell-non-inflammatory to T cell-inflammatory tumors, CD8 + The number of T cells increased and their effector function was enhanced. In addition, the combination of VV and ICI induced tumor regression with improved survival and anti-metastatic effects. Our findings suggest that VV combined with ICI induces strong anti-cancer immunity, thus overcoming resistance to immunotherapy.
[0239] introduce
[0240] Cancer immunotherapy using immune checkpoint inhibitors (ICIs) targeting PD-1 or CTLA-4 has demonstrated potent and durable therapeutic efficacy and has emerged as a new weapon in the war against cancer (Hegde et al., 2016; Topalian et al., 2015; Wolchok and Chan, 2014). However, the clinical efficacy of ICIs is limited to tumors with a T cell-inflamed tumor microenvironment (TME) (Gajewski, 2015; Topalian et al., 2016). In tumors with poor immunogenicity and low numbers of tumor infiltrating lymphocytes (TILs), the TME lacks type I interferon signatures and chemokines for T cell recruitment (Gajewski et al., 2013). In addition, tumor vasculature and stromal components can create obstacles to the intratumoral trafficking of T cells and their effector functions on tumor cells (DePalma and Jain, 2017; Rivera and Bergers, 2015; Sharma et al., 2017). Therefore, for these non-T cell-inflamed tumors, additional therapeutic interventions are needed to appropriately reshape the TME and thus make these tumors more sensitive to ICI treatment.
[0241] Oncolytic viruses (OVs) are considered a new class of anticancer therapeutics, and OVs with different backbones and transgenes are currently being evaluated in clinical trials (Bell, 2014; Lichty et al., 2014). Although the success of OVs was initially evaluated by their faster replication and enhanced oncolytic ability over the past decade, they have begun to be considered as an immunotherapeutic agent due to the strongest and most durable responses after oncolytic virus treatment and the successful induction of antitumor immunity and increased tumor-specific effector and memory T cells (Bell, 2014; Chiocca and Rabkin, 2014; Thorne, 2014). However, since the immunosuppressive TME greatly hinders the therapeutic efficacy of OVs, releasing the brakes of the immune system is crucial to maximizing the immunotherapeutic efficacy of OVs (Bell and Ilkow, 2017; Hou et al., 2016; Liu et al., 2017). Therefore, the combination of OVs and ICIs is a reasonable and attractive strategy to overcome the poorly immunogenic and immunosuppressive TME.
[0242] JX-594 (pexastimogene devacirepvec, Pexa-vec) is an oncolytic vaccinia virus (VV) that is engineered to express the immune-activating transgene GM-CSF and the viral thymidine kinase gene is disrupted (Kirn and Thorne, 2009). JX-594 has shown impressive anticancer activity and low toxicity in preclinical and clinical studies and has become one of the most viable and promising OV platforms in clinical development (Breitbach et al., 2011a; Cripe et al., 2015; Heo et al., 2013; Park et al., 2008). In addition to its oncolytic and vascular disruption activities, JX-594 also has an in situ cancer vaccination effect because it can trigger an adaptive immune response against tumor antigens, thereby selectively destroying tumors and subsequently releasing other tumor antigens (Breitbach et al., 2011b; Breitbach et al., 2015a). Although JX-594 is now in a phase III randomized clinical trial for advanced hepatocellular carcinoma (Abou-Alfa et al., 2016), few studies have characterized its immunomodulatory function in the primary TME and distant lesions after JX-594 treatment (Kim et al., 2018). In addition, the optimal combination of JX-594 with immunotherapeutic agents such as ICIs has not yet been sought and validated.
[0243] Here, we comprehensively dissected the dynamic remodeling of the TME by the JX-594 (mJX-594, WR.TK mGM-CSF) mouse variant and investigated its immunotherapeutic potential to provide a rational combination strategy for ICI in poorly immunogenic tumor models.
[0244] result
[0245] mJX-594 converts immunosuppressive non-inflammatory tumors into inflammatory tumors
[0246] To determine the immunomodulatory potential of the oncolytic virus mJX-594, we examined temporal changes in the tumor microenvironment in poorly immunogenic Renca tumors after a single mJX-594 injection. mJX-594 levels were already high on day 1 after injection, peaked on day 3, and were barely detectable on day 7 ( Fig.33A and 33B In contrast, tumor vasculature responded in the opposite direction to virus levels; tumor vascular density decreased significantly between days 1 and 3 but recovered by day 7 post-injection and thereafter ( Fig.33A and 33B ), indicating that mJX-594 induces effective but transient tumor vascular destruction. Notably, CD8 + The cytotoxic T cell population (which comprises the most critical aspect of anti-cancer immunity) began to rise significantly on day 5, peaked on day 7, and remained at high density for 2 weeks after injection ( Fig.33A and 33B ), clearly demonstrating that mJX-594 significantly and durably transformed non-inflamed tumors into T cell-inflamed tumors. In contrast, CD11c + Dendritic cells (DC) appeared transiently on day 3 and then decreased ( Fig.33A and 33B PD-L1 expression levels were minimal on day 0 and were upregulated after mJX-594 treatment ( Fig.33A and 33B Interestingly, PD-L1 upregulation closely follows CD8 + After a large influx of TIL ( Fig.33C ), suggesting activation of negative feedback pathways that attempt to suppress T cell-mediated immunity. Most cells expressing PD-L1 are cytokeratin + Tumor cells, and some CD11b + Myeloid cells also express PD-L1, but T cells do not ( Fig.33D ). Therefore, mJX-594 is a potent and durable anticancer immune enhancer that + T cells are recruited to cold tumors and transiently disrupt tumor vasculature.
[0247] To elucidate the cancer immune pathways modulated by mJX-594, we used the Pancancer Immunoassay Panel to comprehensively analyze the changes in the expression levels of 750 immune-related genes after mJX-594 monotherapy. The results showed that there were significant differences in gene-related immune signatures between control and mJX-594-treated tumors ( Fig.33E Approximately 100 immunoregulatory genes showed statistically significant changes in their expression levels, including those involved in type I IFN signaling activation, DC maturation, and T cell activation ( Fig.33F In particular, we observed generally higher expression of inhibitory (including Pd-1, Pd-11, Ctla-4, and Lag-3) and agonistic (including Icos, Gitr, and Cd27) immune checkpoint molecules in the TME compared with controls ( Figure 33G ). In addition, further analysis of the TME showed an increase in genes associated with Th1 and Th2 responses, suggesting immunomodulatory effects of mJX-594 monotherapy ( Figure 33G We also found that several genes involved in TME and myeloid cells were significantly increased ( Figure 33G ). Notably, the increase in Nos2 and Cd86 expression represents the polarization of myeloid cells toward M1 macrophages. These results suggest that mJX-594 triggers long-term immune activation through dynamic changes in the TME, thereby remodeling non-inflammatory tumors into T cell-inflamed tumors that are responsive to immune checkpoint blockade.
[0248] mJX-594 enhances CD8 + T cells infiltrate tumors and induce myeloid cell repolarization
[0249] The tumor growth delay induced by mJX-594 was dose-dependent ( Fig.34A and 34B ). At the same time, mJX-594-induced CD8 + The increased infiltration of T cells in the peritumoral and intratumoral regions was also dose-dependent ( Fig.34C and 34D Indeed, flow cytometric subgroup analysis of the lymphoid cell compartment also revealed mJX-594-induced intratumoral CD8 + and CD4 + The absolute number of T cells increased in a dose-dependent manner ( Fig.34E and 34G ). Although CD4 + Foxp3 + CD25 + The number of regulatory T cells also increased ( Fig.34H ), but CD8 +The ratio of T cells to regulatory T cells was 5.3-fold higher than that of control treatment ( Fig.34I ), which means that T cell effector function in the TME was generally increased by mJX-594 treatment. In addition, the expression of ICOS and granzyme B (GzB), which are markers of co-stimulation and T cell activation, was increased in CD8 + Increased in T cells ( Fig.34J ). Further subgroup analysis of the myeloid cell compartment revealed that CD11b + Gr1 + There was no significant change in myeloid cell fraction ( Figure 34K ). However, CD11b + 6G - Ly6C + The mononuclear myeloid cell fraction increased, while CD11b + 6G + Ly6C int The fraction of granulocytic myeloid cells decreased, indicating polarization of myeloid cells after administration of mJX-594 ( Figure 34L and 34M ). These findings demonstrate that repeated administration of mJX-594 enhances anti-cancer immunity, producing increased infiltration of activated T cells and repolarization of myeloid cells.
[0250] Intratumoral injection of mJX-594 induces systemic and cancer-specific immune responses
[0251] To determine whether local injection of mJX-594 could induce a systemic immune response in uninjected distant tumors, we administered mJX-594 to the right Renca tumor after implantation into both flanks. This treatment inhibited the growth of both right and left (opposite, uninjected) Renca tumors ( Fig.35A ). Consistent with the inhibition of bilateral tumor growth, CD8 + T cell infiltration in the intratumoral region increased 7.9-fold and 5.5-fold in right and left Renca tumors, respectively ( Fig.35B and 35C ), indicating that local mJX-594 virotherapy can strongly activate systemic anticancer immunity.
[0252] Next, to exclude the possibility of direct spread of virus to distant tumors via systemic circulation after local viral treatment, we examined viral replication in the left uninjected Renca tumor and found no detectable vaccinia virus in the left tumor ( Fig.41 ), indicating that the anticancer activity of mJX-594 is immune-mediated rather than the result of systemic viral spread.
[0253] To evaluate whether the observed systemic immune response was tumor-specific, we performed similar experiments using mice implanted with Renca tumors in the right flank and CT26 tumors in the left flank. Intratumoral treatment of right-sided Renca tumors with mJX-594 significantly reduced the growth of the injected tumors, whereas the growth of left-sided untreated CT26 tumors was unaffected ( Fig.35D ). Microscopic analysis provided consistent results, namely that CD8 + T cells accumulated in Renca but not in CT26 tumors ( Fig.35E and 35F ), indicating that mJX-594 viral therapy induces tumor-specific CD8 + These results therefore suggest that local mJX-594 treatment elicits systemic anticancer immunity with tumor-specific lymphocyte infiltration even in distant tumors.
[0254] Anti-cancer immunity plays a crucial role in the overall efficacy of JX
[0255] To determine which components of the immune system are responsible for the therapeutic efficacy of mJX-594, we examined its effects on tumors in mice treated with neutralizing antibodies against CD8, CD4, or GM-CSF ( Fig.36A ). It is particularly noteworthy that CD8 + or CD4 + Depletion of T cells abolished the potent inhibitory effect of mJX-594 monotherapy on tumor growth ( Fig.36B and 36C ), highlighting the importance of immune-mediated mechanisms rather than direct oncolysis in mJX-594-induced tumor suppression. Interestingly, upon mJX-594 injection, CD4 + Depletion of T cells interestingly reduced CD8 + Intratumoral infiltration of T cells ( Fig.36D ), indicating that CD4 + T cells participate in the TME in CD8 + Activation and recruitment of T cells. However, CD8 + Depletion of T cells did not significantly alter CD4 + Infiltration of T cells ( Fig.36E ), indicating that CD8 + T cells do not affect CD4 + These data suggest that intratumoral treatment with mJX-594 induces CD8 + and CD4 +Activation of T cells, which can interact with each other to mediate anticancer immunity. Previous herpes virus and vaccinia virus-based virotherapy has utilized GM-CSF as an immune-activating transgene, which recruits and activates antigen-presenting cells (APCs) that subsequently elicit T cell responses. However, the use of GM-CSF remains controversial due to its potential immunosuppressive effects in tumor progression, such as inducing the proliferation of myeloid-derived suppressor cells (MDSCs) (Thorne, 2014). Therefore, we investigated whether GM-CSF is required for the therapeutic effect of mJX-594. Interestingly, depletion of GM-CSF abrogated the antitumor effects of mJX-594 and reduced CD8 + and CD4 + T cell levels, indicating that GM-CSF is important for the immunotherapeutic efficacy of mJX-594 ( Figures 36C-36E ). Therefore, CD8 + and CD4 + T cells are indispensable mediators of the anticancer effects of mJX-594, while GM-CSF can provide immunotherapeutic benefits.
[0256] The combination of mJX-594 and immune checkpoint blockers produces a synergistic anticancer effect and enhances the infiltration of T lymphocytes into tumors
[0257] To overcome resistance to ICI monotherapy, we evaluated the benefit of mJX-594 in combination with ICI. The combination of αPD-1 and mJX-594 reduced tumor growth by 70%, while each αPD-1 and mJX-594 monotherapy delayed tumor growth by 22.8% and 44% ( Fig.37A and 37B In support of these findings, microscopic analysis revealed that CD8 + T cell recruitment was significantly increased ( Fig.37C and 37D ). CD31 + Tumor vascularity was significantly reduced in these regions (1.8- and 2.6-fold, respectively; Fig.37C and 37D In addition, more extensive tumor cell apoptosis was observed in tumors treated with the combination therapy compared with controls ( Fig.37C and 37D Although PD-L1 expression was minimal in control tumors, it was highly upregulated after mJX-594 treatment ( Fig.37C and 37DThis finding suggests that induced PD-L1 expression in the TME is an adaptive negative feedback mechanism that suppresses anticancer immunity after oncolytic virus therapy, thus providing a rationale for the combination of mJX-594 and PD-1 / PD-L1 blockade to enhance the immunotherapeutic effect of mJX-594 ( Fig.37E ).
[0258] Taken together, these results suggest that combination therapy can enhance CD8 + T cell infiltration enhances anticancer immunity to overcome resistance to mJX594 or αPD-1 monotherapy.
[0259] Similarly, combination therapy with αCTLA-4 and mJX-594 was also synergistic. Although monotherapy with either mJX-594 (42.0%) or αCTLA-4 (20.0%) modestly suppressed tumor growth, a stronger inhibitory effect (57.6%) was observed with the combination therapy ( Fig.42A and 42B In addition, after combined treatment, CD8 + Higher accumulation of T cells ( Fig.42C and 42D ). As CD8 + Increased levels of T cells, compared with controls, CD31 + Blood vessels were also significantly damaged in the peripheral and central regions (reduced by 2.1-fold and 3.8-fold, respectively; Fig.42C and 42E ). In addition, flow cytometry showed that the combination of mJX-594 and αCTLA-4 also increased CD8 + and CD4 + Intratumoral infiltration of T cells ( Figures 42F-42H ).
[0260] Together, these results suggest that combination therapy with mJX-594 and ICIs can overcome immunotherapy resistance in the immunosuppressive TME, resulting in a synergistic anticancer effect.
[0261] The efficacy of intratumoral mJX-594 and ICI combination immunotherapy is largely unaffected by treatment regimen
[0262] Because ICIs can negatively affect viral replication and lead to premature clearance of OVs, several studies have explored the optimal treatment regimen using combination therapy with systemic oncolytic virotherapy and ICIs, and some combination regimens have been reported to induce antagonistic therapeutic effects (Liu et al., 2017; Rojas et al., 2015). However, similar studies examining local oncolytic virotherapy have not been reported. To establish the optimal combination regimen for intratumoral mJX-594 and ICIs, we compared the following: (1) simultaneous administration of mJX-594 and ICIs (regimen I); (2) initiation of ICIs 3 days after mJX-594 administration (regimen II); and (3) administration of mJX-594 3 days after the start of ICIs (regimen III; Fig.38A All combinations delayed tumor growth by approximately 40% ( Fig.38B and 38C ). Similarly, tumor-infiltrating CD8 + and CD4 + The levels of T cells increased by >8-fold and >4.0-fold, respectively, which also showed that in CD8 + The expression levels of ICOS and GzB in T cells were significantly increased ( Figures 38D-38F ).
[0263] Similar to the combination therapy with mJX-594 and αPD-1, the combination of mJX-594 and αCTLA-4 inhibited tumor growth by approximately 40% ( Fig.43A and 43B ). In addition, regardless of the treatment regimen, CD8 + and CD4 + Intratumoral infiltration of T lymphocytes (increased >7-fold and >7-fold, respectively) and CD8 + GzB and ICOS expression were greater in T cells ( Figures 43C-43E ).
[0264] In conclusion, combination therapy of intratumoral injection of mJX-594 and systemic immune checkpoint blockade generated potent anticancer immune responses regardless of treatment regimen, suggesting that intratumoral administration of mJX-594 was not significantly affected by changes in ICI administration regimens.
[0265] The triple combination of mJX-594, αPD1, and αCTLA4 induces complete tumor regression and provides long-term survival benefit in implanted renal cancer
[0266] Since the dual combination of mJX-594 and ICI did not induce complete tumor regression, we explored triple therapy using mJX-594, αPD-1, and αCTLA-4. The dual combination of αPD-1 and αCTLA-4 delayed tumor growth by 14.5%, mJX-594 monotherapy inhibited tumor growth by 36.9%, and the triple combination inhibited tumor growth by 76.5% ( Fig.39A and 39B ). Notably, a minority (approximately 40%) of the triplet group resulted in complete tumor regression, which was not observed in any of the other groups ( Fig.39C ).
[0267] To confirm whether the potent anticancer effects induced by triple therapy could translate into long-term survival benefits, we performed survival analysis in tumor-bearing mice. Indeed, mice treated with triple therapy showed a significant survival benefit compared with other treatments ( Fig.39D Furthermore, mice with complete tumor regression remained tumor-free for more than 12 weeks after the end of treatment and were fully protected from rechallenge with tumor cells, indicating the establishment of effective long-term immune memory ( Fig.39E ).
[0268] These findings demonstrate the potential of triple immunotherapy to induce complete tumor regression and long-term survival.
[0269] Triple therapy enhances anticancer immune responses in a spontaneous breast cancer model
[0270] To clearly demonstrate the long-term immunotherapeutic effect of the triple therapy in immune-tolerant tumors, we used the MMTV-PyMT transgenic mouse model, a spontaneous breast cancer model that is intrinsically resistant to cancer immunotherapy (Schmittnaegel et al., 2017). After 4 weeks of treatment, mice treated with the triple combination of mJX-594, αPD-1, and αCTLA-4 exhibited a 38.7% total tumor burden and a significant decrease in the number of palpable mammary tumor nodules compared to control mice ( Figures 40A-40D In addition, the triple therapy reduced the mean size of each tumor nodule by 48.1% and improved overall survival compared with other therapies ( Figures 40E-40F Histological analysis ( Figure 40G , see figure legend for detailed explanation) showed that the triple combination group had less invasive cancer and well-preserved tumor margins, indicating that the triple combination effectively delayed tumor progression and invasion. On the other hand, tumors treated with the dual combination of αPD-1 and αCTLA-4 showed an invasive cancer phenotype comparable to that of the control group, which had invaded surrounding tissues and formed solid sheets of tumor cells. Therefore, after triple combination therapy, CD8 +Intratumoral recruitment of T cells was significantly increased by >50-fold ( Figure 40H and 40I ). However, tumor vascular density was similar between treatment groups ( Fig.40J ). These findings suggest that enhanced anticancer immunity, rather than vascular disruption, is critical for the long-term efficacy of triple immunotherapy using mJX-594 and ICI. Finally, the number of hematogenous lung metastases was significantly reduced in the triple therapy group ( Figure 40K and 40L ), indicating that the triple therapy has an effective anti-metastatic effect.
[0271] Together, these results demonstrate that triple immunotherapy with mJX-594 and ICI can elicit a robust anticancer immune response even in a spontaneous breast cancer model with poor immunogenicity.
[0272] discuss
[0273] Here, we demonstrate that combination therapy with mJX-594 and ICI is an effective therapeutic strategy for immune-resistant tumors. Combination therapy produces an immunological "boiling point" where cold, non-inflammatory tumors are fully ignited, allowing the host immune system to eradicate tumor cells. The effect of triple immunotherapy with mJX-594, anti-PD-1, and anti-CTLA4 was the most significant, causing complete regression in approximately 40% of Renca tumors, one of the most resistant homologous tumors to immunotherapy. This powerful synergistic effect can be explained by the complementary cooperation of OV and ICI.
[0274] JX-594 is an OV in the most advanced stage of clinical trials and is known to work through various mechanisms (Abou-Alfa et al., 2016). Although it can rapidly induce direct oncolysis and vascular destruction in tumors, these effects are transient and mostly diminish within 1 week of injection. Thereafter, CD8 + T cells extensively infiltrate tumors to elicit anticancer immune responses. However, at the same time, tumors begin to develop to avoid immune-mediated elimination by upregulating immunosuppressive checkpoint molecules in the TME (such as PD-1, PD-L1, or CTLA-4). Since OVs achieve the most effective and durable anticancer effects while successfully inducing and maintaining antitumor immunity, it is reasonable to combine ICIs with OVs to prevent the early shutdown of OV-induced anticancer immunity.
[0275] Although ICI monotherapy has revolutionized cancer treatment, its remarkable therapeutic responses are limited to a subset of patients. This has led to the concept of immunologically “hot” or “cold” tumors; hot tumors respond well to ICIs because they are immune-inflamed by TILs and have high expression of PD-L1, while cold tumors respond well to ICIs because they are CD8 +Tumors are refractory to ICIs due to the lack of TILs and immunosuppressive TME (Bell and Ilkow, 2017; Gajewski et al., 2013). Therefore, current efforts are focused on overcoming resistance to ICIs by converting immunologically cold tumors into hot tumors. In this regard, our results suggest that mJX-594 is an ideal combination partner for ICIs. It can selectively replicate in tumor cells, destroy them, and release tumor antigens to stimulate the host immune system. In addition, our studies show that the TME can be significantly converted from a cold state to a hot state by inducing intratumoral inflammatory responses: induction of Th1 responses, activation and recruitment of T cells, upregulation of PD-L1, and polarization of myeloid cells toward antitumor activity. Interestingly, it is known that the replication and spread of OVs are more active in cold tumors, where there are few immune cells to eliminate OVs, while hot tumors with ample resident TILs can induce premature clearance of OVs and weaken their therapeutic effects (Bell and Ilkow, 2017). Therefore, together with the results of this study, mJX-594 is an optimal combination partner for ICIs, especially for non-inflamed, cold tumors that are intrinsically resistant to immunotherapy.
[0276] GM-CSF is the most commonly used therapeutic genetic payload for OVs. T-Vec and Pexa-Vec (JX-594), two OVs in the most advanced stages of clinical trials, are both equipped with GM-CSF. Although GM-CSF is generally known to induce the proliferation of various immune cells such as DCs, concerns remain about the deleterious proliferation of immunosuppressive cells such as MDSCs (Hou et al., 2016). In this study, we revealed that mJX-594 did not significantly alter intratumoral CD11b expression. + Gr1 + Furthermore, neutralization of GM-CSF abolished the therapeutic efficacy of mJX-594, which was partly due to the CD8 + The reduction in TILs indicated that GM-CSF plays an indispensable role in mJX-594-induced cancer immunity.
[0277] Previous studies have reported that although the combination of OV and ICI elicits an impressive immune response, its therapeutic effect may be largely affected by the route of administration and treatment schedule. In particular, when OV and ICI are systemically administered simultaneously, the combination may be antagonistic because ICI-induced antiviral immunity can promote premature clearance of the virus, indicating the importance of sufficient time interval between OV treatments to induce successful anticancer immunity. In the present study, local injection of mJX-594 continuously induced anticancer immunity without being significantly affected by the order of administration. We speculate that this is because intratumoral injection provides OV with sufficient time to inflame the TME before it is eliminated by systemic antiviral immunity. Therefore, in the design of clinical trials for combined ICI and OV therapy, intratumoral OV treatment may be more feasible than systemic OV treatment in terms of dosing schedule.
[0278] In addition to our encouraging results with the combination of mJX-594 and ICIs, several clinical trials are already underway to investigate the efficacy of JX-594 in combination with αPD-1, αCTLA-4, or αPD-L1 targeting various solid cancers, including liver, kidney, and colon cancer (ClinicalTrials.GoV: NCT03071094, NCT02977156, NCT03294083, and NCT03206073). Therefore, we will be able to validate the findings of this study in a clinical setting in the near future.
[0279] In conclusion, this study demonstrated that intratumoral injection of mJX-954 could induce a transition of the TME from a cold to a hot state and trigger potent anticancer immunity in combination with ICI, thereby overcoming resistance to immunotherapy.
[0280] Experimental Procedure
[0281] Mice and cell lines
[0282] Male BALB / c mice aged 6-8 weeks were purchased from Orient Bio Inc. (Seongnam, Gyeonggi-do, South Korea) and female MMTV-PyMT transgenic mice (FVB / N) were purchased from Jackson Laboratory (Bar Harbor, Maine, USA, #002374). Mice were kept in a specific pathogen-free animal facility at CHA University (Seongnam, Gyeonggi-do, South Korea). All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC, #170025) of CHA University and performed according to the approved protocol. Renca mouse renal cancer cell line and CT26 mouse colon cancer cell line were obtained from the American Type Culture Collection (Manassas, Virginia, USA, #CRL-2947) and the Korean Cell Line Bank (Seoul, South Korea, #80009). The cells were maintained in Roswell Park Memorial Institute (RPMI) 1640 medium or Dulbecco's modified Eagle's medium (DMEM), each supplemented with 10% fetal bovine serum (FBS) and 1% penicillin / streptomycin, and incubated at 37° C. in a 5% CO 2 incubator.
[0283] Virus production and quantification
[0284] mJX-594, provided by Sillajen, Inc. (Seoul, South Korea), is a Western Reserve (WR) strain of vaccinia virus encoding murine GM-CSF in the vaccinia thymidine kinase locus under the control of the p7.5 promoter and was used throughout the study. The virus was amplified in HeLaS3 cells before purification. Briefly, HeLaS3 cells were infected with recombinant vaccinia virus for 3 days, collected by centrifugation, and then homogenized and centrifuged again. The supernatant containing the virus was plated on a 36% sucrose cushion, centrifuged at 32900g, and the purified virus pellet was resuspended in 1mM Tris, pH 9.0. To determine the virus titer, the virus serially diluted in serum-free DMEM was applied to U-2OS cell monolayers for 2 hours, followed by the addition of 1.5% carboxymethylcellulose in DMEM supplemented with 2% FBS. After 72 hours, the cells were stained with 0.1% crystal violet and plaques were counted.
[0285] Tumor models and treatment options
[0286] 2 × 10 by subcutaneous injection 5 Renca cells were used to implant tumors into the right flank of wild-type BALB / c mice. 3 Every 3 days, PBS or 1 × 10 7 Plaque forming units (pfu) of mJX-594 were used to treat mice. For the bilateral tumor model, 2×105 Renca cells were implanted subcutaneously on the right side of the abdomen, and 1×10 5 Renca or CT26 cells were implanted subcutaneously in the left flank. For cell depletion studies, antibodies against CD4 (200 μg, clone GK1.5, BioxCell), CD8 (200 μg, clone 53-6.72, BioxCell), or GM-CSF (200 μg, clone MP1-22E9, BioxCell) were injected intraperitoneally together with mJX-594. For immune checkpoint blockers, anti-PD-1 (10 mg / kg, clone J43, BioxCell) and / or anti-CTLA-4 (4 mg / kg, clone 9D9, BioxCell) antibodies were injected intraperitoneally every 3 days, depending on the dosing schedule, with or without mJX-594. Tumors were measured every 2 or 3 days using a digital caliper and the modified ellipsoid formula (1 / 2 × (length × width)) was used. 2 )) Tumor volume was calculated. On day 50, 2 × 10 5 Surviving mice with complete tumor regression were re-challenged with 100 Renca cells and monitored for tumor growth and survival. Mice were euthanized when tumors reached 1.5 cm in diameter or when mice were moribund.
[0287] Female MMTV-PyMT transgenic mice were purchased from Jackson Laboratory. At 9 weeks after birth, each palpable tumor nodule (>20 mm 3 ) volume, and the total volume of all tumors combined was used to calculate the tumor burden of each mouse. MMTV-PyMT mice were randomized according to their initial tumor burden and treated with 1×10 7 pfu of mJX-594. After 4 weeks of treatment, mice were anesthetized and tissues were collected for further analysis. MMTV-PyMT analysis was performed as previously described (Kim et al., 2014; Park et al., 2016).
[0288] Histological analysis
[0289] For hematoxylin and eosin (H&E) staining, tumors were fixed in 4% paraformaldehyde (PFA) overnight. After tissue processing using standard procedures, samples were embedded in paraffin and cut into 3 μm sections, followed by H&E staining. Immunofluorescence was performed on frozen tissue sections. Tumors were fixed in 1% PFA at room temperature and rinsed several times with PBS, infiltrated with 30% sucrose, and frozen in OCT compound. Cryosections (50 μm thick) were blocked with 5% normal goat serum in PBS-T (0.1% Triton X-100 in PBS) and then incubated overnight with the following primary antibodies: anti-vaccinia virus (rabbit, Abcam), anti-CD31 (hamster, clone 2H8, Millipore; rabbit, Abcam), anti-CD8 (rat, clone 53-6.7, BD Pharmingen), anti-CD11c (hamster, clone HL3, BD Pharmingen), anti-PD-L1 (rabbit, clone 28-8, Abcam), anti-caspase 3 (rabbit, R&D Systems), anti-pan-cytokeratin (mouse, clone AE1 / AE3, DAKO), anti-CD11b (rat, clone M1 / 70, BD Pharmingen), or anti-CD3e (Hamster, clone 145-2C11, BD Pharmingen). After washing several times, the samples were incubated with the following secondary antibodies for 2 hours at room temperature: FITC, Cy3, or Cy5-conjugated anti-rabbit IgG (Jackson ImmunoResearch), FITC-conjugated anti-rat IgG (Jackson ImmunoResearch), FITC- or Cy3-conjugated anti-hamster IgG (Jackson ImmunoResearch), or FITC-conjugated anti-mouse IgG (Jackson ImmunoResearch). The nuclei were counterstained with 4',6-diamidino-2-phenylindole (DAPI, Invitrogen). Finally, the samples were mounted with fluorescent mounting medium (DAKO) and images were acquired with a Zeiss LSM 880 microscope (Carl Zeiss).
[0290] Morphometric analysis
[0291] ImageJ software ( http: / / rsb.info.nih.gov / ij ) were used to measure the density of vaccinia virus, blood vessels, T lymphocytes and dendritic cells, and the area of myeloid cells. To determine the level of vaccinia virus infection, the number of cells per random 0.49 mm2 tumor sections was calculated. 2 The VV+ area of the visual field. For vascular density, every random 0.49 mm2 was calculated in the peritumoral and intratumoral regions. 2 CD31 +The extent of cytotoxic T lymphocyte infiltration was expressed as 0.49 mm per random area in the peritumoral and intratumoral regions. 2 CD8 + Area percentage. By calculating random 0.49mm 2 CD11c + The percentage of area was used to measure the level of dendritic cells. The degree of apoptosis was expressed as a percentage of area per random 0.49 mm 2 Caspase 3 + To define the percentage of PD-L1 + Cells, at random 0.01mm 2 Identification of PD-L1 in the field of vision + With Pan-CK + 、CD11b + and CD3 + Lung metastasis in MMTV-PyMT mice was quantified by measuring tumor foci >100 μm in diameter. All measurements were performed in at least 5 fields per mouse.
[0292] Flow cytometric analysis of tumor-infiltrating immune cells
[0293] Tumors from each treatment group were minced before incubation with shaking at 37°C for 1 hour in the presence of collagenase D (20 mg / ml, Roche) and DNase I (2 mg / ml, Roche). Cell suspensions were generated by repeated pipetting and then filtered through a 70 μm cell strainer and lysed to remove red blood cells. After washing with PBS, the resuspended cells were filtered through a nylon mesh. Single cell suspensions from tumor tissues were blocked with an antibody against CD 16 / 32 (clone 2.4G2, BD Pharmingen) and stained with a fixable viability dye (eFlouor450, eBioscience) to distinguish live cells. To analyze surface markers, cells were stained with antibodies against CD45 (30-F11, BD Pharmingen), CD4 (RM4-5, BD Pharmingen), CD8 (53-6.7, BD Pharmingen), CD3 (17A2 or 145-2C11, eBioscience), ICOS (7E.17G9 or 15F9, eBioscience), CD11b (M1 / 70, BD Pharmingen), F4 / 80 (BM8, eBioscience), MHC II (M5 / 114.15.2, eBioscience), Ly6C (HK1.4, eBioscience), Ly6G (1A8-Ly6g or RB6-8C5, eBioscience), or CD206 (MR5D3, eBioscience) in PBS containing 1% FBS for 30 minutes on ice. Cells were further permeabilized using the FoxP3 fixation and permeabilization kit (eBioscience) and stained for FoxP3 (FJK-16s, eBioscience), CD25 (PC61.5, eBioscience), or granzyme B (NGZB, eBioscience). Labeled cells were acquired using a CytoFLEX flow cytometer (Beckman Coulter) and analyzed using FlowJo software (TreeStar Inc., Ashland, OR).
[0294] RNA isolation and NanoString gene expression analysis
[0295] Total RNA was extracted from whole tumor lysates using TRIzol (Invitrogen) and purified with ethanol; RNA quality was confirmed using a fragment analyzer (Advanced Analytical Technologies, Iowa, USA). Immunoassays were performed using a digital multiplex NanoString nCounter Pancancer Immunoassay Mouse Panel (NanoString Technologies) using 100 ng of total RNA isolated from tumor tissue. Hybridization was performed at 65°C for 16-30 hours by combining 5 μl of each RNA sample with 8 μl of nCounter Reporter probe and 2 μl of nCounter Capture probe in hybridization buffer, with a total reaction volume of 15 μl. Excess probes were removed by a two-step purification based on magnetic beads using the nCounter Prep Station (NanoString Technologies). The abundance of specific target molecules was quantified using the nCounter digital analyzer by counting individual fluorescent barcodes and evaluating the corresponding target molecules. For each assay, a high-density scan including 280 fields of view was performed. After collecting images of the fluorescent reporter molecules fixed in the sample box with a CCD camera, the data were collected using an nCounter digital analyzer. Data analysis was performed using nSolver software (NanoString Technologies). mRNA analysis data were normalized to housekeeping genes and analyzed using R software (www.r-project.org).
[0296] Statistical analysis
[0297] Statistical analysis was performed using GraphPad Prism 7.0 software (GraphPad Software, La Jolla, California) and PASWstatistics 18 (SPSS). Unless otherwise indicated, values are expressed as mean + / - standard error of the mean (SEM). Statistical differences between mean values were tested using an unpaired Student's t-test. Survival curves were generated using the Kaplan-Meier method, and the log-rank test was used to analyze the statistical differences between the curves. The statistical significance level was set at p < 0.05.
[0298] References
[0299] Abou-Alfa, GK, Galle, PR, Chao, Y., Brown, KT, Heo, J., Borad, MJ, Luca, A., Pelusio, A., Agathon, D., and Lusky, M. (2016). PHOCUS: A phase 3 randomized, open-label study comparing the oncolytic immunotherapy Pexa-Vec followed by sorafenib(SOR) vs SOR in patientswith advanced hepatocellular carcinoma(HCC)without prior systemic therapy. In (2016 ASCO Annual Meeting).
[0300] Bell, J. (2014). Oncolytic viruses: immune or cytolytic therapy? Molecular Therapy 22, 1231-1232.
[0301] Bell, JC, and Ilkow, CS (2017). Aviro-immunotherapy triple play for the treatment of glioblastoma. Cancer Cell 32, 133-134.
[0302] Breitbach, CJ, Burke, J., Jonker, D., Stephenson, J., Haas, AR, Chow, LQ, Nieva, J., Hwang, TH, Moon, A., Patt, R., et al. (2011a). Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature, 477, 99-102.
[0303] Breitbach, CJ, De Silva, NS, Falls, TJ, Aladl, U., Evgin, L., Paterson, J., Sun, YY, Roy, DG, Rintoul, JL, Daneshmand, M., et al. (2011b). Targeting tumor vasculature with an oncolytic virus. Molecular therapy: the journal of the American Society of Gene Therapy, 19, 886-894.
[0304] Breitbach, CJ, Parato, K., Burke, J., Hwang, T.-H., Bell, JC, and Kirn, DH (2015a). Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic. Current opinion in virology 13, 49-54.
[0305] Breitbach, CJ, Parato, K., Burke, J., Hwang, TH, Bell, JC, and Kirn, DH (2015b). Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic. Current opinion in virology 13, 49-54.
[0306] Chiocca, EA and Rabkin, SD (2014). Oncolytic viruses and their application to cancer immunotherapy. Cancer immunology research 2, 295-300.
[0307] Cripe, TP, Ngo, MC, Geller, JI, Louis, CU, Currier, MA, Racadio, JM, Towbin, AJ, Rooney, CM, Pelusio, A., Moon, A., et al. (2015). Phase 1 study of intratumoral Pexa-Vec (mJX-594), an oncolytic and immunotherapeutic vacciniavirus, in pediatric cancer patients. Molecular therapy: the journal of the American Society of Gene Therapy 23, 602-608.
[0308] De Palma, M. and Jain, RK (2017). CD4+ T cell activation and vascular normalization: Two sides of the same coin? Immunity 46, 773-775.
[0309] Gajewski, TF (2015). The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment. Seminars in Oncology 42, 663-671.
[0310] Gajewski, TF, Schreiber, H., and Fu, YX (2013). Innate and adaptive immune cells in the tumor microenvironment. Nature immunology, 14, 1014-1022.
[0311] Hegde, P.S., Karanikas, V., and Evers, S. (2016). The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition. Clinical cancer research: an official journal of the American Association for Cancer Research, 22, 1865-1874.
[0312] Heo, J., Reid, T., Ruo, L., Breitbach, CJ, Rose, S., Bloomston, M., Cho, M., Lim, HY, Chung, HC, Kim, CW, et al. (2013). Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia mJX-594 in liver cancer. Nature medicine 19, 329-336.
[0313] Hou, W., Sampath, P., Rojas, J. J., and Thorne, S. H. (2016). Oncolytic Virus-Mediated Targeting of PGE2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy. Cancer Cell 30, 108-119.
[0314] Kim, C., Yang, H., Fukushima, Y., Saw, P. E., Lee, J., Park, J.-S., Park, I., Jung, J., Kataoka, H., and Lee, D. (2014). Vascular RhoJ is an effective and selective target for tumor angiogenesis and vascular disruption. Cancer Cell, 25, 102-117.
[0315] Kim, M., Nitschke, M., Sennino, B., Murer, P., Schriver, B.J., Bell, A., Subramanian, A., McDonald, C.E., Wang, J., & Cha, H. (2018). Amplification of oncolytic vaccinia viruswidespread tumor cell killing by sunitinib through multiple mechanisms. Cancer Research, 78, 922-937.
[0316] Kirn, DH and Thorne, SH (2009). Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nature Reviews Cancer 9, 64.
[0317] Lichty, BD, Breitbach, CJ, Stojdl, DR, and Bell, JC (2014). Going viral with cancer immunotherapy. Nature Reviews Cancer, 14, 559.
[0318] Liu, Z., Ravindranathan, R., Kalinski, P., Guo, ZS, & Bartlett, DL (2017). Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nature Communications 8, 14754.
[0319] Park, BH, Hwang, T., Liu, TC, Sze, DY, Kim, JS, Kwon, HC, Oh, SY, Han, SY, Yoon, JH, Hong, SH, et al. (2008). Use of a targeted oncolytic poxvirus, mJX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. The Lancet Oncology 9, 533-542.
[0320] Park, J.-S., Kim, I.-K., Han, S., Park, I., Kim, C., Bae, J., Oh, S.J., Lee, S., Kim, J.H., and Woo, D.-C. (2016). Normalization of tumor vessels by Tie2 activation and Ang2 inhibition enhances drug delivery and produces a favorable tumor microenvironment. Cancer cell, 30, 953-967.
[0321] Rivera, LB and Bergers, G. (2015). Intertwined regulation of angiogenesis and immunity by myeloid cells. Trends in immunology 36, 240-249.
[0322] Rojas, JJ, Sampath, P., Hou, W., and Thorne, SH (2015). Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy. Clinical cancer research: an official journal of the American Association for Cancer Research, 21, 5543-5551.
[0323] Schmittnaegel, M., Rigamonti, N., Kadioglu, E., Cassara, A., Rmili, C. W., Kiialainen, A., Kienast, Y., Mueller, H.-J., Ooi, C.-H., and Laoui, D. (2017). Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade. Science translational medicine 9, eaak9670.
[0324] Sharma, P., Hu-Lieskovan, S., Wargo, JA, & Ribas, A. (2017). Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell, 168, 707-723.
[0325] Thorne, SH (2014). Immunotherapeutic potential of oncolytic vaccinia virus. Frontiers in Oncology 4, 155.
[0326] Topalian, SL, Drake, CG, and Pardoll, DM (2015). Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450-461.
[0327] Topalian, SL, Taube, JM, Anders, RA, and Pardoll, DM (2016). Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nature Reviews Cancer 16, 275.
[0328] Wolchok, JD and Chan, TA (2014). Cancer: Antitumour immunity gets a boost. Nature 575, 496.
[0329] According to the present disclosure, all compositions and / or methods disclosed and claimed herein can be prepared and implemented without excessive experimentation. Although the compositions and methods of the present invention have been described according to preferred embodiments, it will be apparent to those skilled in the art that the steps or sequence of steps of the compositions and / or methods and methods described herein can be changed without departing from the concept, spirit and scope of the present invention. More specifically, it will be apparent that certain reagents related to chemistry and physiology can replace the reagents described herein while obtaining the same or similar results. All these similar substitutions and modifications apparent to those skilled in the art are considered to be within the spirit, scope and concept of the present invention as defined by the appended claims.
[0330] The above examples are provided to give those of ordinary skill in the art a complete disclosure and description of embodiments of the compositions, systems and methods of the present invention, and are not intended to limit the scope of what the inventors regard as their invention. Modifications of the above modes for carrying out the present invention that are apparent to those skilled in the art are intended to fall within the scope of the appended claims. All patents and publications mentioned in the specification are indicative of the technical level of those skilled in the art to which the present invention belongs. All references cited in this disclosure are incorporated herein by reference to the same extent as if each reference had been incorporated herein by reference in its entirety individually.
[0331] All headings and section names are used for clarity and reference purposes only and should not be considered limiting in any way. For example, those skilled in the art will appreciate the usefulness of appropriately combining various aspects from different headings and sections in accordance with the spirit and scope of the invention described herein.
[0332] All references cited herein are hereby incorporated by reference in their entirety and for all purposes to the same extent as if each individual publication or patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety for all purposes.
[0333] Without departing from the spirit and scope of the present invention, many modifications and changes can be made to the present application, which will be apparent to those skilled in the art. The specific embodiments and examples described herein are provided as examples only, and the present application is limited only by the terms of the appended claims and the full scope of the equivalent schemes authorized by the claims.
[0334] Specifically, the present invention includes but is not limited to the following:
[0335] 1. A method for treating and / or preventing cancer in a subject in need of cancer treatment, comprising simultaneously administering to the subject an effective amount of a composition comprising (a) a replicating oncolytic vaccinia virus and (b) one or more immune checkpoint inhibitors.
[0336] 2. The method of claim 1 , wherein the replicative oncolytic vaccinia virus is administered intratumorally, intravenously, intraarterially or intraperitoneally.
[0337] 3. The method of claim 2, wherein the replicative oncolytic vaccinia virus is administered intratumorally.
[0338] 4. A method according to any one of items 1-3, wherein the replicative oncolytic vaccinia virus is administered in an amount effective to induce expression of immune checkpoint proteins in the tumor.
[0339] 5. The method of any one of items 1-4, wherein prior to administration of the replicative oncolytic vaccinia virus, the tumor does not express the immune checkpoint protein or expresses the immune checkpoint protein at a relatively low level.
[0340] 6. A method according to any one of items 1-5, wherein the immune checkpoint inhibitor is an antibody or a fragment thereof that specifically binds to the immune checkpoint protein, preferably a monoclonal antibody, a humanized antibody, a fully human antibody, a fusion protein or a combination thereof.
[0341] 7. A method according to any one of items 1-6, wherein the checkpoint inhibitor inhibits an immune checkpoint protein selected from the group consisting of: cytotoxic T lymphocyte antigen 4 (CTLA4), programmed cell death protein 1 (PD-1), PD-L1, PD-L2, B7-H3, B7-H4, herpes virus entry mediator (HVEM), T cell membrane protein 3 (TIM3), galectin 9 (GAL9), lymphocyte activation gene 3 (LAG3), T cell activation inhibitor (VISTA) containing V domain immunoglobulin (Ig), killer cell immunoglobulin-like receptor (KIR), B and T lymphocyte attenuator (BTLA), T cell immune receptor with Ig and II′IM domains (TIGIT), indoleamine 2,3-dioxygenase (IDO) or a combination thereof.
[0342] 8. The method according to claim 7, wherein the immune checkpoint inhibitor is a monoclonal antibody that selectively binds to PD-1 or PD-L1, preferably selected from the group consisting of BMS-936559, atezolizumab, durvalumab, avelumab, nivolumab, pembrolizumab and lambrolizumab.
[0343] 9. The method according to item 7, wherein the immune checkpoint inhibitor is a monoclonal antibody that selectively binds to CTLA4, preferably selected from the group consisting of ipilimumab and tremelimumab.
[0344] 10. The method of any one of items 1-9, wherein multiple checkpoint inhibitors are administered to the subject simultaneously with the oncolytic vaccinia virus.
[0345] 11. The method according to item 10, wherein the subject is simultaneously administered:
[0346] (a) CTLA4 inhibitors, PD-1 inhibitors, and replicative oncolytic vaccinia viruses;
[0347] (b) CTLA4 inhibitors, IDO inhibitors, and replication-inhibiting oncolytic vaccinia viruses;
[0348] (c) PD-1 inhibitors, IDO inhibitors, and replication-inhibiting oncolytic vaccinia viruses; or
[0349] (d) PD-1 inhibitors, CTLA4 inhibitors, IDO inhibitors, and replicative oncolytic vaccinia viruses;
[0350] (e) LAG3 inhibitors, PD-1 inhibitors, and replication-inhibiting oncolytic vaccinia viruses; or
[0351] (f) TIGIT inhibitors, PD-1 inhibitors, and replication-resistant oncolytic vaccinia viruses.
[0352] 12. The method according to any one of items 1-11, wherein the replicative oncolytic vaccinia virus is a Wyeth strain, a West Reserve strain, a Lister strain or a Copenhagen strain.
[0353] 13. A method according to any one of items 1 to 12, wherein the vaccinia virus comprises one or more genetic modifications to increase the selectivity of the virus for cancer cells, preferably the virus is engineered to lack functional thymidine kinase and / or lack functional vaccinia growth factor.
[0354] 14. The method according to any one of items 1 to 13, wherein the vaccinia virus comprises a functional 14L and / or F4L gene.
[0355] 15. The method according to any one of items 1 to 14, wherein the vaccinia virus is engineered to express (i) a cytokine, which is preferably selected from GM-CSF, IL-2, IL-4, IL-5, IL-7, IL-12, IL-15, IL-18, IL-21, IL-24, IFN-γ, TNF-α, and / or (ii) a tumor antigen, which is preferably selected from BAGE, GAGE-1, GAGE-2, CEA, AIM2, CDK4, BMI1, COX-2, MUM-1, M UC-1, TRP-1, TRP-2, GP100, EGFRvIII, EZH2, LICAM, Livin, Livinβ, MRP-3, Nestin, OLIG2, SOX2, Human papillomavirus E6, Human papillomavirus E7, ART1, ART4, SART1, SART2, SART3, B-cyclin, β-catenin, Glil, Cav-1, Cathepsin B, CD74, E-cadherin, EphA2 / Eck, Fra-1 / Fosl 1, Ganglioside / GD2, GnT-V, β1,6-N, Her2 / neu, Ki67, Ku70 / 80, IL-13Ra2, MAGE-1, MAGE-3, NY-ESO-1, MART-1, PROX1, PSCA, SOX10, SOX11, survivin, caspase-8, UPAR, CA-125, PSA, p185HER2, CD5, IL-2R, Fap-α, tenascin, melanoma-associated antigen p97, and WT-1, regulator of G protein signaling 5 (RGS5), Surivin (BIRC5 = baculovirus inhibitor of apoptosis containing repeat structure 5) , insulin-like growth factor binding protein 3 (IGF-BP3), thymidylate synthase (TYMS), hypoxia-inducible protein 2, hypoxia-inducible lipid droplet-associated protein (HIG2), matrix metallopeptidase 7 (MMP7), prune homologous protein 2 (PRUNE2), RecQ protein-like (DNA helicase Q1-like protein) (RECQL), leptin receptor (LEPR), ERBB receptor feedback inhibitor 1 (ERRFI1), lysosomal protein transmembrane protein 4 alpha (LAPTM4A), RAB1B, RAS oncogene family (RABIB), CD24, Homo sapiens thymosin beta 4. X-linked (TMSB4X) protein, Homo sapiens S100 calcium-binding protein A6 (S100A6), Homo sapiens adenosine A2 receptor (ADORA2B), chromosome 16 open reading frame 61 antibody (C16orf61), ROD1 differentiation regulator 1 (ROD1), NAD-dependent deacetylase sirtuin-2 (SIR2L), tubulin alpha 1c (TUBA1C), ATPase inhibitory factor 1 (ATPIF1), matrix antigen 2 (STAG2), nuclear casein kinase and cyclin-dependent substrate 1 (NUCKS1).
[0356] 16. The method according to any one of items 1 to 15, wherein the vaccinia virus is about 10 7 to about 10 11 pfu, preferably about 10 8 -10 10 pfu, more preferably about 10 9 -10 10 pfu were administered.
[0357] 17. A method according to any one of items 1-16, wherein the checkpoint inhibitor is administered in an amount of about 2 mg / kg to 15 mg / kg.
[0358] 18. A method according to any one of items 1-17, wherein the subject has a cancer selected from hepatocellular carcinoma, colorectal cancer, renal cell carcinoma, bladder cancer, lung cancer (including non-small cell lung cancer), gastric cancer, esophageal cancer, sarcoma, mesothelioma, melanoma, pancreatic cancer, head and neck cancer, ovarian cancer, cervical cancer and liver cancer.
[0359] 19. A method according to claim 18, wherein the subject has renal cell carcinoma.
[0360] 20. A method according to any one of items 1-19, wherein at least one previous chemotherapy or immunotherapy treatment for the subject has failed.
[0361] 21. A method according to claim 20, wherein the subject has a cancer that is refractory to immune checkpoint inhibitor therapy, preferably the cancer is resistant to treatment with anti-PD-1 antibodies and / or anti-CTLA-4 antibodies.
[0362] 22. A method according to claim 21, wherein the subject is identified as a candidate for immune checkpoint inhibitor therapy.
[0363] 23. A method according to any one of items 1-22, comprising administering to the subject an additional therapy selected from chemotherapy (alkylating agents, nucleoside analogs, cytoskeletal regulators, cytostatics) and radiotherapy.
[0364] 24. A method according to any one of items 1-23, comprising administering to the subject other oncolytic virus therapy (e.g., rhabdovirus, Semliki Forest virus)
[0365] 25. A method according to any one of items 1-24, wherein the subject is human.
[0366] 26. A method according to any one of items 1-25, wherein a first dose of the replicative oncolytic vaccinia virus and a first dose of the immune checkpoint inhibitor are administered to the subject simultaneously, and then the virus and the checkpoint inhibitor are administered to the subject simultaneously at least once in succession.
[0367] 27. The method of claim 26, comprising administering the replicative oncolytic vaccinia virus and the checkpoint inhibitor to the subject simultaneously at least a first, second, and third time in a row.
[0368] 28. The method of claim 27, comprising administering the replicative oncolytic vaccinia virus and the checkpoint inhibitor to the subject simultaneously at least a first, second, third, and fourth time in a row.
[0369] 29. A method according to any one of items 26-28, wherein the first dose of replicative oncolytic vaccinia virus and the first dose of immune checkpoint inhibitor are administered simultaneously, and then the virus and the checkpoint inhibitor are administered to the subject simultaneously at least once in a row, and then at least one dose of the checkpoint inhibitor is administered to the subject alone.
[0370] 30. The method according to any one of items 26-29, comprising an interval of 1-3 weeks between consecutive simultaneous administrations of the agents, preferably comprising an interval of about 1 week, about 2 weeks or about 3 weeks.
[0371] 31. A method of treating a tumor in a human, comprising simultaneously administering to the human a composition comprising (a) a replicating oncolytic vaccinia virus and (b) an inhibitor of an immune checkpoint protein.
[0372] 32. The method of claim 31, wherein the replicative oncolytic vaccinia virus is administered intratumorally, intravenously, intraarterially or intraperitoneally.
[0373] 33. A method according to claim 31, wherein the replicative oncolytic vaccinia virus is administered intratumorally.
[0374] 34. A method according to claim 31, wherein the replicative oncolytic vaccinia virus is administered in an amount effective to induce expression of immune checkpoint proteins in the tumor.
[0375] 35. The method of claim 31, wherein prior to administration of the replicative oncolytic vaccinia virus, the tumor does not express the immune checkpoint protein or expresses the immune checkpoint protein at a relatively low level.
[0376] 36. A method according to item 34 or 35, comprising a step of measuring the expression level of the immune checkpoint protein in the tumor before administering the composition.
[0377] 37. A method according to any one of items 31-36, wherein the immune checkpoint protein is selected from PD-1, PD-L1, CTLA-4, LAG3, TM3 and TIGIT.
[0378] 38. A method according to claim 31, wherein the immune checkpoint protein is CTLA-4.
[0379] 39. A method according to claim 31, wherein the immune checkpoint protein is PD-L1.
[0380] 40. A method according to claim 31, wherein the immune checkpoint protein is LAG3.
[0381] 41. A method according to claim 31, wherein the immune checkpoint protein is TIGIT.
[0382] 42. A method according to claim 31, wherein the immune checkpoint protein is PD-1.
[0383] 43. A method according to claim 31, wherein the immune checkpoint protein is TIM3.
[0384] 44. A method according to any one of items 31-43, wherein the tumor is a solid cancer.
[0385] 45. A method according to any one of items 31-43, wherein the tumor is colorectal cancer.
[0386] 46. A method according to any one of items 31-43, wherein the tumor is renal cell carcinoma.
[0387] 47. A method according to item 39 or 42, wherein the inhibitor of the immune checkpoint protein is a monoclonal antibody that selectively binds to PD-1 or PD-LL, preferably selected from the group consisting of BMS-936559, atezolizumab, durvalumab, avelumab, nivolumab, pembrolizumab and lanlorizumab.
[0388] 48. A method according to claim 38, wherein the inhibitor of the immune checkpoint protein is a monoclonal antibody that selectively binds to CTLA-4, preferably selected from the group consisting of ipilimumab and tesimumab.
[0389] 49. A method for treating a tumor in a human, comprising simultaneously administering to the human a composition comprising (a) a replicating oncolytic vaccinia virus, (b) an inhibitor of PD-1 and / or PD-L1, and (c) an inhibitor of an immune checkpoint protein.
[0390] 50. The method of claim 49, wherein prior to administration of the replicative oncolytic vaccinia virus, the tumor does not express the immune checkpoint protein or expresses the immune checkpoint protein at a relatively low level.
[0391] 51. The method of claim 49, wherein the replicative oncolytic vaccinia virus is administered intratumorally, intravenously, intraarterially or intraperitoneally.
[0392] 52. The method of claim 49, wherein the replicative oncolytic vaccinia virus is administered intratumorally.
[0393] 53. A method according to claim 49, wherein the replicative oncolytic vaccinia virus is administered in an amount effective to induce expression of immune checkpoint proteins in the tumor.
[0394] 54. A method according to claim 49, wherein prior to administration of the replicative oncolytic vaccinia virus, the tumor does not express the immune checkpoint protein or expresses the immune checkpoint protein at a relatively low level.
[0395] 55. A method according to item 53 or 54, comprising a step of measuring the expression level of the checkpoint protein in the tumor before administering the composition.
[0396] 56. A method according to any one of items 49-55, wherein the immune checkpoint protein is selected from CTLA-4, LAG3, TIM3 and TIGIT.
[0397] 57. A method according to claim 56, wherein the immune checkpoint protein is CTLA-4.
[0398] 58. A method according to claim 56, wherein the immune checkpoint protein is LAG3.
[0399] 59. A method according to claim 56, wherein the immune checkpoint protein is TIGIT.
[0400] 60. A method according to claim 56, wherein the immune checkpoint protein is T1M3.
[0401] 61. A method according to any one of items 49-60, wherein the tumor is a solid cancer.
[0402] 62. A method according to any one of items 49-61, wherein the tumor is colorectal cancer.
[0403] 63. A method according to any one of items 49-62, wherein the tumor is renal cell carcinoma.
[0404] 64. A method according to claim 49, wherein the inhibitor of the immune checkpoint protein is a monoclonal antibody that selectively binds to PD-1 or PD-L1, preferably selected from the group consisting of BMS-936559, atezolizumab, durvalumab, avelumab, nivolumab, pembrolizumab and lanlorizumab.
[0405] 65. A method according to claim 57, wherein the inhibitor of the immune checkpoint protein is a monoclonal antibody that selectively binds to CTL.A-4, preferably selected from the group consisting of ipilimumab and tesimumab.
Claims
1. A method for treating and / or preventing cancer in a subject in need of cancer treatment, comprising simultaneously administering to the subject an effective amount of a composition comprising (a) a replicating oncolytic vaccinia virus and (b) one or more immune checkpoint inhibitors.
2. The method of claim 1, wherein the replicating oncolytic vaccinia virus is administered intratumorally, intravenously, intraarterially, or intraperitoneally.
3. The method of claim 2, wherein the replicating oncolytic vaccinia virus is administered intratumorally.
4. The method of any one of claims 1-3, wherein the replicative oncolytic vaccinia virus is administered in an amount effective to induce expression of an immune checkpoint protein in the tumor.
5. The method according to any one of claims 1-4, wherein prior to administration of the replicative oncolytic vaccinia virus, the tumor does not express the immune checkpoint protein or expresses the immune checkpoint protein at a relatively low level.
6. The method according to any one of claims 1-5, wherein the immune checkpoint inhibitor is an antibody or a fragment thereof that specifically binds to the immune checkpoint protein, preferably a monoclonal antibody, a humanized antibody, a fully human antibody, a fusion protein or a combination thereof.
7. The method of any one of claims 1-6, wherein the checkpoint inhibitor inhibits an immune checkpoint protein selected from the group consisting of cytotoxic T lymphocyte antigen 4 (CTLA4), programmed cell death protein 1 (PD-1), PD-L1, PD-L2, B7-H3, B7-H4, herpes virus entry mediator (HVEM), T cell membrane protein 3 (TIM3), galectin 9 (GAL9), lymphocyte activation gene 3 (LAG3), V domain immunoglobulin (Ig) containing T cell activation inhibitor (VISTA), killer cell immunoglobulin-like receptor (KIR), B and T lymphocyte attenuator (BTLA), T cell immunoreceptor with Ig and II′IM domains (TIGIT), indoleamine 2,3-dioxygenase (IDO), or a combination thereof.
8. The method of claim 7, wherein the immune checkpoint inhibitor is a monoclonal antibody that selectively binds to PD-1 or PD-L1, preferably selected from the group consisting of BMS-936559, atezolizumab, durvalumab, avelumab, nivolumab, pembrolizumab and lambrolizumab.
9. The method according to claim 7, wherein the immune checkpoint inhibitor is a monoclonal antibody that selectively binds to CTLA4, preferably selected from the group consisting of ipilimumab and tremelimumab.
10. The method of any one of claims 1-9, wherein a plurality of checkpoint inhibitors are administered to the subject simultaneously with the oncolytic vaccinia virus.
